Document:

Gilead Sciences, Inc. Severance Plan

 Exhibit 10.61 
 GILEAD SCIENCES, INC. 
 SEVERANCE PLAN 
 Adopted on March 23, 2004, 
 to be effective January 29, 2003 

 Amended and Restated on May 9, 2006, 
 to be effective January 1, 2005 
 Amended and Restated on May 8, 2007 
 to be effective May 8, 2007 
 Amended on February 8, 2008 
 to be effective January 1, 2008 

 TABLE OF CONTENTS 
  

					
			
	 I.
	  	 INTRODUCTION
	  	1
			
	 II.
	  	 COMMENCEMENT OF PARTICIPATION
	  	1
			
	 III.
	  	 TERMINATION OF PARTICIPATION
	  	1
			
	 IV.
	  	 SEVERANCE PAY BENEFIT
	  	2
			
	 V.
	  	 TIME AND FORM OF SEVERANCE PAY BENEFIT
	  	5
			
	 VI.
	  	 DEATH OF A PARTICIPANT
	  	6
			
	 VII.
	  	 AMENDMENT AND TERMINATION
	  	7
			
	 VIII.
	  	 NON-ALIENATION OF BENEFITS
	  	8
			
	 IX.
	  	 SUCCESSORS AND ASSIGNS
	  	8
			
	 X.
	  	 LEGAL CONSTRUCTION
	  	8
			
	 XI.
	  	 ADMINISTRATION AND OPERATION OF THE PLAN
	  	8
			
	 XII.
	  	 CLAIMS, INQUIRIES AND APPEALS
	  	10
			
	 XIII.
	  	 BASIS OF PAYMENTS TO AND FROM PLAN
	  	12
			
	 XIV.
	  	 OTHER PLAN INFORMATION
	  	12
			
	 XV.
	  	 STATEMENT OF ERISA RIGHTS
	  	12
			
	 XVI.
	  	 AVAILABILITY OF PLAN DOCUMENTS FOR EXAMINATION
	  	13
			
	 XVII.
	  	 DEFINITIONS
	  	14
			
	 XVIII.
	  	 EXECUTION
	  	19
		
	 APPENDIX A Chief Executive Officer Severance Benefits
	  	20
		
	 APPENDIX B Executive Vice President and Senior Vice President Severance Benefits
	  	25
		
	 APPENDIX C Vice President and Senior Advisor Severance Benefits
	  	29
		
	APPENDIX D Severance Benefits for Eligible Employees other than Chief Executive Officer, Executive Vice President, Senior Vice President, Vice President and Senior
Advisor	  	33

  

 i 

 GILEAD SCIENCES, INC. 
 SEVERANCE PLAN 
 AND 
 SUMMARY PLAN DESCRIPTION 
 (As Amended and Restated Effective May 8, 2007
and As Subsequently Amended Effective 
 January 1, 2008) 
  

	I.	INTRODUCTION 

 The
Gilead Sciences, Inc. Severance Plan (the “Plan”) was originally adopted by the Company effective January 29, 2003, and was subsequently amended and restated effective January 1, 2005. The Plan was further amended and restated on
May 8, 2007 and subsequently amended on February 8, 2008 in order to effect the following: (i) bring the Plan into documentary compliance with Section 409A of the Code and the final Treasury Regulations thereunder and
(ii) incorporate certain transitional relief in accordance with (A) Treasury Notice 2005-1, Q&A-19, as modified by the preamble to the proposed and the final regulations pursuant to Section 409A of the Code, published in the
Federal Register on October 4, 2005 and April 17, 2007, respectively, and (B) Treasury Notice 2007-86. This Plan and Summary Plan Description is effective January 1, 2008 to effect such full documentary compliance under
Section 409A of the Code and replaces all severance or similar plans or programs of the Company previously in effect. The Company has no severance or similar plan or program other than this Plan.1 
 The purpose of the Plan is to provide a Severance Pay Benefit to certain Eligible
Employees whose employment with the Company terminates under certain prescribed circumstances. The Company is the Plan Administrator for purposes of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”). The Plan is
intended to comply with the requirements of Section 409A of the Code. 
 Capitalized terms used in this Plan shall have the meaning set forth in Section
XVII. 
  

	II.	COMMENCEMENT OF PARTICIPATION 

 An Eligible Employee shall commence
participation in the Plan upon the later of (i) January 29, 2003 or (ii) his or her date of hire. 
  

	III.	TERMINATION OF PARTICIPATION 

 A Participant’s participation in the
Plan shall terminate upon the occurrence of the earliest of the following: 
  

	(a)	The Participant’s employment terminates without meeting the requirements of Section IV(a)(i)(1). 

  
  

	 1
	 The Triangle Pharmaceuticals, Inc. Severance Plan remained in effect until January 23, 2004 and provided benefits
to employees of Triangle who were involuntarily terminated. 

  

 1 

	(b)	The Participant’s employment terminates with a provision of Section IV(a)(ii) being applicable. 

  

	(c)	The Participant fails to meet the requirements of Section IV(a)(i)(2). 

  

	(d)	The Participant has received a complete distribution of his or her Severance Pay Benefit. 

  

	(e)	The Participant ceases to be an Eligible Employee (other than by reason of termination of his or her employment with the Company). 

  

	(f)	The Plan terminates. 

  

	IV.	SEVERANCE PAY BENEFIT 

  

	(a)	Eligibility for Severance Pay Benefit 

  

	 	(i)	Subject to Section IV(a)(ii), a Participant shall be eligible for a Severance Pay Benefit only if the Participant meets the requirements of Section IV(a)(i)(1) and Section
IV(a)(i)(2). 

  

	 	(1)	The Participant incurs a Separation from Service as a result of an involuntary termination of his or her Employee status by the Company because of a Company-wide or departmental
reorganization or a significant restructuring of the Participant’s job duties; provided, however, that a Participant’s Employee status shall also be deemed to have been involuntarily terminated by the Company if he or she resigns because
of (A) a transfer to a new work location that is more than 50 miles from his or her previous work location, and (B) in the case of a Participant whose Severance Pay Benefit is determined with reference to Appendix A, B or C, a Constructive
Termination (as defined in Section 11(d) of the 2004 Equity Incentive Plan) in conjunction with a Change in Control and within the time specified in Appendix A, B or C, as applicable. 

  

	 	(2)	The Participant executes the Release within the time frame prescribed therein, but in no event more than forty-five (45) days after his or her Separation from Service, and the
period (if any such period is prescribed in the Release) for revoking the execution of the Release under the Older Workers’ Benefit Protection Act, 29 U.S.C. § 626(f), expires without the Participant’s revocation of such Release.

 Under no circumstances shall a Participant be eligible for a Severance Pay Benefit under the Plan if he or she terminates
Employee status for the purpose of accepting employment with the entity that effectuates a Change in Control, its subsidiaries or affiliates. 
  

	 	(ii)	Notwithstanding Section IV(a)(i), a Participant shall be disqualified from receiving a Severance Pay Benefit upon the occurrence of any of the following: 

 

	 	(1)	The Participant voluntarily terminates Employee status for any reason prior to the termination date set by the Company; 

  

 2 

	 	(2)	The Participant’s Employee status is terminated by death or for cause (including, without limitation, gross misconduct or dereliction of duty) or for failure to meet
performance goals or objectives as determined by the Company; 

  

	 	(3)	If the Participant is receiving short-term sick leave benefits on the date his or her Employee status terminates, the Participant fails to execute and deliver to the Company, within
thirty (30) days after his or her Separation from Service, a written waiver of any short-term sick leave benefits that might otherwise be payable after such termination of Employee status; 

  

	 	(4)	The Participant terminates Employee status in order to accept employment with an organization that is wholly or partly owned (directly or indirectly) by the Company or an Affiliate;

  

	 	(5)	The Participant accepts any job with a Buyer or Outsourcing Supplier; 

  

	 	(6)	The Participant is offered full-time employment with a Buyer or Outsourcing Supplier at a new work location 50 miles or less from his or her previous work location with the Company
and taking such position would not result in a reduction in his or her Regular Earnings; 

  

	 	(7)	Except in the case of a Severance Pay Benefit payable on account of a Change in Control of the Company, the Participant received a severance benefit in connection with an
acquisition by the Company within 24 months prior to his or her Separation from Service; or 

  

	 	(8)	Except for a Severance Pay Benefit payable on account of a Change in Control of the Company, the Participant has not completed six months of Continuous Service as of the date of his
or her termination of Employee status; provided, however, that, effective May 8, 2007, such service requirement shall not be applicable to Employees who are Vice Presidents or in Grades 21 through 34. 

 The business decisions that may result in a Participant qualifying for a Severance Pay Benefit are decisions to be made by the Company in its sole
discretion. In making these decisions, similarly situated organizations, locations, functions, classifications, and/or Participants need not be treated in the same manner. Each Participant remains an employee at will, and the date selected by the
Company to terminate the Participant’s Employee status is within its sole discretion. 
  

 3 

	(b)	Amount of Severance Pay Benefit 

  

	 	(i)	Subject to Section IV(b)(ii), the Severance Pay Benefit payable to a Participant shall be as set forth in the applicable Appendix: 

  

	 	(1)	Appendix A – Chief Executive Officer. 

  

	 	(2)	Appendix B – Executive Vice Presidents and Senior Vice Presidents. 

  

	 	(3)	Appendix C – Vice Presidents and Senior Advisors. 

  

	 	(4)	Appendix D – All Eligible Employees not covered by Appendix A, B, or C. 

 Senior Advisors covered under Appendix C shall only be eligible for a Severance Pay Benefit in connection with a Change in Control. 
  

	 	(ii)	Notwithstanding Section IV(b)(i), the total Severance Pay Benefit otherwise payable to a Participant under the Plan shall be subject to reduction (but not below zero) as follows:

  

	 	(1)	If a Participant is reemployed by the Company or an Affiliate within the number of weeks after his or her Separation from Service that is equal to the number of weeks taken into
consideration in calculating the Severance Pay Benefit, the total Severance Pay Benefit payable to such Participant shall be reduced to the dollar amount that the Participant’s Regular Earnings would have been for the period from the date of
termination to the date of reemployment. In all cases, the reduced benefit will be based on the Participant’s Regular Earnings used to calculate such Participant’s Severance Pay Benefit under the Plan. A Participant will be considered
“reemployed” under the Plan for purposes of the foregoing repayment provision if he or she is rehired as an Employee or if he or she is retained at a Company facility as or through a contractor for more than a full-time equivalent of more
than 45 work days. 

  

	 	(2)	If a Participant is employed by a Buyer or Outsourcing Vendor within the number of weeks after his or her Separation from Service that is equal to the number of weeks taken into
consideration in calculating the Severance Pay Benefit, the total Severance Pay Benefit payable to such Participant shall be reduced to the dollar amount that the Participant’s Regular Earnings would have been for the period from the date of
termination to the date of employment with the Buyer or Outsourcing Vendor. 

 Section IV(b)(ii)(2) may be waived in writing by
the Company in its sole discretion. 
  

 4 

	 	(3)	By severance pay or other similar benefits payable under any other plan or policy of the Company or an Affiliate or government required payment (other than unemployment compensation
under United States law), including, but not limited to, any benefit enhancement program adopted as part of a pension plan, but only to the extent the time and form of such alternative payments do not otherwise result in an impermissible
acceleration or deferral under Code Section 409A of the Severance Pay Benefit payable under this Plan. 

  

	 	(4)	By any amounts payable pursuant to the Worker Adjustment and Retraining Notification Act (“WARN”) or any other similar federal, state or local statute.

  

	 	(5)	By the amount of any indebtedness to the Company, but only to the extent such offset would not otherwise contravene any applicable limitations of Code Section 409A.

  

	(c)	Repayment of the Severance Pay Benefit 

 If the Participant
has received payment under the Plan in excess of the Severance Pay Benefit, as reduced in accordance with Section IV(b)(ii), the Participant must agree as a condition of reemployment that such excess will be repaid to the Company within sixty
(60) days after the date his or her reemployment commences. 
  

	V.	TIME AND FORM OF SEVERANCE PAY BENEFIT 

  

	(a)	The Severance Pay Benefit for each Participant shall be paid in equal periodic installments over the total number of weeks taken into account in determining the amount of the
Severance Pay Benefit to which such Participant in entitled. Except as set forth below, such installments shall be payable over the applicable period on the regularly scheduled pay dates for the Participant’s former job and location, beginning
with (i) the first such pay date within the sixty (60)-day period measured from the date of his or her Separation from Service on which both (A) the Release delivered by the Participant in accordance with Section IV(a)(i)(2) is effective
following the expiration of any applicable revocation period and (B) any waiver required of the Participant pursuant to Section IV(a)(ii)(3) is delivered to the Company or (if earlier) the last day of such sixty (60)-day period, provided such
Release and waiver are each delivered to the Company within the required time period following the Participant’s Separation from Service, as set forth in Section IV. 

  

	(b)	 Notwithstanding any provision to the contrary in this Section V or any other Section of the Plan, no Severance Pay Benefit that is deemed to constitute
“nonqualified deferred compensation” within the meaning of and subject to Section 409A of the Code shall commence with respect to a Participant until the earlier of (i) the first day of the seventh (7th) month following the
date of such Participant’s Separation from Service or (ii) the date of his or her death, if the Participant is deemed at the time of such Separation from Service to be a Specified Employee and such delayed commencement is
otherwise 

  

 5 

	 	 
required in order to avoid a prohibited distribution under Code Section 409A(a)(2). Upon the expiration of the applicable deferral period, all payments
deferred pursuant to this Section V(a)(ii) shall be paid in a lump sum to the Participant, and any remaining Severance Pay Benefit shall be paid in accordance with the schedule described in Section V(a) above. 

  

	(c)	Notwithstanding Section V(b), should a Participant who is a Specified Employee at the time of his or her Separation from Service become entitled to a General Severance Pay Benefit
prior to the occurrence of a Change in Control, then the portion of that Severance Pay Benefit that does not exceed the dollar limit described below and is otherwise scheduled to be paid no later than the last day of the second calendar year
following the calendar year in which his or her Separation from Service occurs will not be subject to any deferred commencement date under Section V(b) and shall be paid to such Participant as it becomes due under Section V(a), provided and
only if such portion qualifies as an involuntary separation pay plan in accordance with the requirements set forth in Section 1.409A-1(b)(9)(iii) of the Treasury Regulations. For purposes of this paragraph (iii), the applicable dollar
limitation will be equal to two (2) times the lesser of (A) the Participant’s annualized compensation (based on his or her annual rate of pay for the taxable year preceding the taxable year of his or her Separation from Service,
adjusted to reflect any increase during that taxable year which was expected to continue indefinitely had such Separation from Service not occurred) or (B) the compensation limit under Section 401(a)(17) of the Code as in effect in the
year of the Separation from Service. To the extent the portion of the Severance Pay Benefit to which such Participant would otherwise be entitled under Section V(a) during the deferral period under Section V(b) exceeds the foregoing dollar
limitation, such excess shall be paid in a lump sum upon the expiration of that deferral period, in accordance with the payment delay provisions of Section V(b), and the remainder of the Severance Pay Benefit (if any) shall be paid in accordance
with the schedule described in Section V(a). In no event, however, shall this paragraph (iii) be applicable to any Severance Pay Benefit (or any portion thereof) which does not qualify as an involuntary separation pay plan under
Section 1.409A-(b)(9)(iii) of the Treasury Regulations. 

  

	(d)	Notwithstanding any other provision of the Plan to the contrary, no distribution shall be made from the Plan that would constitute an impermissible acceleration of payment as
defined in Section 409A(3) of the Code and the Treasury Regulations thereunder. 

  

	(e)	No interest shall be paid on a Severance Pay Benefit required to be deferred in accordance with the foregoing. 

  

	VI.	DEATH OF A PARTICIPANT 

 If a Participant dies after qualifying for a
Severance Pay Benefit but before such benefit is completely paid, the balance of the Severance Pay Benefit shall be paid in a lump sum to the Participant’s Beneficiary not later than the later of (i) December 31 of the year in which
the Participant’s death occurred or (ii) the fifteenth (15th) day of the third (3rd) calendar month following the date of the Participant’s death. 
  

 6 

	VII.	AMENDMENT AND TERMINATION 

  

	(a)	General Rule. 

 Although the Company expects to continue
the Plan indefinitely, inasmuch as future conditions cannot be foreseen, (subject to Sections VII(b) and (c)) the Company reserves the right to amend or terminate the Plan at any time by action of its board of directors or by action of a committee
or individual(s) acting pursuant to a valid delegation of authority of the board of directors. However, no amendment or termination shall adversely affect the right of a Participant who incurs a Separation from Service prior to the date of such
amendment or termination to: 
  

	 	(i)	receive the unpaid balance of any Severance Pay Benefit that has become payable in accordance with the foregoing provisions of the Plan; or 

  

	 	(ii)	qualify for a Severance Pay Benefit by the timely execution and delivery of the requisite Release after the date of such amendment or termination. 

  

	(b)	Restrictions on Amendments. 

 Notwithstanding Section
VII(a) of the Plan, and except to the extent required to comply with applicable law, no termination of the Plan and no amendment described below shall be effective if adopted within six months before or at any time after the public announcement of
an event or proposed transaction which would constitute a Change in Control (as such term is defined prior to such amendment); provided, however, that such an amendment or termination of the Plan may be effected, even if adopted after such a public
announcement, if (a) the amendment or termination is adopted after any plans have been abandoned to cause the event or effect the transaction which, if effected, would have constituted the Change in Control, and the event which would have
constituted the Change in Control has not occurred, and (b) within a period of six months after such adoption, no other event constituting a Change in Control has occurred, and no public announcement of a proposed transaction which would
constitute a Change in Control has been made, unless thereafter any plans to effect the Change in Control have been abandoned and the event which would have constituted the Change in Control has not occurred. 
 The amendments prohibited by this Section VII(b) include any amendment which is executed (or would otherwise become effective) at the request of a third
party who effectuates a Change in Control or any amendment which, if adopted and given effect would: 
  

	 	(i)	Deprive any individual who is an Eligible Employee as of the Change in Control of coverage under the Plan as in effect at the time of such amendment; 

  

	 	(ii)	Limit eligibility for or reduce the amount of any Severance Pay Benefit; or 

  

	 	(iii)	Amend Section VII, IX, or the definitions of the terms “Change in Control” or “Successors and Assigns” in Section XVII of the Plan. 

  

 7 

 No person shall take any action that would directly or indirectly have the same effect as any of the
prohibited amendments or termination described in this Section VII(b). 
  

	(c)	No Change in Payment Schedule 

 Under no circumstances
shall any amendment or termination of the Plan affect or modify the payment schedule in effect for a Participant’s Severance Pay Benefit in a manner which would otherwise result in an impermissible acceleration or deferral of that payment
schedule under Code Section 409A. 
  

	(d)	Amendments to Comply with Section 409A of the Code. 

 Notwithstanding any provision of Section VII to the contrary, the Company reserves the right, to the extent the Company deems necessary or advisable in its sole discretion, to unilaterally amend or modify this Plan as may be necessary to
ensure the Severance Pay Benefits provided under this Plan are made in a manner that qualifies for exemption from, or otherwise complies with, Section 409A of the Code; provided, however, that the Company makes no representation that the
Severance Pay Benefit provided under this Plan will be exempt from or comply with Section 409A of the Code and makes no undertaking to preclude Section 409A of the Code from applying to the Severance Pay Benefits provided under this Plan.

  

	VIII. 	NON-ALIENATION OF BENEFITS 

 To the full extent permitted by law and except
as expressly provided in the Plan, no Severance Pay Benefit shall be subject to anticipation, alienation, sale, transfer, assignment, pledge, encumbrance, or charge, and any attempt to do so shall be void. 
  

	IX.	SUCCESSORS AND ASSIGNS 

 The Plan shall be binding upon the Company, its
Successors and Assigns. Notwithstanding that the Plan may be binding upon such Successors and Assigns by operation of law, the Company shall require any Successor or Assign to expressly assume and agree to be bound by the Plan in the same manner and
to the same extent that the Company would be if no succession or assignment had taken place. 
  

	X.	LEGAL CONSTRUCTION 

 This Plan is governed by and shall be construed in
accordance with the Code and ERISA and, to the extent not preempted by ERISA, with the laws of the State of California. 
  

	XI.	ADMINISTRATION AND OPERATION OF THE PLAN 

  

	(a)	Plan Sponsor and Plan Administrator. 

 The Company is the
“Plan Sponsor” and the “Plan Administrator” of the Plan as such terms are used in ERISA. 
  

 8 

	(b)	Administrative Power and Responsibility. 

 The Company in
its capacity as Plan Administrator of the Plan is the named fiduciary that has the authority to control and manage the operation and administration of the Plan. The Company shall make such rules, regulations, interpretations, and computations and
shall take such other action to administer the Plan as it may deem appropriate. The Company shall have the sole discretion to interpret the provisions of the Plan and to determine eligibility for benefits pursuant to the objective criteria set forth
in the Plan. In administering the Plan, the Company shall at all times discharge its duties with respect to the Plan in accordance with the standards set forth in section 404(a)(l) of ERISA. The Company may engage the services of such persons or
organizations to render advice or perform services with respect to its responsibilities under the Plan as it shall determine to be necessary or appropriate. Such persons or organizations may include (without limitation) actuaries, attorneys,
accountants and consultants. 
  

	(c)	Review Panel. 

 Upon receipt of a request for review, the
Company shall appoint a Review Panel that shall consist of three or more individuals. The Review Panel shall be the named fiduciary that shall have authority to act with respect to appeals from denial of benefits under the Plan. 
  

	(d)	Service in More Than One Fiduciary Capacity. 

 Any person
or group of persons may serve in more than one fiduciary capacity with respect to the Plan. 
  

	(e)	Performance of Responsibilities. 

 The responsibilities of
the Company under the Plan shall be carried out on its behalf by its officers, employees, and agents. The Company may delegate any of its fiduciary responsibilities under the Plan to another person or persons pursuant to a written instrument that
specifies the fiduciary responsibilities so delegated to each such person. 
  

	(f)	Employee Communications and Other Plan Activities. 

 In
communications with its employees and in any other activities relating to the Plan, the Company shall comply with the rules, regulations, interpretations, computations, and instructions that were issued to administer the Plan. With respect to
matters relating to the Plan, directors, officers, and employees of the Company shall act on behalf or in the name of the Company in their capacity as directors, officers, and employees and not as individual fiduciaries. 
  

 9 

	XII.	CLAIMS, INQUIRIES AND APPEALS 

  

	(a)	Claims for Benefits and Inquiries. 

 All claims for
benefits and all inquiries concerning the Plan or present or future rights to benefits under the Plan, shall be submitted to the Plan Administrator in writing and addressed as follows: “Gilead Sciences, Inc., Plan Administrator under the Gilead
Sciences, Inc. Severance Plan, 333 Lakeside Drive, Foster City, CA 94404 “ or such other location as communicated to the Participant. A claim for benefits shall be signed by the Participant, or if a Participant is deceased, by such
Participant’s spouse or registered domestic partner, designated beneficiary or estate, as the case may be. 
  

	(b)	Denials of Claims. 

 In the event that any claim for
benefits is denied, in whole or in part, the Plan Administrator shall notify the claimant in writing of such denial and of the right to a review thereof. Such written notice shall set forth in a manner calculated to be understood by the claimant,
specific reasons for such denial, specific references to the Plan provision on which such denial is based, a description of any information or material necessary to perfect the claim, an explanation of why such material is necessary, an explanation
of the Plan’s review procedure which includes information on how to appeal the denial and a statement regarding the claimant’s right to bring a civil action under ERISA section 502(a) following an adverse benefit determination on review.
Such written notice shall be given to the claimant within 90 days after the Plan Administrator receives the claim, unless special circumstances require an extension of time of up to an additional 90 days for processing the claim. If such an
extension of time for processing is required, written notice of the extension shall be furnished to the claimant prior to the termination of the initial 90-day period. This notice of extension shall indicate the special circumstances requiring the
extension of time and the date by which the Plan Administrator expects to render its decision on the claim for benefits. The claimant shall be permitted to appeal such denial in accordance with the Review Procedure set forth below. 
  

	(c)	Review Panel. 

 The Plan Administrator shall appoint a
“Review Panel,” consisting of three or more individuals who may (but need not) be employees of the Company. The Review Panel shall be the named fiduciary that has the authority to act with respect to any appeal from a denial of benefits.

  

	(d)	Requests for a Review. 

 Any person whose claim for
benefits is denied in whole or in part, or such person’s duly authorized representative, may appeal from such denial by submitting a request for a review of the claim to the Review Panel within 60 days after receiving written notice of such
denial from the Plan Administrator. A request for review shall be in writing and shall be addressed as follows: “Review Panel under the Gilead Sciences, Inc. Severance Plan, 333 Lakeside Drive, Foster City, CA 94404” or such other location
as 

  

 10 

 
communicated to the Participant. A request for review shall set forth all of the grounds on which it is based, all facts in support of the request and any
other matters that the claimant deems pertinent. As part of the review procedure, the claimant or the claimant’s duly authorized representative may submit written comments, documents, records and other information related to the claim. The
Review Panel will consider all comments, documents, records and other information submitted by the claimant or the claimant’s duly authorized representative relating to the claim, without regard to whether such information was submitted or
considered in the initial benefit determination. The claimant will be provided, upon request and free of charge, reasonable access to and copies of all documents, records or other information (all of which must not be privileged) relevant to the
benefit claim. The Review Panel may require the claimant to submit such additional facts, documents or other material as it may deem necessary or appropriate in making its review. 
  

	(e)	Decision on Review. 

 The Review Panel shall act on each
request for review and notify the claimant within 60 days after receipt thereof unless special circumstances require an extension of time, up to an additional 60 days, for processing the request. If such an extension for review is required, written
notice of the extension shall be furnished to the claimant within the initial 60-day period. The Review Panel shall give prompt, written notice of its decision to the claimant and to the Plan Administrator. In the event that the Review Panel
confirms the denial of the claim for benefits, in whole or in part, such notice shall set forth, in a manner calculated to be understood by the claimant, the specific reasons for such denial, specific references to the Plan provisions on which the
decision is based, a statement that the claimant is entitled to receive, upon request and free of charge, reasonable access to and copies of all documents, records and other information relevant to the benefit claim, a statement describing any
voluntary appeal procedures offered by the Plan and the claimant’s right to obtain information about such procedures, and a statement informing the claimant of his or her right to bring a civil action under ERISA section 502(a). 
  

	(f)	Rules and Procedures. 

 The Review Panel shall establish
such rules and procedures, consistent with the Plan and with ERISA, as it may deem necessary or appropriate in carrying out its responsibilities under this Section XII. The Review Panel may require a claimant who wishes to submit additional
information in connection with an appeal from the denial of benefits to do so at the claimant’s own expense. 
  

	(g)	Exhaustion of Remedies. 

 No legal action for benefits
under the Plan shall be brought unless and until the claimant: 
  

	 	(i)	has submitted a written claim for benefits in accordance with Section XII(a); 

  

	 	(ii)	has been notified by the Plan Administrator that the claim is denied; 

  

 11 

	 	(iii)	has filed a written request for a review of the claim in accordance with Section XII(d); and 

  

	 	(iv)	has been notified in writing that the Review Panel has affirmed the denial of the claim. 

  

	XIII. 	BASIS OF PAYMENTS TO AND FROM PLAN 

 All Severance Pay Benefits under the
Plan shall be paid by the Company. The Plan shall be unfunded and benefits hereunder shall be paid only from the general assets of the Company. 
  

	XIV.	OTHER PLAN INFORMATION 

  

	(a)	Plan Identification Numbers. 

 The Employer Identification
Number (EIN) assigned to the Plan Sponsor (Gilead Sciences, Inc.) by the Internal Revenue Service is 94-3047598. The Plan Number (PN) assigned to the Plan by the Plan Sponsor pursuant to instructions of the Internal Revenue Service is 508.

  

	(b)	Ending Date of the Plan’s Fiscal Year. 

 The date of
the end of the year for the purpose of maintaining the Plan’s fiscal records is December 31. 
  

	(c)	Agent for the Service of Legal Process. 

 The agent for the
service of legal process with respect to the Plan is the Secretary of Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404. The service of legal process may also be made on the Plan by serving the Plan Administrator. 
  

	(d)	Plan Sponsor and Administrator. 

 The “Plan
Sponsor” and the “Plan Administrator” of the Plan is Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404; 650-522-5800 or such other location as communicated to the Participant. The Plan Administrator is the named
fiduciary charged with responsibility for administering the Plan. 
  

	XV.	STATEMENT OF ERISA RIGHTS 

  

	(a)	As a participant in this Plan (which is a welfare plan sponsored by the Company), you are entitled to the following rights and protection under ERISA: 

  

	(b)	Examine, without charge, at the Plan Administrator’s office and at other specified locations such as work sites, all Plan documents, collective bargaining agreements and copies
of all documents filed by the Plan with the U.S. Department of Labor and available at the Public Disclosure of the Employee Benefits Security Administration. 

  

 12 

	(c)	Obtain copies of all Plan documents and other Plan information upon written request to the Plan Administrator. The Plan Administrator may make a reasonable charge for the copies.

  

	(d)	In addition to creating rights for Plan Participants, ERISA imposes duties upon the people responsible for the operation of the employee benefit Plan. The people who operate your
Plan, called “fiduciaries” of the Plan, have a duty to do so prudently and in the interest of you and other Plan Participants and Beneficiaries. 

  

	(e)	No one, including your employer, your union, nor any other person, may fire you or otherwise discriminate against you in any way to prevent you from obtaining a Plan benefit or
exercising your rights under ERISA. If your claim for a Plan benefit is denied in whole or in part, you must receive a written explanation of the reason for the denial. You have the right to have the claim reviewed and reconsidered.

  

	(f)	Under ERISA, there are steps you can take to enforce the above rights. For instance, if you request materials from the Plan and do not receive them within 30 days, you may file suit
in a federal court. In such a case, the court may require the Plan Administrator to provide the materials and pay you up to $110 a day until you receive the materials, unless the materials were not sent because of reasons beyond the control of the
Plan Administrator. If you have a claim for benefits which is denied or ignored, in whole or in part, you may file suit in a state or federal court. If it should happen that the Plan fiduciaries misuse the Plan’s money, or if you are
discriminated against for asserting your rights, you may seek assistance from the U.S. Department of Labor, or you may file suit in a federal court. The court will decide who should pay court costs and legal fees. If you are successful, the court
may order the person you have sued to pay these costs and fees. If you lose, the court may order you to pay these costs and fees, for example, if it finds your claim is frivolous. 

  

	(g)	If you have any questions about your Plan, you should contact the Plan Administrator. If you have any questions about this statement or about your rights under ERISA, you should
contact the nearest office of the Employee Benefits Security Administration, U.S. Labor, listed in your telephone directory or the Division of Technical Assistance and Inquiries, Employee Benefits Security Administration, U.S. Department of Labor,
200 Constitution Avenue N.W., Washington, D.C. 20210. You may also obtain certain publications about your rights and responsibilities under ERISA by calling the publications hotline of the Employee Benefits Security Administration.

  

	XVI. AVAILABILITY	OF PLAN DOCUMENTS FOR EXAMINATION 

 ERISA requires Gilead Sciences, Inc.,
as the Plan Administrator of a benefit plan sponsored by the Company, to make available for your examination the Plan documents under which the Plan is established and operated. 
 The pertinent Plan documents include official Plan texts and any other documents under which the Plan is established or operated, and applicable collective bargaining agreements. 
  

 13 

 These Plan documents are available for your examination at the Plan Administrator’s office, 333 Lakeside Drive,
Foster City, CA 94404, and at certain other locations such as the Company’s Human Resources offices. 
  

	XVII. DEFINITIONS	

  

	(a)	“Affiliate” means a member of the Affiliated Group other than Gilead Sciences, Inc. and any Subsidiary. 

  

	(b)	“Affiliated Group” means the Company and each member of the group of commonly controlled corporations or other businesses that include the Company, as determined in
accordance with Section 414(b) and (c) of the Code and the Treasury Regulations issued thereunder. 

  

	(c)	“Beneficiary” means the person or persons so designated by a Participant. A Participant may change or revoke a designation of a Beneficiary at any time. To be effective,
any designation of a Beneficiary, or any change or revocation thereof, must be made in writing on the prescribed form and must be received by the Company (in a form acceptable to the Company) before the Participant’s death. If a Participant
fails to make a valid designation of a Beneficiary, or if the validly designated Beneficiary is not living when a payment is to be made to such Beneficiary hereunder, the Participant’s Beneficiary shall be the Participant’s spouse or
registered domestic partner if then living or, if not, the Participant’s estate. 

  

	(d)	“Buyer” means an entity that purchases (or has purchased) some or all of the Affiliated Group’s interest applicable to the operation in which the Participant is
employed, or an entity that is a direct or indirect successor in ownership or management of the operation in which the Participant is employed. Notwithstanding the above, Buyer shall not include the entity that effectuates a Change in Control.

  

	(e)	“Change in Control” means an event which constitutes a change in control of the Company as defined in Section 2(i) of the Gilead Sciences, Inc. 2004 Equity Incentive
Plan, as it may be amended from time to time or any successor to such provision. 

  

	(f)	“Code” means the Internal Revenue Code of 1986, as amended from time to time, and the regulations promulgated thereunder. 

  

	(g)	“Company” means Gilead Sciences, Inc. Where the context requires, “Company” also includes its Subsidiaries, and any of their Successors and Assigns.

  

	(h)	“Continuous Service” means the sum of the following: 

  

	 	(i)	Any period of time during which a person qualifies as an Eligible Employee or, having once so qualified, is on a leave of absence with pay, a paid vacation or holiday or is
receiving benefits under the Company’s short-term disability plan; or; 

  

 14 

	 	(ii)	Any other period that constitutes Continuous Service under written rules or procedures adopted from time to time by the Company, subject to such terms and conditions as the Company
may establish; and any period of time while employed by the Company’s Successor or Assigns that that would have constituted Continuous Service if the service had been with the Company prior to the Change in Control. 

 If an Eligible Employee’s Continuous Service is interrupted and the Eligible Employee subsequently returns to a status that constitutes Continuous
Service, such prior Continuous Service shall be disregarded for all purposes of the Plan, except that if an Eligible Employee is reemployed within one year following termination of Continuous Service, all prior Continuous Service and the time period
between the date of termination and reemployment will be considered Continuous Service. 
  

	(i)	“Determination Date” means each December 31. 

  

	(j)	“Eligible Employee” means any common law employee on the U.S. dollar payroll of the Company or any Subsidiary who (i) is not on the payroll of a person other than the
Company or such Subsidiary and is for any reason deemed by the Company or any Subsidiary to be a common law employee of the Company or such Subsidiary; (ii) is not considered by the Company or any Subsidiary in its sole discretion to be an
independent contractor, regardless of whether the individual is in fact a common law employee of the Company or such Subsidiary; and (iii) who at the time of his or her Separation from Service with the Company or such Subsidiary is not on a
Leave of Absence Without Pay. An individual’s status as an Eligible Employee shall be determined by the Company in its sole discretion, and such determination shall be conclusively binding on all persons. Notwithstanding the foregoing,
“Eligible Employee” does not include an employee or former employee of an entity the stock or assets of which are acquired by the Company or any Subsidiary, unless and until the Company’s management determines that the Plan shall be
applicable to such employees or former employees. 

  

	(k)	“Employer Group” means the Company and each other member of the group of commonly controlled corporations or other businesses that include the Company, as determined in
accordance with Sections 414(b) and (c) of the Code and the Treasury Regulations thereunder, except that in applying Sections 1563(1), (2) and (3) for purposes of determining the controlled group of corporations under
Section 414(b), the phrase “at least 50 percent” shall be used instead of “at least 80 percent” each place the latter phrase appears in such sections, and in applying Section 1.414(c)-2 of the Treasury Regulations for
purposes of determining trades or businesses that are under common control for purposes of Section 414(c), the phrase “at least 50 percent” shall be used instead of “at least 80 percent” each place the latter phrase appears
in Section 1.4.14(c)-2 of the Treasury Regulations. 

  

	(l)	“Employee” means an individual for so long as he or she is in the employ of at least one member of the Employer Group, subject to the control and direction of the employer
entity as to both the work to be performed and the manner and method of performance. 

  

 15 

	(m)	“ERISA” means the Employee Retirement Income Security Act of 1974, as amended from time-to-time. 

  

	(n)	“Family Leave” means a leave under the Company’s family leave policy. 

  

	(o)	“Leave of Absence Without Pay” means a leave of absence without pay under the Company’s leave of absence policy. 

  

	(p)	“Outsourcing Supplier” means an entity to whom the Company outsources a function performed by Eligible Employees where the Company agrees with such entity in the
outsourcing agreement that it will offer jobs to current Eligible Employees performing that function for the Company. 

  

	(q)	“Participant” means any Eligible Employee who has commenced participation in the Plan pursuant to Section II and whose participation has not terminated pursuant to Section
III. 

  

	(r)	“Plan” means the Gilead Sciences, Inc. Severance Plan. 

  

	(s)	“Plan Administrator” means the Company. 

  

	(t)	“Regular Earnings” means straight-time wages or salary paid to a Participant by any entity within the Employer Group for working a regular work schedule or for a leave of
absence with pay, and shall include any amount that is contributed to any employee benefit plan on behalf of the Participant by any entity within the Employer Group under a salary reduction agreement entered into pursuant to such plan and that is
excluded from the Participant’s gross income under section 125, 132(f), or 402(g) of the Code. 

  

	(u)	“Release” means a Release in the form prescribed by the Company in its sole discretion, pursuant to which the Participant shall waive all employment-related claims in
connection with his or her employment with the Employer Group and the termination of that employment, other than claims for benefits under the actual terms of an employee benefit plan and worker’s compensation. For employees subject to the Age
Discrimination in Employment Act, such Release shall be structured so as to comply with the requirements of the Older Workers’ Benefit Protection Act, 29 U.S.C. § 626(f). The form of Release may vary among categories of employees and from
employee to employee within any category of employees. 

  

	(v)	“Severance Pay Benefit” means a benefit provided by the Plan, as determined pursuant to Section IV. 

  

	(w)	“Specified Employee” shall mean a “key employee” (within the meaning of that term under Code Section 416(i)). Effective as of January 1, 2005, a
Specified Employee is an Eligible Employee who, at any time during the twelve (12)-month period ending with the applicable Determination Date, is: 

  

	 	(i)	An officer of the Company having aggregate annual compensation from the Company and/or one or more other Affiliated Companies greater than the compensation limit in effect at the
time under Section 416(i)(1)(A)(i) of the Code, provided that no more than fifty officers of the Company shall be determined to be Specified Employees as of any Determination Date; 

  

 16 

	 	(ii)	A five percent owner of the Company or any Affiliated Company; or 

  

	 	(iii)	A one percent owner of the Company or any Affiliated Company who has aggregate annual compensation from the Company and/or one or more other Affiliated Companies of more than
$150,000. 

 If an Eligible Employee is determined to be a Specified Employee on a Determination Date, then such Eligible
Employee shall be considered a Specified Employee for purposes of the Plan during the period beginning on the first April 1 following the Determination Date and ending on the next March 31. 
 For purposes of determining an officer’s compensation when identifying Specified Employees, compensation is defined in accordance with Treas. Reg.
§1.415(c)–2(a), without applying any safe harbor, special timing or other special rules described in Treas. Reg. §§ 1.415(c)–2(d), 2(e) and 2(g). 
  

	(x)	“Subsidiary” means any corporation with respect to which Gilead Sciences, Inc., one or more Subsidiaries, or Gilead Sciences, Inc., together with one or more Subsidiaries,
own not less than 80% of the total combined voting power of all classes of stock entitled to vote, or not less than 80% of the total value of all shares of all outstanding classes of stock. 

  

	(y)	“Successors and Assigns” means a corporation or other entity acquiring all or substantially all the assets and business of the Company (including the Plan) whether by
operation of law or otherwise. 

  

	(z)	“Separation from Service” means the Participant’s cessation of Employee status. For purposes of the Plan, a Separation from Service shall be determined in accordance
with the following standards: 

 A Separation from Service will not be deemed to have occurred if the Participant continues to
provide services to one or more members of the Employer Group (whether as a common-law employee or non-employee consultant or contractor) at an annual rate that is 50% or more of the services rendered, on average, during the immediately preceding
36-months of employment with the Employer Group (or if employed by the Employer Group less than 36 months, such lesser period). 
 A
Separation from Service will be deemed to have occurred if the Participant’s service with the Employer Group (whether as a common-law employee or non-employee consultant or contractor) is permanently reduced to an annual rate that is less than
20% of the services rendered, on average, during the immediately preceding 36 months of employment with the Employer Group (or if employed by the Employer Group less than 36 months, such lesser period). 
  

 17 

 If such services are permanently reduced by more than 20% but less than 50% of the average over the prior
36 months (or lesser period), a Separation from Service may be deemed to occur based on the facts and circumstances, including, but not limited to, whether the Participant is treated as an employee for other purposes, such as participation in
employee benefit programs, and whether the Participant is able to perform services for other unrelated entities. 
 In addition to the
foregoing, a Separation from Service will not be deemed to have occurred while the Participant is on military leave, sick leave, or other bona fide leave of absence if the period of such leave does not exceed six months or any longer
period for which such Participant’s right to reemployment with one or more members of the Employer Group is provided either by statute or contract; provided, however, that in the event of a Participant’s leave of absence due
to any medically determinable physical or mental impairment that can be expected to result in death or to last for a continuous period of not less than six (6) months and that causes such individual to be unable to perform his or her duties as
an Employee, no Separation from Service shall be deemed to occur during the first twenty-nine (29) months of such leave. If the period of leave exceeds six (6) months (or twenty-nine (29) months in the event of disability as indicated
above) and the Participant’s right to reemployment is not provided either by statute or contract, then such Participant will be deemed to have a Separation from Service on the first day immediately following the expiration of such six (6)-month
or twenty-nine (29)-month period. 
 This definition of Separation from Service shall not be interpreted as limiting the right of the Company
or any other member of the Employer Group to terminate the employment of an individual while on military leave, sick leave or other bona fide leave of absence, to the extent permissible under applicable law. 
 (aa) “2004 Equity Incentive Plan” means the Gilead Sciences, Inc. 2004 Equity Incentive Plan, as it may be amended from time to time or any successor to such
provision 
 (bb) “Year of Continuous Service” means the number of days (as defined by the Company in written rules adopted by it from time to time)
of Continuous Service, divided by 365. A Participant’s Severance Pay Benefit calculation shall include both full and any partial Years of Continuous Service. 
  

 18 

	XVIII. 	EXECUTION 

 The Company has caused its duly-authorized officer to execute
the foregoing Plan as amended and restated effective as of January 1, 2008. 
  

			
	GILEAD SCIENCES, INC.
		
	By:	 	/s/ Kristen M. Metza
		 	Kristen M. Metza
		 	Senior Vice President, Human Resources
		 	Date: February 8, 2008

  

 19 

 APPENDIX A 
 Chief Executive Officer 
 Severance Benefits 
  

	A.	Change in Control Severance Pay Benefit. 

 If a Severance
Pay Benefit under Section IV(a)(i) becomes payable either within the 24-month period following a Change in Control or within the applicable period, as specified in the definition thereof in Section 11(d) of the 2004 Equity Incentive Plan, that
precedes such Change in Control (the “Change in Control Period”), the Severance Pay Benefit shall be: 
  

	 	1.	Three times annual Regular Earnings, plus three times the greater of (a) the last bonus paid under the Company’s annual bonus plan applicable to the Participant Bonus Plan
or (b) the target bonus under the Company’s annual bonus plan applicable to the Participant for the bonus year in which employment terminates. 

  

	 	2.	 Provided the Participant elects to continue medical care coverage under the Company’s medical benefit plans pursuant to the provisions of the Consolidated
Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”), the Company will provide such continuation coverage for the Participant (including, if applicable, the Participant’s eligible family members) under the Company’s
group health plan (or other arrangement as provided herein) until the earlier of (a) the end of the thirty-six (36)-month period following the date of the Participant’s Separation from Service or (b) the date the
Participant secures comparable group health plan coverage from another employer. During the period of such continued medical care coverage which is coincidental with the Participant’s COBRA continuation period, the Company shall pay its share
of the monthly premium (if any) for group health plan coverage to the same extent it pays for coverage for similarly situated active employees; provided, however, that such payment shall be contingent upon the Participant’s timely payment of
the employee portion of any monthly premium. Following the completion of such COBRA continuation coverage, the same arrangement shall continue in effect, to the extent such coverage is provided by one more insured group health plans maintained by
the Company for its current and former employees. In the absence of such insured plans, the Participant shall, following the expiration of the COBRA coverage period, obtain medical care insurance for himself or herself and his or her eligible family
members. The Participant shall submit appropriate evidence of each periodic premium paid for such insurance within sixty (60) days after the required premium payment date, and to the extent such premium payment represents the cost of medical
care coverage at a level not greater than the level of coverage in effect for the Participant and his or her eligible family members at the end of the COBRA coverage period, the Company shall within thirty (30) days after such submission
reimburse the Participant for the portion of that premium payment in excess of the monthly premiums the Participant would have paid for the 

  

 20 

	 	 
comparable period of such coverage under the Company’s group health plan had the Participant continued to be covered under such plan. During the period
such medical care coverage remains in effect hereunder following the COBRA continuation period, the following provisions shall govern the arrangement: (a) the amount of medical care expenses or premium payments eligible for reimbursement in any
one calendar year of such coverage (or any in-kind medical care coverage provided in any one calendar year) shall not affect the amount of expenses or premium payments eligible for reimbursement (or the in-kind benefits to be provided) in any
subsequent calendar year for which medical care coverage is to be provided hereunder; (ii) any reimbursement of medical care expenses or premium payments covered hereunder shall be made by the Company as soon as administratively practicable
following the incurrence of those expenses or premium payments, but in no event later than the close of the calendar year following the calendar year in which those expenses or premium payments are made or incurred; and (iii) the right to such
continued medical care coverage cannot be liquidated or exchanged for any other benefit. Further, as a condition of the coverage provided under this section A.2, the Participant will be required to notify the Company upon securing comparable
coverage from another employer during such thirty-six (36)-month period. The period of continuation coverage provided by the Company shall reduce the number of months of continuation coverage which the Participant (including, if applicable, the
Participant’s eligible family members) is entitled to receive under COBRA. 

  

	 	3.	Outplacement services for 12 months following the date of Separation from Service. 

  

	 	4.	 An additional payment in an amount such that after payment by the Participant of all taxes (including, without limitation, any income and employment taxes and any
interest and penalties imposed thereon) and the excise tax imposed on such additional payment pursuant to Section 4999 of the Code, there remains an amount equal to the excise tax imposed pursuant to Section 4999 of the Code on the
Severance Pay Benefit and any other payment in the nature of compensation that constitutes a “parachute payment” under Section 280G of the Code (the “Excise Tax”). All calculations required pursuant to this provision shall
be performed by an independent registered public company accounting firm retained by the Company for such purpose and shall be based on information supplied by the Company and the Participant. For any parachute payments occurring at the time of the
Change in Control, the relevant calculations shall be completed within ten (10) business days after the effective date of such Change in Control, and for any parachute payments attributable to the Participant’s Separation from Service, the
calculations shall be completed within ten (10) business days after the effective date of such Separation from Service. Such calculations shall be conclusive and binding on all interested persons. The additional payment resulting from such
calculations shall be made to the Participant within ten (10) business days following the completion of such calculations or (if later) at the time the related Excise Tax is remitted to the appropriate tax authorities. In the 

  

 21 

	 	 
event that the Participant’s actual Excise Tax liability is determined by a Final Determination to be greater than the Excise Tax liability taken into
account for purposes of the additional payment initially made to the Participant pursuant to the preceding provisions of this section A.4, then within forty-five (45) days following that Final Determination, the Participant shall notify
the Company of such determination, and a new Excise Tax calculation based upon that Final Determination shall be made within the next forty-five (45) days. The Company shall make a supplemental tax gross up payment (as calculated in the same
manner as the initial payment hereunder) to the Participant attributable to that excess Excise Tax liability within ten (10) business days following the completion of the applicable calculations or (if later) at the time such excess tax
liability is remitted to the appropriate tax authorities. In the event that the Participant’s actual Excise Tax liability is determined by a Final Determination to be less than the Excise Tax liability taken into account for purposes of the
additional payment made to him or her pursuant to the preceding provisions of this section A.4, then the Participant shall refund to the Company, promptly upon receipt, any federal or state tax refund attributable to the Excise Tax overpayment.
For purposes of this section A.4, a “Final Determination” means an audit adjustment by the Internal Revenue Service that is either (i) agreed to by both the Participant and the Company (such agreement by the Company to be not
unreasonably withheld) or (ii) sustained by a court of competent jurisdiction in a decision with which the Participant and the Company concur or with respect to which the period within which an appeal may be filed has lapsed without a notice of
appeal being filed. Notwithstanding anything to the contrary in the foregoing, the additional payment and any supplemental payments under this section A.4 shall be subject to the hold-back provisions of Section V(b) of the Plan, to the extent those
payments relate to any amounts and benefits provided hereunder that constitute parachute payments attributable to the Participant’s Separation from Service. In addition, such additional payment and any supplemental payments shall in no event be
made later than the end of the calendar year that follows the calendar year in which the related taxes are remitted to the appropriate tax authorities, or such other specified time or schedule that may be permitted under Section 409A of the
Code. 

  

	B.	Severance Pay Benefit. 

 If a Severance Pay Benefit under
Section IV(a)(i) becomes payable upon completion of six or more months of Continuous Service and at any time other than within the Change in Control Period as defined in paragraph A of the Appendix A, then the Severance Pay Benefit shall be:

  

	 	1.	Two times annual Regular Earnings plus two times the target bonus under the Company’s annual bonus plan applicable to the Participant for the bonus year in which employment
terminates, prorated for the number of months of employment in the bonus year. 

  

 22 

	 	2.	 Provided the Participant elects to continue medical care coverage under the Company’s medical benefit plans pursuant to COBRA, the Company will provide such
continuation coverage for the Participant (including, if applicable, the Participant’s eligible family members) under the Company’s group health plan (or other arrangement as provided herein) until the earlier of (a) the end of the
twenty-four (24) month period following the date of Separation from Service or (b) the date the Participant secures comparable group health plan coverage from another employer. During the period of such continued medical care coverage
which is coincidental with the Participant’s COBRA continuation period, the Company shall pay its share of the monthly premium (if any) for group health plan coverage to the same extent it pays for coverage for similarly situated active
employees; provide, however, that such payment shall be contingent upon the Participant’s timely payment of the employee portion of any monthly premium. Following the completion of such COBRA continuation coverage, the same arrangement shall
continue in effect, to the extent such coverage is provided by one more insured group health plans maintained by the Company for its current and former employees. In the absence of such insured plans, the Participant shall, following the expiration
of the COBRA coverage period, obtain medical care insurance for himself or herself and his or her eligible family members. The Participant shall submit appropriate evidence of each periodic premium paid for such insurance within sixty (60) days
after the required premium payment date, and to the extent such premium payment represents the cost of medical care coverage at a level not greater than the level of coverage in effect for the Participant and his or her eligible family members at
the end of the COBRA coverage period, the Company shall within thirty (30) days after such submission reimburse the Participant for the portion of that premium payment in excess of the monthly premiums the Participant would have paid for the
comparable period of such coverage under the Company’s group health plan had the Participant continued to be covered under such plan. During the period such medical care coverage remains in effect hereunder following the COBRA continuation
period, the following provisions shall govern the arrangement: (a) the amount of medical care expenses or premium payments eligible for reimbursement in any one calendar year of such coverage (or any in-kind medical care coverage provided in
any one calendar year) shall not affect the amount of expenses or premium payments eligible for reimbursement (or the in-kind benefits to be provided) in any subsequent calendar year for which medical care coverage is to be provided hereunder;
(ii) any reimbursement of medical care expenses or premium payments covered hereunder shall be made by the Company as soon as administratively practicable following the incurrence of those expenses or premium payments, but in no event later
than the close of the calendar year following the calendar year in which those expenses or premium payments are made or incurred; and (iii) the right to such continued medical care coverage cannot be liquidated or exchanged for any other
benefit. Further, as a condition of the coverage provided under this section B.2, the Participant will be required to notify the Company upon securing comparable coverage from another employer during such twenty-four (24)-month 

  

 23 

	 	 
period. The period of continuation coverage provided by the Company shall reduce the number of months of continuation coverage which the Participant
(including, if applicable, the Participant’s eligible family members) is entitled to receive under COBRA. 

  

	 	3.	Outplacement services for 12 months following the date of Separation from Service. 

  

 24 

 APPENDIX B 
 Executive Vice President and 
 Senior Vice President 
 Severance Benefits 
  

	A.	Change in Control Severance Pay Benefit. 

 If a Severance
Pay Benefit under Section IV(a)(i) becomes payable either within the 18- month period following a Change in Control or within the applicable period, as specified in the definition thereof in Section 11(d) of the 2004 Equity Incentive Plan, that
precedes such Change in Control (the “Change in Control Period”), the Severance Pay Benefit shall be: 
  

	 	1.	2.5 times annual Regular Earnings, plus 2.5 times the greater of (a) the last bonus paid under the Company’s annual bonus plan applicable to the Participant or
(b) the target bonus under the Company’s annual bonus plan applicable to the Participant for the bonus year in which employment terminates. 

  

	 	2.	 Provided the Participant elects to continue medical care coverage under the Company’s medical benefit plans pursuant to the provisions of the Consolidated
Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”), the Company will provide such continuation coverage for the Participant (including, if applicable, the Participant’s eligible family members) under the Company’s
group health plan (or other arrangement as provided herein) until the earlier of (a) the end of the thirty (30)-month period following the date of Separation from Service or (b) the date the Participant secures comparable group health plan
coverage from another employer. During the period of such continued medical care coverage which is coincidental with the Participant’s COBRA continuation period, the Company shall pay its share of the monthly premium (if any) for group health
plan coverage to the same extent it pays for coverage for similarly situated active employees; provided, however, that such payment shall be contingent upon the Participant’s timely payment of the employee portion of any monthly premium.
Following the completion of such COBRA continuation coverage, the same arrangement shall continue in effect, to the extent such coverage is provided by one more insured group health plans maintained by the Company for its current and former
employees. In the absence of such insured plans, the Participant shall, following the expiration of the COBRA coverage period, obtain medical care insurance for himself or herself and his or her eligible family members. The Participant shall submit
appropriate evidence of each periodic premium paid for such insurance within sixty (60) days after the required premium payment date, and to the extent such premium payment represents the cost of medical care coverage at a level not greater
than the level of coverage in effect for the Participant and his or her eligible family members at the end of the COBRA coverage period, the Company shall within thirty (30) days after such submission reimburse the Participant for the portion
of that premium payment in 

  

 25 

	 	 
excess of the monthly premiums the Participant would have paid for the comparable period of such coverage under the Company’s group health plan had the
Participant continued to be covered under such plan. During the period such medical care coverage remains in effect hereunder following the COBRA continuation period, the following provisions shall govern the arrangement: (a) the amount of
medical care expenses or premium payments eligible for reimbursement in any one calendar year of such coverage (or any in-kind medical care coverage provided in any one calendar year) shall not affect the amount of expenses or premium payments
eligible for reimbursement (or the in-kind benefits to be provided) in any subsequent calendar year for which medical care coverage is to be provided hereunder; (ii) any reimbursement of medical care expenses or premium payments covered
hereunder shall be made by the Company as soon as administratively practicable following the incurrence of those expenses or premium payments, but in no event later than the close of the calendar year following the calendar year in which those
expenses or premium payments are made or incurred; and (iii) the right to such continued medical care coverage cannot be liquidated or exchanged for any other benefit. Further, as a condition of the coverage provided under this section A.2, the
Participant will be required to notify the Company upon securing comparable coverage from another employer during such thirty (30)-month period. The period of continuation coverage provided by the Company shall reduce the number of months of
continuation coverage which the Participant (including, if applicable, the Participant’s eligible family members) is entitled to receive under COBRA. 

  

	 	3.	Outplacement services for 6 months following the date of Separation from Service. 

  

	 	4.	 An additional payment in an amount such that after payment by the Participant of all taxes (including, without limitation, any income and employment taxes and any
interest and penalties imposed thereon) and the excise tax imposed on such additional payment pursuant to Section 4999 of the Code, there remains an amount equal to the excise tax imposed pursuant to Section 4999 of the Code on the
Severance Pay Benefit and any other payment in the nature of compensation that constitutes a “parachute payment” under Section 280G of the Code (the “Excise Tax”). All calculations required pursuant to this provision shall
be performed by an independent registered public company accounting firm retained by the Company for such purpose and shall be based on information supplied by the Company and the Participant. For any parachute payments occurring at the time of the
Change in Control, the relevant calculations shall be completed within ten (10) business days after the effective date of such Change in Control, and for any parachute payments attributable to the Participant’s Separation from Service, the
calculations shall be completed within ten (10) business days after the effective date of such Separation from Service. Such calculations shall be conclusive and binding on all interested persons. The additional payment resulting from such
calculations shall be made to the Participant within ten (10) business days following the completion of such calculations or (if later) at the time the related Excise Tax is remitted to the appropriate tax authorities. In the 

  

 26 

	 	 
event that the Participant’s actual Excise Tax liability is determined by a Final Determination to be greater than the Excise Tax liability taken into
account for purposes of the additional payment initially made to the Participant pursuant to the preceding provisions of this section A.4, then within forty-five (45) days following that Final Determination, the Participant shall notify
the Company of such determination, and a new Excise Tax calculation based upon that Final Determination shall be made within the next forty-five (45) days. The Company shall make a supplemental tax gross up payment (as calculated in the same
manner as the initial payment hereunder) to the Participant attributable to that excess Excise Tax liability within ten (10) business days following the completion of the applicable calculations or (if later) at the time such excess tax
liability is remitted to the appropriate tax authorities. In the event that the Participant’s actual Excise Tax liability is determined by a Final Determination to be less than the Excise Tax liability taken into account for purposes of the
additional payment made to him or her pursuant to the preceding provisions of this section A.4, then the Participant shall refund to the Company, promptly upon receipt, any federal or state tax refund attributable to the Excise Tax overpayment.
For purposes of this section A.4, a “Final Determination” means an audit adjustment by the Internal Revenue Service that is either (i) agreed to by both the Participant and the Company (such agreement by the Company to be not
unreasonably withheld) or (ii) sustained by a court of competent jurisdiction in a decision with which the Participant and the Company concur or with respect to which the period within which an appeal may be filed has lapsed without a notice of
appeal being filed. Notwithstanding anything to the contrary in the foregoing, the additional payment and any supplemental payments under this section A.4 shall be subject to the hold-back provisions of Section V(b) of the Plan, to the extent those
payments relate to any amounts and benefits provided hereunder that constitute parachute payments attributable to the Participant’s Separation from Service. In addition, such additional payment and any supplemental payments shall in no event be
made later than the end of the calendar year that follows the calendar year in which the related taxes are remitted to the appropriate tax authorities, or such other specified time or schedule that may be permitted under Section 409A of the
Code. 

  

	B.	Severance Pay Benefit. 

 If a Severance Benefit under
Section IV(a)(i) becomes payable upon completion of six or more months of Continuous Service and at any time other than within the Change in Control Period as defined in paragraph A of this Appendix B, then the Severance Pay Benefit shall be:

  

	 	1.	1.5 times annual Regular Earnings plus 1.0 times the target bonus under the Company’s annual bonus plan applicable to the Participant for the bonus year in which employment
terminates, prorated for the number of months of employment in the bonus year. 

  

 27 

	 	2.	Provided the Participant elects to continue medical care coverage under the Company’s medical benefit plans pursuant to COBRA, the Company will provide such continuation
coverage for the Participant (including, if applicable, the Participant’s eligible family members) under the Company’s group health plan (or other arrangement as provided herein) until the earlier of (a) the end of the eighteen
(18)-month period following the date of Separation from Service or (b) the date the Participant secures comparable group health plan coverage from another employer. During the period of such continued medical care coverage which is coincidental
with the Participant’s COBRA continuation period, the Company shall pay its share of the monthly premium (if any) for group health plan coverage to the same extent it pays for coverage for similarly situated active employees; provided, however,
that such payment shall be contingent upon the Participant’s timely payment of the employee portion of any monthly premium. Following the completion of such COBRA continuation coverage, the same arrangement shall continue in effect, to the
extent such coverage is provided by one more insured group health plans maintained by the Company for its current and former employees. In the absence of such insured plans, the Participant shall, following the expiration of the COBRA coverage
period, obtain medical care insurance for himself or herself and his or her eligible family members. The Participant shall submit appropriate evidence of each periodic premium paid for such insurance within sixty (60) days after the required
premium payment date, and to the extent such premium payment represents the cost of medical care coverage at a level not greater than the level of coverage in effect for the Participant and his or her eligible family members at the end of the COBRA
coverage period, the Company shall within thirty (30) days after such submission reimburse the Participant for the portion of that premium payment in excess of the monthly premiums the Participant would have paid for the comparable period of
such coverage under the Company’s group health plan had the Participant continued to be covered under such plan. During the period such medical care coverage remains in effect hereunder following the COBRA continuation period, the following
provisions shall govern the arrangement: (a) the amount of medical care expenses or premium payments eligible for reimbursement in any one calendar year of such coverage (or any in-kind medical care coverage provided in any one calendar year)
shall not affect the amount of expenses or premium payment eligible for reimbursement (or the in-kind benefits to be provided) in any subsequent calendar year for which medical care coverage is to be provided hereunder; (ii) any reimbursement
of medical care expenses or premium payments covered hereunder shall be made by the Company as soon as administratively practicable following the incurrence of those expenses or premium payments, but in no event later than the close of the calendar
year following the calendar year in which those expenses or premium payments are made or incurred; and (iii) the right to such continued medical care coverage cannot be liquidated or exchanged for any other benefit. Further, as a condition of
the coverage provided under this section B.2, the Participant will be required to notify the Company upon securing comparable coverage from another employer during such eighteen (18)-month period. The period of continuation coverage provided by the
Company shall reduce the number of months of continuation coverage which the Participant (including, if applicable, the Participant’s eligible family members) is entitled to receive under COBRA. 

  

	 	3.	Outplacement services for 6 months following the date of Separation from Service. 

  

 28 

 APPENDIX C 
 Vice President and Senior Advisor 
 Severance Benefits 
  

	A.	Change in Control Severance Pay Benefit – For All Vice Presidents and Senior Advisors. 

 If a Severance Pay Benefit under Section IV(a)(i) becomes payable either within the 12-month period following a Change in Control or within the applicable
period, as specified in the definition thereof in Section 11(d) of the 2004 Equity Incentive Plan, that precedes such Change in Control (the “Change in Control Period”), the Severance Pay Benefit shall be: 
  

	 	1.	1.5 times annual Regular Earnings, plus 1.5 times the greater of (a) the last bonus paid under the Company’s annual bonus plan applicable to the Participant or
(b) the target bonus under the Company’s annual bonus plan applicable to the Participant for the bonus year in which employment terminates. 

  

	 	2.	Provided the Participant elects to continue medical care coverage under the Company’s medical benefit plans pursuant to the provisions of the Consolidated Omnibus Budget
Reconciliation Act of 1985, as amended (“COBRA”), the Company will provide such continuation coverage for the Participant (including, if applicable, the Participant’s eligible family members) under the Company’s group health plan
until the earlier of (a) the end of the eighteen (18)-month period following the date of Separation from Service or (b) the date the Participant secures comparable group health plan coverage from another employer. During the period of such
continued medical care coverage (which is coincidental with the Participant’s COBRA continuation period), the Company shall pay its share of the monthly premium (if any) for group health plan coverage to the same extent it pays for coverage for
similarly situated active employees; provided, however, that such payment shall be contingent upon the Participant’s timely payment of the employee portion of any monthly premium. Further, as a condition of the coverage provided under this
section A.2, the Participant will be required to notify the Company upon securing comparable coverage from another employer during such eighteen (18)-month period. The period of continuation coverage provided by the Company shall reduce the number
of months of continuation coverage which the Participant (including, if applicable, the Participant’s eligible family members) is entitled to receive under the COBRA. 

  

	 	3.	Outplacement services for 6 months following the date of Separation from Service. 

  

	 	4.	 An additional payment in an amount such that after payment by the Participant of all taxes (including, without limitation, any income and employment taxes and any
interest and penalties imposed thereon) and the excise tax imposed on such additional payment pursuant to Section 4999 of the Code, there remains an 

  

 29 

	 	 
amount equal to the excise tax imposed pursuant to Section 4999 of the Code on the Severance Pay Benefit and any other payment in the nature of
compensation that constitutes a “parachute payment” under Section 280G of the Code (the “Excise Tax”). All calculations required pursuant to this provision shall be performed by an independent registered public company
accounting firm retained by the Company for such purpose and shall be based on information supplied by the Company and the Participant. For any parachute payments occurring at the time of the Change in Control, the relevant calculations shall be
completed within ten (10) business days after the effective date of such Change in Control, and for any parachute payments attributable to the Participant’s Separation from Service, the calculations shall be completed within ten
(10) business days after the effective date of such Separation from Service. Such calculations shall be conclusive and binding on all interested persons. The additional payment resulting from such calculations shall be made to the Participant
within ten (10) business days following the completion of such calculations or (if later) at the time the related Excise Tax is remitted to the appropriate tax authorities. In the event that the Participant’s actual Excise Tax liability is
determined by a Final Determination to be greater than the Excise Tax liability taken into account for purposes of the additional payment initially made to the Participant pursuant to the preceding provisions of this section A.4, then within
forty-five (45) days following that Final Determination, the Participant shall notify the Company of such determination, and a new Excise Tax calculation based upon that Final Determination shall be made within the next forty-five
(45) days. The Company shall make a supplemental tax gross up payment (as calculated in the same manner as the initial payment hereunder) to the Participant attributable to that excess Excise Tax liability within ten (10) business days
following the completion of the applicable calculations or (if later) at the time such excess tax liability is remitted to the appropriate tax authorities. In the event that the Participant’s actual Excise Tax liability is determined by a Final
Determination to be less than the Excise Tax liability taken into account for purposes of the additional payment made to him or her pursuant to the preceding provisions of this section A.4, then the Participant shall refund to the Company,
promptly upon receipt, any federal or state tax refund attributable to the Excise Tax overpayment. For purposes of this section A.4, a “Final Determination” means an audit adjustment by the Internal Revenue Service that is either
(i) agreed to by both the Participant and the Company (such agreement by the Company to be not unreasonably withheld) or (ii) sustained by a court of competent jurisdiction in a decision with which the Participant and the Company concur or
with respect to which the period within which an appeal may be filed has lapsed without a notice of appeal being filed. Notwithstanding anything to the contrary in the foregoing, the additional payment and any supplemental payments under this
section A.4 shall be subject to the hold-back provisions of Section V(b) of the Plan, to the extent those payments relate to any amounts and benefits provided hereunder that constitute parachute payments attributable to the Participant’s
Separation from Service. In addition, such additional payment and any supplemental payments shall in no event be made later than the end of the calendar year that follows the calendar year in which the related taxes are remitted to the appropriate
tax authorities, or such other specified time or schedule that may be permitted under Section 409A of the Code. 

  

 30 

	B.	Severance Pay Benefit for Vice Presidents with at least Six Months of Continuous Service 

 For Vice Presidents who have completed six or more months of Continuous Service at the time they become eligible for a severance benefit under Section IV(a)(i), if the Severance Pay Benefit becomes payable at any
time other than the Change in Control Period as defined in paragraph A of this Appendix C, then the Severance Pay Benefit shall be: 
  

	 	1.	1.0 times annual Regular Earnings. 

  

	 	2.	Provided the Participant elects to continue medical care coverage under the Company’s medical benefit plans pursuant to COBRA, the Company will provide such continuation
coverage for the Participant (including, if applicable, the Participant’s eligible family members) under the Company’s group health plan until the earlier of (a) the end of the twelve (12)-month period following the date of Separation
from Service or (b) the date the Participant secures comparable group health plan coverage from another employer. During the period of such continued medical care coverage, the Company shall pay its share of the monthly premium (if any) for
group health plan coverage to the same extent it pays for coverage for similarly situated active employees; provide, however, that such payment shall be contingent upon the Participant’s timely payment of the employee portion of any monthly
premium. Further, as a condition of the coverage provided under this section B.2, the Participant will be required to notify the Company upon securing comparable coverage from another employer during such twelve (12)-month period. The period of
continuation coverage provided by the Company shall reduce the number of months of continuation coverage which the Participant (including, if applicable, the Participant’s eligible family members) is entitled to receive under COBRA.

  

	 	3.	Outplacement services for 6 months following the date of Separation from Service. 

  

	C.	Severance Pay Benefit for Vice Presidents with less than Six Months of Continuous Service 

 For Vice Presidents who have not completed six or more months of Continuous Service but are otherwise eligible for a severance benefit under Section IV(a)(i), if the Severance Pay Benefit becomes payable at any
time other than the Change in Control Period as defined in paragraph A of this Appendix C, then the Severance Pay Benefit shall be: 
  

	 	1.	4 months of Regular Earnings. 

  

 31 

	 	2.	Provided the Participant elects to continue medical care coverage under the Company’s medical benefit plans pursuant to COBRA, the Company will provide such continuation
coverage for the Participant (including, if applicable, the Participant’s eligible family members) under the Company’s group health plan until the earlier of (a) the end of the four (4)-month period following the date of Separation
from Service or (b) the date the Participant secures comparable group health plan coverage from another employer. During the period of such continued medical care coverage, the Company shall pay its share of the monthly premium (if any) for
group health plan coverage to the same extent it pays for coverage for similarly situated active employees; provide, however, that such payment shall be contingent upon the Participant’s timely payment of the employee portion of any monthly
premium. Further, as a condition of the coverage provided under this section C.2, the Participant will be required to notify the Company upon securing comparable coverage from another employer during such four (4)-month period. The period of
continuation coverage provided by the Company shall reduce the number of months of continuation coverage which the Participant (including, if applicable, the Participant’s eligible family members) is entitled to receive under COBRA.

  

	 	3.	Outplacement services for 1 month following the date of Separation from Service. 

 Senior Advisors shall not be entitled to any benefits under Sections B and C of this Appendix C. 
  

 32 

 APPENDIX D 
 Severance Benefits for Eligible Employees 
 other than Chief Executive Officer, 
 Executive Vice President, 
 Senior
Vice President, 
 Vice President and Senior Advisor 
 This Appendix is effective for covered individuals who cease Employee status on or after May 8, 2007, unless they have a pre-existing contract providing a different level of severance pay. 
  

	A.	Change in Control Severance Pay Benefit. 

 If a Severance
Pay Benefit under Section IV(a)(i) becomes payable within the 12-month period following a Change in Control (the “Change in Control Period”), then regardless of the period of Continuous Service the Severance Pay Benefit shall be:

  

	 	1.	Eligible Employees in Grades 31 through 34: 

  

	 	1.	Three weeks of Regular Earnings times Years of Continuous Service, with a maximum of 52 weeks of Regular Earnings and a minimum of 22 weeks of Regular Earnings.

  

	 	2.	Provided the Participant elects to continue medical care coverage under the Company’s medical benefit plans pursuant to the provisions of the Consolidated Omnibus Budget
Reconciliation Act of 1985, as amended (“COBRA”), the Company will provide such continuation coverage for the Participant (including, if applicable, the Participant’s eligible family members) under the Company’s group health plan
until the earlier of (a) the end of the severance payment period following the date of Separation from Service or (b) the date the Participant secures comparable group health plan coverage from another employer. During the period of such
continued medical care coverage, the Company shall pay its share of the monthly premium (if any) for group health plan coverage to the same extent it pays for coverage for similarly situated active employees; provided, however, that such payment
shall be contingent upon the Participant’s timely payment of the employee portion of any monthly premium. Further, as a condition of such coverage, the Participant will be required to notify the Company upon securing comparable coverage from
another employer during the severance payment period. The period of continuation coverage provided by the Company shall reduce the number of months of continuation coverage which the Participant (including, if applicable, the Participant’s
eligible family members) is entitled to receive under COBRA. 

  

	 	3.	Outplacement services for 6 months following the date of Separation from Service. 

  

 33 

	 	2.	Eligible Employees in Grades 25 through 30: 

  

	 	a.	Three weeks of Regular Earnings times Years of Continuous Service, with a maximum of 39 weeks of Regular Earnings and a minimum of 13 weeks of Regular Earnings.

  

	 	b.	Provided the Participant elects to continue medical care coverage under the Company’s medical benefit plans pursuant to COBRA, the Company will provide such continuation
coverage for the Participant (including, if applicable, the Participant’s eligible family members) under the Company’s group health plan until the earlier of (a) the end of the severance payment period following the date of Separation
from Service or (b) the date the Participant secures comparable group health plan coverage from another employer. During the period of such continued medical care coverage, the Company shall pay its share of the monthly premium (if any) for
group health plan coverage to the same extent it pays for coverage for similarly situated active employees; provide, however, that such payment shall be contingent upon the Participant’s timely payment of the employee portion of any monthly
premium. Further, as a condition of such coverage, the Participant will be required to notify the Company upon securing comparable coverage from another employer during the severance payment period. The period of continuation coverage provided by
the Company shall reduce the number of months of continuation coverage which the Participant (including, if applicable, the Participant’s eligible family members) is entitled to receive under COBRA. 

  

	 	c.	Outplacement services for 3 months following the date of Separation from Service. 

  

	 	3.	Eligible Employees in Grades 21 through 24: 

  

	 	a.	Three weeks of Regular Earnings times Years of Continuous Service, with a maximum of 26 weeks of Regular Earnings and a minimum of 9 weeks of Regular Earnings.

  

	 	b.	 Provided the Participant elects to continue medical care coverage under the Company’s medical benefit plans pursuant to COBRA, the Company will provide such
continuation coverage for the Participant (including, if applicable, the Participant’s eligible family members) under the Company’s group health plan until the earlier of (a) the end of the severance payment period following the date
of Separation from Service or (b) the date the Participant secures comparable group health plan coverage from another employer. During the period of such continued medical care coverage, the Company shall pay its share of the monthly premium
(if any) for group health plan coverage to the same extent it pays for coverage for similarly situated active employees; provided, however, 

  

 34 

	 	 
that such payment shall be contingent upon the Participant’s timely payment of the employee portion of any monthly premium. Further, as a condition of
such coverage, the Participant will be required to notify the Company upon securing comparable coverage from another employer during the severance payment period. The period of continuation coverage provided by the Company shall reduce the number of
months of continuation coverage which the Participant (including, if applicable, the Participant’s eligible family members) is entitled to receive under COBRA. 

  

	 	c.	Outplacement services for 1week following the date of Separation from Service. 

  

	B.	General Severance Pay Benefit. 

 If a Severance Benefit
under Section IV(a)(i) becomes payable upon completion of six or more months of Continuous Service and at any time other than within the Change in Control Period as defined in paragraph A of this Appendix D, then the Severance Pay Benefit shall be:

  

	 	1.	Eligible Employees in Grades 31 through 34. 

  

	 	a.	Three weeks of Regular Earnings times Years of Continuous Service, with a maximum of 39 weeks of Regular Earnings and a minimum of 13 weeks of Regular Earnings.

  

	 	b.	Provided the Participant elects to continue medical care coverage under the Company’s medical benefit plans pursuant to COBRA, the Company will provide such continuation
coverage for the Participant (including, if applicable, the Participant’s eligible family members) under the Company’s group health plan until the earlier of (a) the end of the severance payment period following the date of Separation
from Service or (b) the date the Participant secures comparable group health plan coverage from another employer. During the period of such continued medical care coverage, the Company shall pay its share of the monthly premium (if any) for
group health plan coverage to the same extent it pays for coverage for similarly situated active employees; provide, however, that such payment shall be contingent upon the Participant’s timely payment of the employee portion of any monthly
premium. Further, as a condition of such coverage, the Participant will be required to notify the Company upon securing comparable coverage from another employer during the severance payment period. The period of continuation coverage provided by
the Company shall reduce the number of months of continuation coverage which the Participant (including, if applicable, the Participant’s eligible family members) is entitled to receive under COBRA. 

  

 35 

	 	c.	Outplacement services for 3 months following the date of Separation from Service. 

  

	 	2.	Eligible Employees in Grades 25 through 30: 

  

	 	a.	Three weeks of Regular Earnings times Years of Continuous Service, with a maximum of 39 weeks of Regular Earnings and a minimum of 13 weeks of Regular Earnings.

  

	 	b.	Provided the Participant elects to continue medical care coverage under the Company’s medical benefit plans pursuant to COBRA, the Company will provide such continuation
coverage for the Participant (including, if applicable, the Participant’s eligible family members) under the Company’s group health plan until the earlier of (a) the end of the severance payment period following the date of Separation
from Service or (b) the date the Participant secures comparable group health plan coverage from another employer. During the period of such continued medical care coverage, the Company shall pay its share of the monthly premium (if any) for
group health plan coverage to the same extent it pays for coverage for similarly situated active employees; provided, however, that such payment shall be contingent upon the Participant’s timely payment of the employee portion of any monthly
premium. Further, as a condition of such coverage, the Participant will be required to notify the Company upon securing comparable coverage from another employer during the severance payment period. The period of continuation coverage provided by
the Company shall reduce the number of months of continuation coverage which the Participant (including, if applicable, the Participant’s eligible family members) is entitled to receive under COBRA. 

  

	 	c.	Outplacement services for 3 months following the date of Separation from Service. 

  

	 	3.	Eligible Employees in Grades 21 through 24: 

  

	 	a.	Three weeks of Regular Earnings times Years of Continuous Service, with a maximum of 26 weeks of Regular Earnings and a minimum of 9 weeks of Regular Earnings.

  

	 	b.	 Provided the Participant elects to continue medical care coverage under the Company’s medical benefit plans pursuant to COBRA, the Company will provide such
continuation coverage for the Participant (including, if applicable, the Participant’s eligible family members) under the Company’s group health plan until the earlier of (a) the end of the severance payment period following the date
of Separation from Service or (b) the date the Participant secures comparable group health plan coverage from another employer. During the period of such continued 

  

 36 

	 	 
medical care coverage, the Company shall pay its share of the monthly premium (if any) for group health plan coverage to the same extent it pays for coverage
for similarly situated active employees; provided, however, that such payment shall be contingent upon the Participant’s timely payment of the employee portion of any monthly premium. Further, as a condition of such coverage, the Participant
will be required to notify the Company upon securing comparable coverage from another employer during the severance payment period. The period of continuation coverage provided by the Company shall reduce the number of months of continuation
coverage which the Participant (including, if applicable, the Participant’s eligible family members) is entitled to receive under COBRA. 

  

	 	c.	Outplacement services for 1 week following the date of Separation from Service. 

  

	C.	General Severance Pay Benefit Without Six Months of Continuous Service. 

 For Eligible Employees in Grades 21 through 34 who have not completed six or more months of Continuous Service but are eligible for a severance benefit under Section IV(a)(i), if the Severance Pay Benefit becomes
payable at any time other than within the Change Control Period as defined in paragraph A of this Appendix D, then the Severance Pay Benefit shall be: 
  

	 	1.	4 weeks of Regular Earnings. 

  

	 	2.	Continuation of coverage under and Company contributions toward the cost of the Company’s medical benefit plans for the period of severance pay. Such continuation period shall
reduce the period of COBRA coverage to which the Participant is entitled. At the end of this period of continuation coverage the Participant may, at his or her own expense, continue COBRA coverage for the remainder of the period, if any, for which
the Participant is eligible under COBRA. 

  

	 	3.	Outplacement services for 1 week following the date of Separation from Service. 

  

 37Commercialization Agreement dated December 10, 2007

 Exhibit 10.62 
 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 
 COMMERCIALIZATION AGREEMENT 
 BETWEEN 
 GILEAD SCIENCES LIMITED 
 AND 
 BRISTOL-MYERS SQUIBB COMPANY

 DATED AS OF DECEMBER 10, 2007 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 TABLE OF CONTENTS 
  

					
	 SECTION 1 DEFINITIONS
	  	1
	 SECTION 2 COLLABORATION MANAGEMENT
	  	17
	 2.1
	  	Generally	  	17
	 2.2
	  	Joint Executive Committee	  	18
	 2.3
	  	Joint Finance Committee	  	19
	 2.4
	  	EU Operating Committee	  	21
	 2.5
	  	Alliance Managers	  	23
	 2.6
	  	Resolution of Disputes	  	24
	 2.7
	  	Commercialization Budget Deadlocks; Commercialization Plan Deadlocks	  	25
	 2.8
	  	Relationship to Other Committees	  	28
	 2.9
	  	Committee-Related Expenses	  	28
	 SECTION 3 REGULATORY MATTERS
	  	28
	 3.1
	  	Generally	  	28
	 3.2
	  	Regulatory Filings	  	28
	 3.3
	  	Regulatory Documentation	  	29
	 3.4
	  	Regulatory Communications	  	30
	 3.5
	  	Medical Affairs and Medical Communications	  	30
	 3.6
	  	Records	  	31
	 3.7
	  	Compliance-Related Matters	  	31
	 3.8
	  	Local Regulatory Expenses	  	32
	 SECTION 4 PRICING AND REIMBURSEMENT
	  	32
	 4.1
	  	Pricing and Reimbursement; Discounts	  	32
	 4.2
	  	Pricing and Other Contract Negotiations	  	38
	 4.3
	  	Consequence of Generic Launch on Pricing	  	39
	 4.4
	  	Pricing of Single Agent Products/Double Agent Product	  	39
	 4.5
	  	Net Selling Price of Stocrin Information	  	40
	 SECTION 5 COMMERCIALIZATION ACTIVITIES
	  	41
	 5.1
	  	Generally; Arrangements for Certain Territory A Countries	  	41
	 5.2
	  	Co-Promotion Agreements	  	44
	 5.3
	  	Promotion Obligations	  	44
	 5.4
	  	Distribution Obligations and Related Matters	  	45
	 5.5
	  	[*]	  	46
	 5.6
	  	Marketing Materials	  	46
	 5.7
	  	Use of Trademarks	  	48
	 5.8
	  	Commercialization Plan and Budget	  	48
	 5.9
	  	Commercialization Expenses	  	50
	 5.10
	  	Reports	  	51
	 5.11
	  	Records	  	51
	 5.12
	  	Samples and Product Donations	  	53
	 SECTION 6 SUPPLY-RELATED MATTERS
	  	54
	 6.1
	  	Generally	  	54
	 6.2
	  	Forecasts and Orders	  	54
	 6.3
	  	Supply-Related Expenses	  	55

  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 i 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

					
	 SECTION 7 LICENSE GRANTS AND INTELLECTUAL PROPERTY
	  	55
	 7.1
	  	Licenses and Related Matters	  	55
	 7.2
	  	Ownership of Trademarks and Related Matters	  	57
	 7.3
	  	Ownership of Marketing Materials	  	57
	 7.4
	  	IP Expenses	  	58
	 SECTION 8 PAYMENTS
	  	58
	 8.1
	  	Authorized Expenses	  	58
	 8.2
	  	Manufacturing Fee	  	60
	 8.3
	  	Sharing of Recoveries Obtained from the Supply JV	  	60
	 8.4
	  	Other Payments	  	61
	 8.5
	  	Adjustment to Country-Specific Percentages Following Generic Launch	  	61
	 8.6
	  	Payment Terms	  	63
	 8.7
	  	Interest	  	63
	 8.8
	  	Taxes	  	63
	 8.9
	  	Royalty Payments to Third Parties	  	63
	 SECTION 9 TERRITORY COMBINATION PRODUCT RECALLS
	  	65
	 SECTION 10 REPRESENTATIONS AND WARRANTIES
	  	65
	 10.1
	  	Generally	  	65
	 10.2
	  	Relationship to Standard Terms	  	65
	 SECTION 11 LIMITATIONS ON LIABILITY AND RELATED MATTERS
	  	65
	 11.1
	  	Limits on Liability	  	65
	 11.2
	  	Exceptions to Standard Terms Limitations	  	65
	 11.3
	  	Relationship to EU Master Agreement	  	66
	 SECTION 12 TERM AND TERMINATION
	  	66
	 12.1
	  	Term	  	66
	 12.2
	  	Voluntary Termination	  	66
	 12.3
	  	Consequences of Expiration or Termination	  	66
	 12.4
	  	Accrued Rights; Survival	  	68
	 SECTION 13 MISCELLANEOUS
	  	69
	 13.1
	  	Standard Terms	  	69
	 13.2
	  	Assignment; Subcontracting	  	69
	 13.3
	  	Employees	  	70
	 13.4
	  	Nonsolicitation of Employees	  	70
	 13.5
	  	Notice	  	70
	 13.6
	  	Public Announcements	  	72
	 13.7
	  	Entire Agreement	  	72

  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 ii 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 COMMERCIALIZATION AGREEMENT 
 This COMMERCIALIZATION AGREEMENT (this “Agreement”) dated and effective as of December 10, 2007 (the “Effective
Date”) is hereby made by and between Gilead Sciences Limited, a limited company organized and existing under the laws of Ireland, having offices at Unit 13 Stillorgan Industrial Park, Blackrock, Co. Dublin, Ireland (“Gilead
Sub”), and Bristol-Myers Squibb Company, a corporation organized and existing under the laws of Delaware, having offices at 345 Park Avenue, New York, New York 10154, USA (“BMS”) (each of Gilead Sub and BMS, a
“Party” and, collectively, the “Parties”). 
 RECITALS 
 WHEREAS, Gilead Sub, a wholly-owned subsidiary of Gilead Sciences, Inc. (“Gilead Parent”), and BMS desire to commercialize the
Combination Product (as defined below) in the European Union and certain other countries; 
 WHEREAS, the Parties, their Affiliates
(as defined below) and certain other Persons (as defined below) have entered into certain other agreements covering the manufacture of the Combination Product for distribution in such countries, the filing of applications with the European Medicines
Agency and any other relevant Regulatory Authorities (as defined below) for approval of the Combination Product by the European Commission or such other relevant Regulatory Authorities, as the case may be, and other related matters; and 

WHEREAS, Gilead Sub and BMS desire to co-promote the Combination Product, and perform certain related activities, in such countries on the
terms and conditions set forth in this Agreement. 
 NOW, THEREFORE, in consideration of the mutual promises and covenants set
forth below and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows: 
 SECTION 1 
 DEFINITIONS 
 As used in this Agreement, the following terms shall have the respective meanings set forth in this Section 1. 
 1.1 “1+1 Approved Reimbursement Price” shall have the meaning set forth in Annex C. 
 1.2 “1+1 EXP”
shall mean, with respect to a country in the Territory, the sum of (a) the EXP (as defined in Annex C) for Sustiva or Stocrin, as applicable, in such country and (b) the EXP for Truvada in such country. 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 1 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 1.3 “Affected Country” shall mean a country in the Territory in which a Generic
Version Launch has occurred. 
 1.4 “Affected Party” shall mean (a) in the case of a Generic Version Launch of Sustiva
or Stocrin, BMS, or (b) in the case of a Generic Version Launch of Viread, Emtriva or Truvada, Gilead Sub. 
 1.5
“Affiliate” of a Person shall mean any other Person that, directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with such Person. For purposes of this definition only,
“control” and, with correlative meanings, the terms “controlled by” and “under common control with” shall mean (a) the possession, directly or indirectly, of the power to direct the management or policies of a
Person, whether through the ownership of voting securities or by contract relating to voting rights or corporate governance, or (b) the ownership, directly or indirectly, of more than fifty percent (50%) of the voting securities or other
ownership interest of a Person. Notwithstanding the foregoing, for the purposes of this definition, none of the US JV, the Supply JV and the MAH shall constitute an Affiliate of either of the Parties, and neither of the Parties shall constitute an
Affiliate of the US JV, the Supply JV or the MAH. 
 1.6 “Agreement” shall have the meaning set forth in the preamble
hereto. 
 1.7 “Alliance Manager” shall have the meaning set forth in Section 2.5. 
 1.8 “Anticipated Agreements” shall mean (a) the Financial Agreement, (b) that certain anticipated amendment and restatement of
the MAH Shareholder Agreement, (c) the Commercial License Agreement, (d) the License Agreements (as defined in the Supply JV Shareholder Agreement), (e) those certain anticipated amendments and restatements of the License Agreements
(as defined in the MAH Shareholder Agreement), other than that certain License Agreement (as so defined) to which Merck and Company, Incorporated, was a party, (f) the Quality Agreement (as defined in the Product Supply Agreement), and
(g) those certain anticipated API Quality Agreements with respect to EFV, TDF and FTC intended for inclusion in Territory Combination Product. 
 1.9 “API” shall mean active pharmaceutical ingredient. 
 1.10 “Applicable Law” shall mean all
applicable laws, rules, regulations, guidelines or other requirements that may be in effect from time to time, including applicable rules, regulations, guidelines or other requirements of Regulatory Authorities, including, for the avoidance of
doubt, with respect to a product, intermediate thereof (including Blended API (as defined in the Product Supply Services Agreement)) or active pharmaceutical ingredient, GMP, or with respect to the Combination Product, any requirements set forth in
the applicable Territory Marketing Authorization. 
 1.11 “Approved Manufacturing Fee Category” shall have the meaning set
forth in Section 2.3(j). 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 2 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 1.12 “Approved Marketing Materials” shall have the meaning set forth in
Section 5.6(a). 
 1.13 “Approved Price” shall mean any Approved Reference Price or Approved Reimbursement Price.

 1.14 “Approved Reference Price” shall have the meaning set forth in Section 4.1(c)(iii). 
 1.15 “Approved Reimbursement Price” shall have the meaning set forth in Annex C. 
 1.16 “Arbitration Matter” shall mean any disputed matter (a) that relates to or arises out of the validity, interpretation or
construction of, or the compliance with or breach of, this Agreement or any Co-Promotion Agreement; (b) that came before the JEC pursuant to Section 2.2(h) (provided that any dispute relating to the Approved Marketing Materials may
be submitted to arbitration only with respect to the issue of whether specific proposed updates are Required Updates); (c) as to whether, for purposes of Section 2.6(e), a proposal by one Party’s member(s) to reverse or modify a
decision of the JEC or such Operating Committee with respect to a matter previously presented to it for decision is based on new information or changed circumstances relevant to the applicable JEC or Operating Committee decision; or (d) that is
designated as an Arbitration Matter hereunder or under any Co-Promotion Agreement; provided that, in each case ((a) through (d)), such disputed matter has been considered, but not resolved, by the Executives pursuant to Section 2.6.
Notwithstanding the foregoing, (i) no disputed matter relating to or arising out of the interpretation or construction of the Pricing Rules or the Discount Rules shall constitute an Arbitration Matter, and (ii) a disputed matter relating
to or arising out of compliance with or breach of a Party’s obligations with respect to providing pricing information to the EU Pricing Discount Committee or to the other Party pursuant to the Pricing Rules shall not constitute an Arbitration
Matter unless and until it has been finally determined pursuant to Section 4.1(e) that such Party provided inaccurate pricing information to the EU Pricing Discount Committee, in which case such matter shall constitute an Arbitration Matter
solely for the limited purposes of (A) determining whether the applicable breach or lack of compliance arose from the gross negligence or intentional misconduct of such Party and (B) determining appropriate remedies, if any. 
 1.17 “Attorney Representative” shall have the meaning set forth in Section 4.1(a)(i). 
 1.18 “Authorized Commercialization Expenses” shall have the meaning set forth in Section 5.9. 
 1.19 “Authorized Distribution Expenses” shall have the meaning set forth in Section 5.4(c). 
 1.20 “Authorized Expenses” shall mean, collectively, the Authorized Commercialization Expenses, Authorized Distribution Expenses,
Authorized Other Expenses and Authorized Supply Expenses. 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 3 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 1.21 “Authorized Other Expenses” shall mean all expenses designated herein as
Authorized Other Expenses. 
 1.22 “Authorized Supply Expenses” shall have the meaning set forth in Section 6.3.

 1.23 “BMS” shall have the meaning set forth in the preamble to this Agreement. 
 1.24 “BMS Licensed Trademarks” shall have the meaning set forth in Section 7.1(a)(ii). 
 1.25 “BMS Product Supply Agreement(s)” shall mean any BMS Product Supply Agreement(s) that may be entered into between Gilead Sub and
certain Affiliates of BMS for sale or other distribution of Territory Combination Product in certain countries in the Territory, each as amended from time to time. 
 1.26 “BMS Sole-Promote Countries” shall mean those countries specified as such in Annex L. 
 1.27 “BMS Territory-Wide Percentage” shall have the meaning set forth in the Financial Agreement. 
 1.28
“BMS Third Party Distributor Countries” shall mean those countries specified as such in Annex L. 
 1.29 “Business
Representative” shall have the meaning set forth in Section 4.1(a)(i). 
 1.30 “Business Day” shall mean a day that
is not a Saturday, Sunday or day on which banking institutions in Dublin, Ireland, New York, New York or San Francisco, California are required by Applicable Law to remain closed. 
 1.31 “Calendar Quarter” shall mean each successive period of three (3) consecutive calendar months commencing on
January 1, April 1, July 1 and October 1, except that the first Calendar Quarter of the Term shall commence on the Effective Date and end on the day immediately prior to the first to occur of
January 1, April 1, July 1 or October 1 after the Effective Date, and the last Calendar Quarter shall end on the last day of the Term. 
 1.32 “Calendar Year” shall mean each successive period of twelve (12) consecutive calendar months commencing on January 1 and ending on December 31, except that the first Calendar Year
of the Term shall commence on the Effective Date and end on December 31 of the year in which the Effective Date occurs and the last Calendar Year of the Term shall commence on January 1 of the year in which the Term ends and end on the
last day of the Term. 
 1.33 “Change of Control” shall have the meaning set forth in Section 13.2(a). 
 1.34 “Combination Product” shall mean the fixed-dose, co-formulated product containing, as its only APIs per single daily dose, 300 mg
TDF, 200 mg FTC, and 600 mg EFV. For the avoidance of doubt, the Combination Product may also be referred to as the fixed-dose, co-formulated product containing, as its only APIs per single daily dose, 245 mg tenofovir disoproxil, 200 mg FTC and 600
mg EFV. 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 4 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 1.35 “Commercial Executives” shall mean (a) the President of EMEA (Europe,
Middle East & Africa) for BMS or any direct report (or other appropriate employee of BMS or its Affiliates designated by the foregoing) and (b) the Vice-President for EU Commercial Operations for Gilead Parent or any direct report (or
other appropriate employee of Gilead Parent or its Affiliates designated by the foregoing). 
 1.36 “Commercial License
Agreement” shall mean that certain commercial license agreement anticipated to be entered into between the US JV and Gilead Sub, as amended from time to time. 
 1.37 “Commercial Record Request” shall have the meaning set forth in Section 5.11(b). 
 1.38 “Commercialization Activities” shall mean Marketing and other activities for the commercialization of the Territory Combination Product, including those set forth in the Commercialization Plan and any other of the
following conducted for the Combination Product in a country in the Territory: execution of product positioning, preparation of promotional and marketing materials, market research and advertising activities, Promotion, advocacy, government and
other public relations activities, pricing under applicable regulations and guidelines and securing local or national drug plan reimbursement. 
 1.39 “Commercialization Budget” shall have the meaning set forth in Section 5.8(b). 
 1.40
“Commercialization Budget Deadlock” shall mean the inability of the JEC to reach agreement on the level of expenditure with respect to a given country in the Territory or the level of aggregate expenditure with respect to Territory
Centralized Expenses in any annual or interim update to any Commercialization Budget. 
 1.41 “Commercialization Plan” shall
have the meaning set forth in Section 5.8(b). 
 1.42 “Commercialization Plan Deadlock” shall mean the inability of the
JEC to reach agreement on the minimum number of Details to be conducted in a given country in the Territory in any annual or interim update to any Commercialization Plan. 
 1.43 “Commercially Reasonable Efforts” shall mean, with respect to the Commercialization Activities that a Party is required to perform with respect to the Combination Product pursuant to the
Commercialization Plan, the level of effort that would generally be used by a Party to conduct such commercialization activities in a manner consistent with the minimum level of expenditure contemplated for such activities by the Commercialization
Budget for a product or compound owned by it or to which it has rights, which is of comparable market potential, profit potential or strategic value to such Party and is at a similar stage in its development or product life, taking into account,
without limitation, issues of safety and efficacy, product profile, the proprietary position, the then-current competitive environment for 

  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 5 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 
such product or compound (and any individual agent comprising part of such product or compound), the likely timing of the product’s or compound’s
(and any such individual agent’s) entry into the market, the then-current market penetration, the return on investment potential of such product (and any individual agent comprising part of such product), the regulatory environment and status
of the product (and any individual agent comprising part of such product), and other relevant scientific, technical and commercial factors, in each case as measured by the facts and circumstances at the time such efforts are due. Such determination
shall be made on a country-by-country basis. 
 1.44 “Competing Product” shall mean (a) in the case of Gilead Sub as
the Transferring Party, a non-nucleoside reverse transcriptase inhibitor, and (b) in the case of BMS as the Transferring Party, a nucleoside reverse transcriptase inhibitor. 
 1.45 “Confidential Information” shall have the meaning set forth in the EU Master Agreement. 
 1.46 “Continuing Party” shall have the meaning set forth in Section 12.2. 
 1.47 “Contract Manufacturer” shall mean any Third Party contract manufacturer with which Gilead Sub (or any of its permitted successors
or assigns) or any of its Affiliates contracts for the Manufacture of the Combination Product pursuant to the Product Supply Services Agreement. 
 1.48 “Contracting Matters” shall have the meaning set forth in Section 4.2(a). 
 1.49 “Co-Promote
Country” shall mean any country in the Co-Promote Territory. 
 1.50 “Co-Promote Territory” shall mean (a) all
countries in Territory B and (b) all of the Territory A Co-Promote Countries. 
 1.51 “Co-Promotion Agreement” shall
have the meaning set forth in Section 5.2. 
 1.52 “Cost Allocation Proposal” shall have the meaning set forth in
Section 5.9. 
 1.53 “Cost of Goods” shall mean, with respect to an API, the cost of Manufacturing such API as calculated
pursuant to Annex A. 
 1.54 “Country Price” shall have the meaning set forth in Annex C. 
 1.55 “Country-Specific Commercialization Budget” shall have the meaning set forth in Section 2.7(a). 
 1.56 “Country-Specific Commercialization Plan” shall mean, with respect to a given country, that certain portion of the
Commercialization Plan that specifies the activities (including Details) to be performed with respect to such country. 
 1.57
“Country-Specific Percentage” shall mean the Gilead Country-Specific Percentage or the BMS Country-Specific Percentage (each as defined in the Financial Agreement), as the case may be. 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 6 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 1.58 “Covered Agreement” shall have the meaning set forth in the EU Master
Agreement. 
 1.59 “Customer” shall have the meaning set forth in Section 4.1(d). 
 1.60 “Designated EUOC Members” shall mean (a) a member of the EUOC that is designated by BMS from time to time, and (b) a
member of the EUOC that is designated by Gilead Sub from time to time, in each case ((a) and (b)) to resolve disputes with respect to Forecasts and Supporting Data as set forth in Section 6. 
 1.61 “Designated Negotiator” shall have the meaning set forth in Section 4.2(c). 
 1.62 “Designated Territory A Countries” shall have the meaning set forth in Annex L. 
 1.63 “Detail” shall mean an in-person presentation to a health care provider who specializes in treatment of HIV infection or AIDS and
has prescribing authority, by a sales representative who is knowledgeable about the Combination Product and any Approved Marketing Materials and the applicable Product SmPC, Labeling and Package Leaflets for the Combination Product, in which
presentation the characteristics of the Combination Product are described by such sales representative in a fair and balanced manner consistent with the requirements of Applicable Law and of this Agreement, and in a manner that is customary in the
industry for the purpose of promoting a prescription pharmaceutical product, but without regard to the position of the presentation within a call to the health care provider. For the avoidance of doubt, a promotional material drop or product
reminder shall not constitute a Detail. When used as a verb, to “Detail” shall mean to engage in a Detail. 
 1.64
“Directive” shall mean European Parliament and Council Directive 2001/83/EC, as amended. 
 1.65 “Discount
Rules” shall mean the rules set forth in Section 2 and Section 3 of Annex C. 
 1.66 “Discounted Price”
shall have the meaning set forth in Section 4.1(d). 
 1.67 “Double Agent Product” shall mean Truvada. 
 1.68 “EDC” shall mean that certain European Development Committee established pursuant to the MAH Shareholder Agreement. 
 1.69 “Effective Date” shall have the meaning set forth in the preamble to this Agreement. 
 1.70 “EFV” shall mean efavirenz. 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 7 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 1.71 “EFV License Agreement” shall mean that certain license agreement, dated as of
September 1, 1994, as amended on May 18, 1998, March 7, 2000 and the Effective Date (and, if applicable, as otherwise amended prior to the Effective Date), between Merck Parent and Merck and Company, Incorporated, on the one
hand, and E.R. Squibb & Sons, L.L.C., as successor in interest to DuPont Pharmaceuticals Company (formerly The DuPont Merck Pharmaceutical Company), on the other hand, as such agreement is amended from time to time. 
 1.72 “Emtriva” shall mean the product sold by Gilead Parent and its Affiliates
under the trademark Emtriva® containing FTC as its only API. 
 1.73 “EU
Marketing Authorization” shall mean that certain marketing authorization granted by the European Commission with respect to Combination Product. 
 1.74 “EU Master Agreement” shall mean that certain EU Master Agreement dated as of the Effective Date by and among the Gilead Sub, BMS, the Supply JV, the MAH and the US JV (or their respective
Affiliates), as amended from time to time. 
 1.75 “EU Operating Committee” or “EUOC” shall mean that
certain operating committee with respect to the Territory established pursuant to Section 2.4. 
 1.76 “EU Pricing Discount
Committee” or “EPDC” shall have the meaning set forth in Section 4.1(a). 
 1.77 “European
Union” shall mean all countries comprising the European Union, as it may be constituted from time to time. 
 1.78
“Executive(s)” shall mean (a) in the case of Gilead Sub, the Chief Executive Officer of Gilead Parent or any direct report designated by the Chief Executive Officer of Gilead Parent and (b) in the case of BMS, the Chief
Executive Officer of BMS or any direct report designated by the Chief Executive Officer of BMS, in each case ((a) and (b)) who shall not be a member of the JEC, the JFC, the EUOC or any JLOC. 
 1.79 “Existing Discount Customers” shall have the meaning set forth in Section 4.1(d)(i). 
 1.80 “Exploitation” shall mean the making, having made, importation, use, sale, offering for sale or disposition of a product or
process, including the research, development, registration, modification, enhancement, Improvement, Manufacturing, optimization, import, export, transport, distribution, promotion or Marketing of a product or process. When used as a verb,
“Exploit” shall mean to engage in any of the foregoing activities. 
 1.81 “Field” shall mean the treatment of HIV
infection in adult humans. 
 1.82 “Field Force” shall mean sales representatives in the Territory, and regional or other
subnational managers of the foregoing. 
 1.83 “Financial Agreement” shall have the meaning set forth in the EU Master
Agreement. 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 8 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 1.84 “Forecast Principles” shall mean the objective forecast principles set forth in
Annex K. 
 1.85 “Forecasts” shall have the meaning set forth in Section 6.2(a). 
 1.86 “FTC” shall mean emtricitabine. 
 1.87 “Generic Version” shall mean, with respect to a country in the Territory and a Single Agent Product, Stocrin or Double Agent Product, a product containing the same API(s) as such product, with
those being the only API(s) in such product, and (a) for any country in the European Union, which product is approved for Marketing in any country in the Territory under Article 10, 10a or 10b of Directive 2001/83/EC or any national
implementations of, or regulations promulgated under, such Articles, including Regulation 726/2004 or (b) for any Other European Country, which product is approved for Marketing in such country under any analogous Applicable Law. 
 1.88 “Generic Version Launch” shall mean, with respect to a country in the Territory and the Single Agent Product, Stocrin or the Double
Agent Product, as the case may be, the later of (a) the Launch in such country of at least one (1) Generic Version of such product and (b) the expiration of the last to expire Patent which claims the composition or use (for the
indication of HIV infection in adult humans) of such product or the API(s) contained therein. 
 1.89 “Gilead Licensed
Trademarks” shall have the meaning set forth in Section 7.1(a). 
 1.90 “Gilead Non-Proprietary Product” shall
have the meaning set forth in Section 8.5(c). 
 1.91 “Gilead Parent” shall have the meaning set forth in the recitals
to this Agreement. 
 1.92 “Gilead Sole-Promote Countries” shall mean those countries specified as such in Annex L.

 1.93 “Gilead Sub” shall have the meaning set forth in the preamble to this Agreement. 
 1.94 “Gilead Territory-Wide Percentage” shall have the meaning set forth in the Financial Agreement. 
 1.95 “GMP” shall mean (a) applicable good manufacturing practice requirements promulgated by applicable European Community law and
guidance as amended from time to time, including the applicable good manufacturing practices set forth in European Community Directive 2003/94/EC, Directive 2001/83/EC, all relevant implementations of such directives, and relevant guidelines
including Volume 4 of the Rules Governing Medicinal Products in the European Union: Medicinal products for human and veterinary use: Good manufacturing practices or (b) in the case of each of the Other European Countries, the equivalent of the
foregoing promulgated by the relevant Regulatory Authorities in such country. 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 9 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 1.96 “GOA” shall have the meaning set forth in Section 4.1(d)(i). 

1.97 “Improvement” shall mean any modification to a compound, composition, product or technology or to any discovery, device, process
or formulation related to such compound, composition, product or technology, whether or not patented or patentable, including any enhancement in the efficiency, operation, Manufacture, ingredients, preparation, presentation, formulation, means of
delivery, packaging or dosage of a compound, composition, product or technology, or of any discovery, device, process or formulation related thereto; any discovery or development of any new or expanded indications or applications for a compound,
composition, product or technology; any discovery or development that improves the stability, safety or efficacy of a compound, composition, product or technology; or any discovery or development of a new dosage regimen for a product or method of
use or administration for a compound, composition, product or technology. 
 1.98 “Independent Accounting Expert” shall mean
an independent Third Party accounting firm or consultant mutually agreed by the Parties. 
 1.99 “Information and
Inventions” shall mean all technical, scientific and other know-how and information, trade secrets, knowledge, technology, means, methods, processes, practices, formulas, instructions, skills, techniques, procedures, experiences, ideas,
technical assistance, designs, drawings, assembly procedures, computer programs, apparatuses, specifications, data, results and other material, including pre-clinical and clinical trial results, Manufacturing procedures, test procedures, and
purification and isolation techniques, (whether or not confidential, proprietary, patented or patentable) in written, electronic or any other form now known or hereafter developed, and all Improvements, whether to the foregoing or otherwise, and all
other discoveries, developments, inventions (whether or not confidential, proprietary, patented or patentable), and tangible embodiments of any of the foregoing. 
 1.100 “Initial Launch Period” shall mean, with respect to each country in the Territory and the Country-Specific Commercialization Plan and Country-Specific Commercialization Budget with respect
thereto, the period commencing with the Launch of the Combination Product in such country and ending twenty-four (24) months after such Launch, or with respect to the Territory Centralized Budget, the period commencing with the Effective Date
and ending twenty-four (24) months after the first Launch of the Combination Product in the Territory. 
 1.101 “Initial Launch
Period Detail Commitment” shall mean, with respect to each Country-Specific Commercialization Plan, that certain minimum number of Details required to be included in such Commercialization Plan for each country in Territory B for the
applicable Initial Launch Period, as set forth in Annex J (which Annex shall be amended by the Parties, prior to the Launch in the applicable country to include such minimum number for any country in Territory B for which such number is not
specified in such Annex as of the Effective Date). 
 1.102 “Initial Launch Period Financial Commitment” shall mean, with
respect to 

  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 10 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 
each Country-Specific Commercialization Budget and the Territory Centralized Commercialization Budget, that certain minimum amount to be specified in such
budget for the applicable Initial Launch Period, as set forth in Annex J (which Annex shall be amended by the Parties, prior to the Launch in the applicable country, to include such minimum amount for any country for which such amount is not
specified in such Annex as of the Effective Date). 
 1.103 “Interim Agreement” shall mean that certain interim agreement
entered into by and between Lawrence Laboratories and Bristol-Myers Squibb EMEA Sarl, on the one hand, and Gilead Sub, on the other hand, dated as of February 1, 2007, as such agreement is amended from time to time. 
 1.104 “Interim Manufacturing Agreement” shall mean that certain interim agreement entered into by and between E.R. Squibb &
Sons, L.L.C. and Bristol-Myers Squibb EMEA Sarl, on the one hand, and Gilead Sub, on the other hand, dated as of June 13, 2007, as such agreement is amended from time to time. 
 1.105 “Joint Executive Committee” or “JEC” shall have the meaning set forth in Section 2.1(a). 
 1.106 “Joint Finance Committee” or “JFC” shall have the meaning set forth in Section 2.1(a). 
 1.107 “Joint Local Operating Committee” or “JLOC” shall mean, with respect to a given country in the Co-Promote Territory,
that certain country-specific commercialization committee established pursuant to the Co-Promotion Agreement for such country, to focus on the planning and implementation of Commercialization Activities in such country. 
 1.108 “Launch” shall mean (a) with respect to the Combination Product, the date on which the Combination Product is first shipped
by or on behalf of Gilead Sub or BMS (or their respective Affiliates) to Third Parties in a country, portion of the Territory or the Territory, as the case may be, or (b) with respect to any Generic Version, the date on which such product is
first available for commercial sale and purchase in a country, portion of the Territory or the Territory, as the case may be. 
 1.109
“Local Demand” shall mean, with respect to a given country in the Territory and with respect to any given period of time specified in any forecast or order prepared hereunder, the unit quantities of the Combination Product required
during such period to meet the treatment needs of HIV patients within such country, as determined objectively in accordance with the Forecast Principles. 
 1.110 “Local Regulatory Lead” shall mean (a) with respect to the BMS Sole-Promote Countries and the BMS Third Party Distributor Countries, BMS or (b) with respect to any other countries in
the Territory, Gilead Sub. 
 1.111 “Local Regulatory Matters” shall have the meaning set forth in Section 3.1.

  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 11 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 1.112 “MAH” shall mean Bristol-Myers Squibb Gilead Sciences And Merck
Sharp & Dohme Limited, an Irish limited company. 
 1.113 “MAH Shareholder Agreement” shall mean that certain
Shareholder Agreement, dated as of September 29, 2006, by and among Gilead Sub, Lawrence Laboratories, the MAH, and Merck Sharp & Dohme B.V. (which, for clarity, is no longer a party to such agreement pursuant to that certain Exit
Agreement among the MAH and its shareholders and Merck and Company, Incorporated, dated as of the Effective Date), governing the conduct of such parties with respect to the MAH’s activities, as such agreement is amended from time to time.

 1.114 “Manufacture” shall mean with respect to the applicable product or compound, the manufacturing, processing,
formulating, packaging, labeling, holding (including storage), and quality control testing (including release), of such product or compound. 
 1.115 “Market” or “Marketing” shall mean all programs and activities relating to the Promotion and sale and other commercialization of the Combination Product, including Detailing, advertising, and press and media
activities, as well as selling, contracting for sale of, and distributing the Combination Product. 
 1.116 “Maximum Percentage
Discount” shall have the meaning set forth in Section 4.1(d)(i). 
 1.117 “Merck Parent” shall mean
Merck & Co., Inc. 
 1.118 “Non-Affected Party” shall mean the Party that is not the Affected Party. 
 1.119 “Non-Affected Product” shall mean (a) Sustiva or Stocrin, as the case may be, in the case of a Generic Version Launch of
Viread, Emtriva or Truvada, or (b) Truvada, in the case of a Generic Version Launch of Sustiva or Stocrin. 
 1.120 “Notice
Address” shall have the meaning set forth in Section 13.5. 
 1.121 “Operating Committee” shall mean the JFC
or the EUOC, as the case may be. 
 1.122 “Order” shall have the meaning set forth in Section 6.2(b). 
 1.123 “Other European Countries” shall mean Iceland, Liechtenstein, Norway and Switzerland. 
 1.124 “Parent” shall mean, in the case of Gilead Sub or any of its Affiliates, Gilead Parent, and in the case of BMS or any of its
Affiliates, BMS. 
 1.125 “Party” and “Parties” shall have the meaning set forth in the preamble to this
Agreement. 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 12 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 1.126 “Patents” shall mean (a) all patents and patent applications (including
provisional applications), (b) any substitutions, divisions, continuations, continuations-in-part, reissues, renewals, registrations, confirmations, re-examinations, extensions, supplementary protection certificates and the like, and
(c) any foreign or international equivalents of any of the foregoing. 
 1.127 “Person” shall mean an individual, sole
proprietorship, partnership, limited partnership, limited liability partnership, corporation, limited liability company, unlimited company, business trust, joint stock company, trust, unincorporated association, joint venture or other similar entity
or organization, including a government or political subdivision, department or agency of a government. 
 1.128 “Premium”
shall mean, with respect to a given country for which, at any time following the earliest to occur of the Generic Version Launch of Sustiva (or Stocrin, as applicable), Viread, Emtriva or Truvada, the then-current positive difference, if any,
between the [*] for such country for a given Calendar Year and the sum of the [*] for such country and such Calendar Year. 
 1.129
“Premium Share” shall mean, with respect to a given country, a given Party and a given Calendar Year, (a) the Premium for such Calendar Year with respect to such country, multiplied by (b) such Party’s Standard
Country-Specific Percentage for the Calendar Year prior to the Calendar Year in which the first Generic Version Launch in such country occurred. 
 1.130 “Price Approval Country” shall have the meaning set forth in Section 4.1(c)(ii). 
 1.131 “Pricing
Rules” shall mean the rules set forth in Section 1 of Annex C. 
 1.132 “Product SmPC, Labeling and Package
Leaflets” shall mean with respect to a product (a) for each country in the European Union, (i) the Summary of Product Characteristics (as required by the Directive), (ii) any display of written, printed or graphic matter upon
the immediate container, outside container, wrapper or other packaging of a product (including any pricing and reimbursement information and other local information contained within the “blue box” on the packaging of such product that is
not included in the EU annexes attached to the European Commission’s Decision with respect to the approval of such product) or (iii) any written, printed or graphic material on or within the package from which a product is to be dispensed,
including the Package Leaflet (as required by the Directive), in each case ((i) through (iii)), as approved by the European Commission or (b) for each of the Other European Countries, the equivalent of each of the foregoing in such country, in
each case, as approved by the applicable Regulatory Authority. 
 1.133 “Product Supply Agreement” shall mean the Product
Supply Agreement dated as of the Effective Date between the Supply JV and Gilead Sub for the supply to Gilead Sub of Combination Product to be distributed in the Territory, as amended from time to time. 
 1.134 “Product Supply Services Agreement” shall mean that certain Product Supply Services Agreement dated as of the Effective Date
between Gilead Sub, in its capacity as Service Provider, and the Supply JV, as amended from time to time. 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 13 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 1.135 “Promotion” shall mean the conduct of activities normally undertaken by a
pharmaceutical company’s field force to implement plans and strategies for marketing and other commercialization aimed at encouraging the approved use of a pharmaceutical product, including Detailing. When used as a verb, “Promote”
shall mean to engage in any of the foregoing activities. 
 1.136 “Proposed Existing Customer Discount” shall have the
meaning set forth in Section 4.1(d)(i). 
 1.137 “Proprietary Product” shall have the meaning set forth in
Section 8.5(c). 
 1.138 “Reference Price Country” shall have the meaning set forth in Section 4.1(c)(iii).

 1.139 “Regulatory Authorities” shall mean any applicable supra-national, federal, national, regional, state, provincial,
or local regulatory agencies, departments, bureaus, commissions, councils, or other government entities, including the European Medicines Agency and the European Commission, or other entity exercising regulatory authority with respect to the
Exploitation of the Combination Product. For the avoidance of doubt, the Regulatory Authorities shall include any entity exercising regulatory authority with respect to the Manufacture of API for supply under any Covered Agreement, whether or not
such entity is located in the Territory. 
 1.140 “Requesting Party” shall have the meaning set forth in
Section 4.1(e). 
 1.141 “SDEA” shall mean that certain safety data exchange agreement dated as of September 25,
2006, by and among Gilead Parent, BMS and Merck Parent and such other Persons as may be parties thereto from time to time, as such agreement may be amended from time to time. 
 1.142 “Selling Entity” shall mean (a) with respect to each country in the Territory in which Gilead Sub is the Selling Party, the
Affiliate of Gilead Sub that sells Territory Combination Product in such country or (b) with respect to each country in the Territory in which BMS is the Selling Party, the Affiliate of BMS that sells Territory Combination Product in such
country. 
 1.143 “Selling Party” shall mean (a) with respect to each country in the Co-Promote Territory, Gilead Sub
or (b) with respect to each other country in the Territory, BMS or Gilead Sub as set forth in Annex L. For clarity, the Selling Party with respect to any Third Party Distributor Country is intended to be the Party that sells (or has an
Affiliate that sells) Territory Combination Product to the Third Party Distributor and has (or has an Affiliate that has) entered into an applicable distributor agreement with such Third Party Distributor that is consistent with this Agreement.

  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 14 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 1.144 “Service Provider” shall mean Gilead Sub, acting in its capacity as service
provider to the Supply JV pursuant to the Product Supply Services Agreement. 
 1.145 “Significant Interim Update” shall
have the meaning set forth in Section 5.8(d). 
 1.146 “Single Agent Product” shall mean each of Viread, Emtriva, and
Sustiva. 
 1.147 “Sole-Promote Countries” shall mean (a) all BMS Sole-Promote Countries and (b) all Gilead
Sole-Promote Countries. 
 1.148 “Sole Promoting Party” shall mean (a) in the case of any BMS Sole-Promote Country, BMS
or (b) in the case of any Gilead Sole-Promote Country, Gilead Sub. 
 1.149 “Standard Country-Specific Percentage”
shall mean, with respect to a Party, the Country-Specific Percentage of such Party as calculated pursuant to the Financial Agreement (without regard to Section 8.5 of this Agreement). 
 1.150 “Standard Terms” shall mean those certain terms set forth in Annex C of the EU Master Agreement. 
 1.151 “Stocrin” shall mean the product sold under the trademark Stocrin® containing EFV as its only API. 
 1.152 “Subsequent Launch Period”
shall mean (a) with respect to each country in the Territory, the twelve (12) month period immediately following the Initial Launch Period with respect to such country or (b) with respect to the Territory Centralized Budget, the
period immediately following the Initial Launch Period with respect thereto and ending upon the end of the Subsequent Launch Period with respect to the country in the Co-Promote Territory with the latest Launch of the Combination Product.

 1.153 “Supply JV” shall mean Tri-Supply Limited, an Irish limited company. 
 1.154 “Supply JV Shareholder Agreement” shall mean that certain Supply JV Shareholder Agreement dated as of the Effective Date by and
among Gilead Sub, Lawrence Laboratories and the Supply JV, as amended from time to time. 
 1.155 “Supporting Data” shall
have the meaning set forth in Annex K. 
 1.156 “Sustiva” shall mean
the product sold by BMS and its Affiliates under the trademark Sustiva® containing EFV as its only API. 
 1.157 “TDF” shall mean tenofovir disoproxil fumarate. 
 1.158 “Term” shall
have the meaning set forth in Section 12.1. 
 1.159 “Terminated Party” shall have the meaning set forth in
Section 12.2. 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 15 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 1.160 “Territory” shall mean the European Union and the Other European Countries.

 1.161 “Territory A” shall mean those countries in the Territory, other than any country that is included in Territory B.
For the avoidance of doubt, Territory A shall include any countries that become part of the Territory after the Effective Date. The countries included in Territory A as of the Effective Date are set forth in Annex L. 
 1.162 “Territory A Co-Promote Countries” shall have the meaning set forth in Annex L. 
 1.163 “Territory B” shall mean France, Germany, Italy, Spain, the United Kingdom and the Republic of Ireland. 
 1.164 “Territory Centralized Budget” shall mean that portion of the Commercialization Budget that sets forth the Territory Centralized
Expenses. 
 1.165 “Territory Centralized Expenses” shall mean those Territory-wide expenses set forth in the
Commercialization Budget (i.e., expenses set forth therein that are not designated as country-specific expenses). 
 1.166
“Territory Centralized Plan” shall mean that portion of the Commercialization Plan setting forth Territory-wide activities (i.e., activities in the Commercialization Plan that are not country-specific activities). 

1.167 “Territory Combination Product” shall mean any Combination Product sold or otherwise distributed (or, if not sold or otherwise
distributed, Manufactured for intended sale or other distribution) pursuant to this Agreement. 
 1.168 “Territory Customer
Orders” shall have the meaning set forth in Section 5.4(a). 
 1.169 “Territory Pricing Information” shall mean
Section 4.1(f). 
 1.170 “Territory Marketing Authorization” shall mean (a) with respect to each country in the European
Union, the EU Marketing Authorization and (b) with respect to any of the Other European Countries, any equivalent of the foregoing granted by the relevant Regulatory Authorities in such country. 
 1.171 “Third Party” shall mean any Person other than (a) the Parties or any of their respective Affiliates or (b) the Supply
JV, the MAH or the US JV. For the avoidance of doubt, the exclusion of a Person from the definition of Third Party hereunder shall not be construed to afford such Person any express or implied rights, including third party beneficiary rights,
hereunder. 
 1.172 “Third Party Acquirer” shall have the meaning set forth in Section 13.2(a). 
 1.173 “Third Party Distributor” shall have the meaning set forth in Section 5.1(b)(i). 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 16 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 1.174 “Third Party Distributor Agreement” shall mean any agreement between a Third
Party Distributor and either Party or any of its Affiliates, which agreement grants such Third Party Distributor the right to distribute the Combination Product in one or more countries in the Territory, including any agreement under which a Third
Party Distributor has the right to purchase Territory Combination Product. 
 1.175 “Third Party Distributor Countries”
shall have the meaning set forth in Section 5.1(b)(i). 
 1.176 “Trademark” shall include any word, name, symbol,
color, designation or device or any combination thereof, including any trademark, trade dress, service mark, service name, brand mark, trade name, brand name, logo or business symbol. 
 1.177 “Transferring Party” shall have the meaning set forth in Section 13.2(a). 
 1.178 “Truvada” shall mean the co-formulated product sold by Gilead Parent and
its Affiliates under the trademark Truvada® containing TDF and FTC as its only APIs. 
 1.179 “US JV” shall mean Bristol-Myers Squibb & Gilead Sciences, LLC. 
 1.180 “US JV
Collaboration Agreement” shall mean that certain Amended and Restated Collaboration Agreement by and among Gilead Parent, Gilead Holdings, LLC, BMS, E.R. Squibb & Sons, L.L.C., and the US JV dated as of September 28,
2006, as such agreement is amended from time to time. 
 1.181 “US JV Operating Agreement” shall mean that certain Operating
Agreement entered into as of December 17, 2004 by and between Gilead Holdings, LLC and E.R. Squibb & Sons, L.L.C, as such agreement is amended from time to time. 
 1.182 “Viread” shall mean the product sold by Gilead Parent and its Affiliates
under the trademark Viread® containing TDF as its only API. 
 SECTION 2 

 COLLABORATION MANAGEMENT 
 2.1 Generally. 
 (a) The Parties desire to expand the role of certain committees established under the US JV
Collaboration Agreement and the US JV Operating Agreement as set forth in this Section 2 and elsewhere in this Agreement. In furtherance of such objective, (i) the Joint Executive Committee established under the US JV Operating Agreement
shall serve as the “Joint Executive Committee” or “JEC” for purposes of this Agreement and (ii) the Joint Finance Committee established under the US JV Collaboration Agreement shall serve as the “Joint Finance
Committee” or “JFC” for purposes of this Agreement. In taking any action pursuant to this Agreement, the JEC and the JFC shall each act in accordance with the terms of this Agreement. Further, any action taken by the JEC or JFC
pursuant to this Agreement shall be deemed to have been taken pursuant to, and governed by, this Agreement and not the US JV Collaboration Agreement or the US JV Operating Agreement, as the case may be. 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 17 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 (b) The JEC and the JFC, with respect to the subject matter of this Agreement, and
the EUOC and the JLOCs, each shall have only the responsibilities and authority delegated to or vested in such committee in this Section 2 or elsewhere in this Agreement or any other Covered Agreement to which the Parties or their respective
Affiliates are parties. 
 2.2 Joint Executive Committee. Except as otherwise provided herein, the JEC shall be governed by, and shall
act in accordance with, Section 6 of the US JV Operating Agreement (without regard to Section 6.2 of such agreement). The JEC shall have overall authority and responsibility with respect to the Commercialization Activities and any other
activities conducted pursuant to the Agreement or any Co-Promotion Agreement (except for those matters reserved to the Parties or their respective Affiliates pursuant to this Agreement or any Co-Promotion Agreement). Without limitation of the
foregoing, the JEC shall have the following powers and duties with respect to the activities conducted pursuant to this Agreement or any Co-Promotion Agreement: 
 (a) to oversee the work of the Operating Committees; 
 (b) if possible, resolve disputes referred to the JEC by the Alliance Managers pursuant to Section 2.5; 
 (c) to approve each annual update and Significant Interim Update of the Commercialization Plan or the Commercialization Budget, as the
case may be; 
 (d) to approve Cost Allocation Proposals; 
 (e) to approve the JFC’s reports submitted hereunder on financial matters that the JEC designates for the implementation of the
financial aspects of the arrangements between the Parties and their Affiliates set forth herein with respect to the Exploitation of Territory Combination Product; 
 (f) to review recommendations of the JFC with respect to, and approve, one or more means of reconciling, one to the other, the internal
reporting and accounting standards of each of the Parties or its applicable Affiliates where reasonably necessary, and methods of charging costs and expenses of each of the Parties and its applicable Affiliates pursuant to this Agreement and the
Co-Promotion Agreements; 
 (g) to review and, if applicable, recommend to the Parties changes to the Pricing Rules and
Discount Rules pursuant to Section 4.1(g); 
 (h) to resolve disputes within the EUOC with respect to (i) the
initially proposed marketing materials for the Combination Product for each country in the Territory, and thereafter, updates of any Approved Marketing Materials, and (ii) a Party’s obligation, if any, pursuant to Section 5.11 to
provide the other Party with access to certain of such Party’s records, documentation and data; 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 18 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 (i) to decide major strategic issues and any other matters relating to the
collaboration between the Parties with respect to the Exploitation of Territory Combination Product that are not (i) within the purview of the EUOC, the JFC or the JLOCs or (ii) reserved to the Parties pursuant to this Agreement;

 (j) to consider any dispute referred to the JEC by a Party pursuant to Section 2.6; 
 (k) to determine, with respect to each country in the Territory (other than with respect to a Designated Territory A Country or a Third
Party Distributor Country, which, in each case, shall require mutual written agreement of the Parties to Launch the Combination Product in such country), whether Launch of the Combination Product in such country should occur and, if so, the timing
thereof (where the Parties acknowledge that as of the Effective Date, the Launch of the Combination Product in the United Kingdom and Germany has been approved); provided, however, that, at any time on or after the date on which all of
the Anticipated Agreements have been executed, in the case of any Price Approval Country or Reference Price Country (in each case, other than any Designated Territory A Country), subject to Section 5.1, the Selling Party shall have the right to
Launch the Combination Product at any time after the Approved Price that corresponds to the price at which the Combination Product is to be sold to wholesalers or others purchasing directly from the Selling Party in such country has been
established, provided that, in the case of a Price Approval Country, such Approved Price is at or above the Minimum Approved Price for such country; and 
 (l) to take such other actions as are reserved to the JEC in this Agreement or any Covered Agreement to which the Parties (or their
respective Affiliates) are parties or as the Parties may mutually agree in writing, except that the JEC may not amend or take any action that would conflict with any provision of this Agreement (or such Covered Agreement if applicable). 

Notwithstanding the enumerated authority of the JEC in this Agreement and the express reservation to the decision-making authority of the Parties with respect to
certain matters herein, in the event that the JEC, acting (i) by unanimous affirmative Member Votes (as defined in the US JV Operating Agreement) pursuant to Section 6.5(d) of the US JV Operating Agreement, or (ii) by unanimous
written consent pursuant to Section 6.5(c) of the US JV Operating Agreement, takes action on a matter relating to the Exploitation of Territory Combination Product, but with respect to which matter authority and responsibility have not been
delegated to or vested in the JEC hereunder, the Parties shall be deemed to waive (and each Party shall cause its Affiliates to waive) any objection to the effect that the JEC acted beyond the scope of its authority or responsibility, and the
resolution of such matter shall be binding on the Parties (and each Party shall cause its Affiliates to be bound) for purposes of this Agreement and any Co-Promotion Agreement. 
 2.3 Joint Finance Committee. Except as otherwise provided herein, the JFC shall be governed by, and shall act in accordance with,
Section 2.6(a) and Section 2.7 of the US JV Collaboration Agreement as if such Sections were incorporated herein. Subject to the oversight of the JEC, the JFC shall have the following powers and duties with respect to the activities
conducted pursuant to this Agreement or any Co-Promotion Agreement: 
 (a) to work with (i) the JEC, the EUOC and the
JLOCs to assist in financial, budgeting and planning matters as required, including assisting in the preparation of budgets and annual and long-term plans and (ii) to the extent applicable, to coordinate with the Joint European Finance
Committee with respect to expenses intended to be allocated on a Territory-wide basis and other matters covered by the Financial Agreement; 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 19 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 (b) in coordination with the EUOC, to oversee the work of the JLOCs; 
 (c) if possible, resolve disputes referred to the JFC by the Alliance Managers pursuant to Section 2.5 or by either Party (or any of
its Affiliates) pursuant to any applicable provisions of the Financial Agreement; 
 (d) to recommend, for approval by the
JEC, procedures, formats and timelines consistent with this Agreement for reporting financial data as well as additional or alternative reporting procedures concerning financial aspects of the arrangements between the Parties and their Affiliates
with respect to the Exploitation of Territory Combination Product; 
 (e) to prepare, for approval by the JEC, reports on such
financial matters as are designated by the JEC for the implementation of the financial aspects of the arrangements between the Parties and their Affiliates with respect to the Exploitation of Territory Combination Product; 
 (f) to make certain determinations and calculations set forth in the Financial Agreement, which determinations and calculations the JFC is
assigned to perform thereunder; 
 (g) to coordinate audits of financial data where appropriate and required or allowed by
this Agreement or any Covered Agreement to which the Parties or their respective Affiliates are parties; 
 (h) to address
issues of implementation relating to the financial mechanics and calculations under this Agreement and the Financial Agreement; 
 (i) to recommend, for approval by the JEC, a means of reconciling, one to the other, the internal reporting and accounting standards of each of the Parties where necessary and the methods of charging costs and expenses of each of the
Parties; 
 (j) to consider, upon request of Gilead Sub, and designate, if appropriate, any category of costs and expenses
incurred by or on behalf of Gilead Sub in connection with the performance of its obligations under the Product Supply Services Agreement, other than any category that is already included in the Manufacturing Fee or Authorized Expenses (in each case,
as defined in the Product Supply Services Agreement), as an “Approved Manufacturing Fee Category” or approved category of Authorized Expenses (as defined in such agreement), as applicable, for the Territory; 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 20 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 (k) to review the appropriate allocation of costs and expenses with respect to
Authorized Expenses, including any Cost Allocation Proposals, and to make recommendations to the JEC with respect to Cost Allocation Proposals; 
 (l) to calculate or cause to be calculated, as the case may be, those matters expressly required to be calculated (or caused to be calculated) by the JFC, if any, pursuant to this Agreement and, if applicable,
pursuant to any Co-Promotion Agreement; 
 (m) to provide updates on the JFC’s activities and achievements hereunder to
the JEC each Calendar Quarter; and 
 (n) to perform such other functions as the Parties may mutually agree in writing from
time to time or as the JEC may delegate from time to time. 
 2.4 EU Operating Committee. 
 The Parties shall establish the EUOC, which shall have certain responsibilities with respect to the Parties’ collaboration under this
Agreement, including to facilitate communications between the Parties with respect to the commercialization of Territory Combination Product, as set forth in this Section 2.4. 
 (a) Membership. Each Party shall appoint four (4) members of the EUOC. BMS shall appoint one (1) of the members
designated by BMS to serve as chairperson of the EUOC through the first anniversary of the Effective Date. Thereafter, a member designated by Gilead Sub and then a member designated by BMS shall serve alternately as chairperson, on a rotating annual
basis from each anniversary of the Effective Date. The initial EUOC members and the chairperson are identified in Annex B hereto. 
 (b) Authority. Subject to the oversight of the JEC, the EUOC shall have the following powers and duties: 
 (i) in coordination with the JFC, to oversee the work of the JLOCs; 
 (ii) if possible, resolve any disputes
referred to the EUOC by the Alliance Managers pursuant to Section 2.5; 
 (iii) to (A) review and propose to the JEC
for its approval each annual update and Significant Interim Update of the Commercialization Plan and Commercialization Budget and (B) review and approve each interim update other than any Significant Interim Update, in each case ((A) and (B))
proposed pursuant to Section 5.8; 
 (iv) to oversee and coordinate the Parties’ activities under the
Commercialization Plan; 
 (v) to oversee the distribution of Territory Combination Product; 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 21 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 (vi) to develop and approve (A) initial marketing materials for the Combination
Product in the Territory, and (B) updates to such materials from time to time as may be reasonably necessary or appropriate, all in accordance with Section 5.6; 
 (vii) to review any Cost Allocation Proposals and make recommendations to the JEC with respect to any such proposal; 
 (viii) to monitor whether the Combination Product is being sold at prices that are permitted by Section 4.1, the Pricing Rules and
the Discount Rules; 
 (ix) to coordinate matters relating to the Manufacturing and labeling of Territory Combination Product
(to the extent that such matters are not within the authority of the EDC) as set forth in Section 6.1; 
 (x) to oversee
the activities of any Third Party Distributors; 
 (xi) to resolve disputes between the Parties with respect to a Party’s
obligation, if any, pursuant to Section 5.11 to provide the other Party with access to certain of such Party’s records, documentation and data relating to the Commercialization Activities; 
 (xii) to oversee the forecasting of Local Demand for the Territory; 
 (xiii) consider and resolve any dispute referred to it by any JLOC pursuant to any Co-Promotion Agreement; 
 (xiv) to provide updates on the EUOC’s activities and achievements to the JEC each Calendar Quarter; 
 (xv) subject to the MAH Shareholder Agreement to the extent applicable, to oversee medical affairs and medical communication activities
with respect to Territory Combination Product; and 
 (xvi) to perform such other functions as the Parties may mutually agree
in writing from time to time or as the JEC may delegate from time to time. 
 (c) Member Qualifications. Any person
appointed to serve as a member of the EUOC shall have appropriate expertise and be otherwise qualified to serve in such capacity. A member of the EUOC may serve on any other (sub)committee established hereunder. The Parties shall endeavor to match
their respective representation on the EUOC in terms of functional areas and management level. 
 (d) Substitutions. A
member of the EUOC may be removed or replaced at any time, with or without cause, by the Party that appointed such member. Such action shall be accomplished by written notice to the other Party. Each member of the EUOC shall serve until a successor
is named by the Party that appointed such committee member (or until his or her earlier resignation or removal). 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 22 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 (e) Meetings. The EUOC shall meet at least once per Calendar Quarter until the
second anniversary of the date on which the Combination Product has been Launched in each country in the Territory in which Launch is anticipated to occur or on such other schedule as may be determined by the EUOC. The EUOC shall meet at times and
places mutually agreed by the members of the EUOC. The EUOC shall keep accurate and complete minutes of its meetings to record all proposals, recommendations and actions taken, which minutes shall be taken and approved as set forth in
Section 2.4(f). All such minutes and other records of the EUOC shall be available to each member of the EUOC and each Party. 
 (f) Notice and Agendas; Minutes. The Alliance Managers, in collaboration with the chairperson of the EUOC, shall organize committee meetings, prepare the meeting agenda based on items submitted by committee members, take or cause to
be taken accurate minutes of meetings, circulate draft minutes promptly after the meeting for approval by the members of such committee, and circulate final minutes to such members promptly following such approval. Notice of, and the agenda for,
each meeting (and any accompanying materials) shall be circulated to the members of the EUOC so that such materials are received reasonably in advance of such meeting. Any member of the EUOC may waive notice of a meeting thereof, and shall be deemed
to waive such notice if he or she attends the meeting and does not object to the meeting because of a lack of notice prior to its commencement. 
 (g) Quorum. At least three (3) members, including at least one (1) member appointed by each Party, shall be in attendance at a meeting of the EUOC to establish a quorum for the conduct of business.
The EUOC members may attend meetings in person or, as long as each attendee is able to hear the others, by telephone or by video conference equipment. 
 (h) Voting. Each member of the EUOC shall have one (1) vote on all matters to be acted upon by the EUOC. The EUOC shall take action with respect to a matter only if: (i) a quorum is present at the
time when such matter is to be acted upon by the EUOC; and (ii) the action proposed to be taken is approved by the affirmative vote of a majority of the EUOC members participating in such meeting, including the affirmative vote of at least one
EUOC member appointed by each Party. Notwithstanding the foregoing, the EUOC may also act by unanimous written consent of its members without a meeting. If the EUOC is unable to reach agreement on a matter properly presented to the EUOC for its
consideration, the matter shall be resolved as set forth in Section 2.6. 
 2.5 Alliance Managers. 
 (a) Gilead Sub and BMS shall each designate within their respective organizations an alliance manager (an “Alliance
Manager”) with responsibility for facilitating the interaction and cooperation between the Parties with respect to the activities conducted hereunder and under the Co-Promotion Agreements. The initial Alliance Managers are identified in
Annex B hereto. Each Party may change its Alliance Manager from time to time upon written notice to the other Party. 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 23 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 (b) The Alliance Managers shall not be members of the JEC or any Operating Committee.
The Alliance Managers shall attend all meetings of the JEC and the EUOC and support the chairpersons of the JEC and the EUOC in the discharge of their responsibilities hereunder. The Alliance Managers shall be nonvoting participants in such
meetings. Each Alliance Manager shall endeavor to create and maintain a collaborative work environment within and among the JEC, and the Operating Committees. In addition, with respect to the activities conducted hereunder and under the Co-Promotion
Agreements, each Alliance Manager: (i) shall coordinate the relevant functional representatives of the Parties; (iii) shall provide a single point of communication for seeking consensus both internally within the respective Parties’
organizations and between the Parties; (iv) shall identify and bring disputes relating to this Agreement or any Co-Promotion Agreement (other than any such disputes that, herein or in the applicable Co-Promotion Agreement, are expressly
excluded from the scope of Section 2.6) to the attention of the JEC or the applicable Operating Committee, as appropriate, in a timely manner; (v) shall plan and coordinate cooperative efforts and internal and external communications; and
(vi) shall take responsibility for ensuring that governance activities, such as the conduct of required JEC and Operating Committee meetings and production of meeting minutes, occur as set forth in this Agreement and in the Co-Promotion
Agreements and that relevant action items agreed upon at such meetings are appropriately carried out or otherwise addressed. 
 2.6
Resolution of Disputes. 
 (a) Disputes may be referred to the JEC for resolution, as follows: (i) if an Operating
Committee is unable to reach agreement on a matter properly presented to such Operating Committee for its decision, the Operating Committee shall refer the matter to the JEC; and (ii) either Party may refer to the JEC any issue arising under or
with respect to this Agreement or any Co-Promotion Agreement that is not covered by clause (i), other than (A) a dispute arising with respect to Forecasts or Supporting Data (which dispute shall be resolved as set forth in Section 6),
(B) a dispute with respect to a matter within the decision-making authority of the EU Pricing Discount Committee, or (C) a dispute that this Agreement (or the applicable Co-Promotion Agreement) expressly excludes from this
Section 2.6. 
 (b) If the JEC is unable to resolve a dispute referred to it by an Operating Committee or by a Party
pursuant to Section 2.6(a) within ten (10) days after such referral, or in the event that the JEC is unable to resolve a dispute arising within the JEC, then the dispute shall be referred for resolution to the Executives. 
 (c) If the Executives are unable to reach agreement on a disputed matter referred to them pursuant to Section 2.6(b) within ten
(10) days after such referral, then either Gilead Sub or BMS may refer the disputed matter to binding arbitration pursuant to Section 6.7 of the Standard Terms if and only if the disputed matter constitutes an Arbitration Matter.

 (d) Each Party shall, and shall cause its Affiliates to, refrain from exercising its rights to pursue arbitration under
Section 2.9(c)(A) of the US JV Collaboration Agreement with respect to any disputed matter arising under or with respect to this Agreement or any Co-Promotion Agreement. 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 24 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 (e) Notwithstanding anything in this Section 2.6 to the contrary, the dispute
resolution procedures set forth in Sections 2.6(a) through (c) shall not apply to any deadlock within the JEC or any Operating Committee resulting from a proposal by one Party’s member(s) to reverse or modify a decision of the JEC or such
Operating Committee with respect to a matter previously presented to it for decision, unless such proposal is based on new information or changed circumstances relevant to the applicable JEC or Operating Committee decision; provided,
however, that this Section 2.6(e) shall not apply to the deliberations and decisions of the EUOC pursuant to Section 5.6, or the deliberations and decisions of the JEC with respect to any disputes that arise within the EUOC with
respect thereto; and provided, further, that the EUOC’s and the JEC’s reconsideration of prior decisions with respect to the matters covered by the preceding proviso shall be governed by Section 5.6, and in the event of
any such reconsideration (and any dispute resolution and arbitration in connection therewith), the prior decision in force at the time of reconsideration shall remain in force and continue to apply until such time, if any, as a modified position may
be agreed by the EUOC or the JEC, or adopted by the Executives or, if applicable, the arbitrator(s), as the case may be. 
 (f) Nothing in this Section 2.6 shall affect the right of a Party to exercise its rights under Section 5.4(a) of the Standard Terms as incorporated herein with respect to a Material Default (as defined in the Standard Terms) by
the other Party concurrently with the exercise of its rights under this Section 2.6. In the event that, at any time prior to completion of the dispute resolution procedures set forth in this Section 2.6, the non-Breaching Party (as defined
in the Standard Terms) delivers a notice of Material Default to the Breaching Party, the cure period set forth in Section 5.4(a) of the Standard Terms shall begin to run upon the receipt of such notice and shall run concurrently with the
procedures set forth in this Section 2.6. 
 (g) The dispute resolution mechanisms set forth in this Section 2.6
shall be the sole method for resolving any Arbitration Matter or any other matter that is the subject of this Section 2.6. 
 2.7
Commercialization Budget Deadlocks; Commercialization Plan Deadlocks. Notwithstanding anything herein to the contrary, in the event of a Commercialization Budget Deadlock or a Commercialization Plan Deadlock, in each case with respect to any
period prior to the end of the Subsequent Launch Period, then in lieu of any other dispute resolution procedures set forth in this Agreement, the Parties agree that the dispute shall be conclusively resolved as follows: 
 (a) If a Commercialization Budget Deadlock arises with respect to the portion of the Commercialization Budget relating to a given country
(such portion, the “Country-Specific Commercialization Budget”) for a given Calendar Year (or part thereof) prior to the end of the Initial Launch Period with respect to such country, the level of aggregate expenditure for such
period with respect to such country shall be fixed, upon notice given by a Party to the other Party, at (i) in the case of disputes as to annual updates of such Country-Specific Commercialization Budget, the level of aggregate expenditure for
such period provided for in the Initial Launch Period Financial Commitment (apportioned, if appropriate, to account for a period in dispute that is shorter than twelve (12) months), or (ii) in the case of disputes as to interim updates of
any Country-Specific Commercialization Budget, the level of aggregate expenditure then in effect for the relevant part of the then-current Calendar Year in such Country-Specific Commercialization Budget. 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 25 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 (b) If a Commercialization Budget Deadlock arises with respect to any
Country-Specific Commercialization Budget for a given Calendar Year (or part thereof) during the Subsequent Launch Period with respect to such country, the level of aggregate expenditure for such period with respect to such country shall be fixed,
upon notice given by a Party to the other Party, at (A) in the case of disputes as to annual updates of such Country-Specific Commercialization Budget, seventy-five percent (75%) of the level of spending set forth in the Initial Launch
Period Financial Commitment for such country for the second twelve (12) month period of the Initial Launch Period for such country (apportioned, if appropriate, to account for a period in dispute that is shorter than twelve (12) months)
unless both Parties, through their respective representatives on the JEC have proposed levels of aggregate expenditure for such country for such period in dispute both of which are lower than the aforesaid seventy-five percent (75%) level, in
which case the level of aggregate expenditure for such period in dispute with respect to such country shall instead be fixed with respect to such country at the higher of the two levels of aggregate expenditure proposed for such period by the
Parties through their respective representatives on the JEC, or (B) in the case of disputes as to interim updates of such Country-Specific Commercialization Budget, the level of aggregate expenditure then in effect for the relevant part of the
current Calendar Year in such Country-Specific Commercialization Budget. 
 (c) For any period after the Subsequent Launch
Period with respect to a given country, any aggregate expenditures in the Country-Specific Commercialization Budget for such period for such country shall be decided by the mutual agreement in writing of the Parties; failure to reach agreement
thereon shall not be subject to dispute resolution pursuant to Section 2.6 or otherwise. 
 (d) Following the resolution
of any Commercialization Budget Deadlock pursuant to this Section 2.7 with respect to a given Calendar Year and a given country, the Parties agree to negotiate in good faith such modifications to the activities set forth in the applicable
Country-Specific Commercialization Plan as may be necessary in light of the modified Country-Specific Commercialization Budget. 
 (e) Any Commercialization Budget Deadlock that arises with respect to the Territory Centralized Budget for a given Calendar Year (or part thereof) prior to the end of the Initial Launch Period shall be resolved as set forth in
Section 2.7(a) (and Section 2.7(d) shall apply) as if (i) it were a Commercialization Budget Deadlock with respect to a given country, and (ii) the Territory Centralized Budget were a Country-Specific Commercialization Budget.

 (f) The Parties acknowledge and agree that the Territory Centralized Budget shall be established at a level of expenditure
that is reasonably necessary to support the Commercialization Activities being conducted with respect to the countries that have a Country-Specific Commercialization Plan in effect as described in Section 5.8(c). Accordingly, if a
Commercialization Budget Deadlock arises with respect to the Territory Centralized Budget for a given Calendar Year (or part thereof) during the Subsequent Launch Period, the Parties shall 

  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 26 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 
attempt to resolve such dispute based on such principle. If no such agreement can be reached, (i) in the case of disputes as to annual updates thereto,
the level of aggregate expenditure for the Territory Centralized Budget for such period shall be an amount that differs from the Territory Centralized Budget for the previous Calendar Year by the same percentage as the level of aggregate expenditure
set forth in the Country-Specific Commercialization Budgets differs from the level of aggregate expenditure set forth in the Country-Specific Commercialization Budgets for the previous Calendar Year, and (ii) in the case of disputes as to
interim updates to the Territory Centralized Budget, the level of aggregate expenditure for such period shall be the level of aggregate expenditure then in effect for the relevant part of the then-current Calendar Year in such Territory Centralized
Budget. (For example, if the Territory Centralized Budget for a given Calendar Year during the Subsequent Launch Period is in dispute and (A) level of expenditure in the Territory Centralized Budget for the prior Calendar Year was $1 million,
(B) level of expenditure in the Country-Specific Commercialization Budgets, in the aggregate, for such prior Calendar Year was $5 million and (C) the level of expenditure in the Country-Specific Commercialization Budgets, in the aggregate,
for the Calendar Year in dispute is $4 million, then the level of expenditure in the Territory Centralized Budget will be set at $800,000.) Further, Section 2.7(d) shall apply to such Territory Centralized Budget as if it were a
Country-Specific Commercialization Budget. 
 (g) For any period after the Subsequent Launch Period with respect to the
Territory Centralized Budget, any aggregate expenditures in the Territory Centralized Budget for such period shall be decided by the mutual agreement in writing of the Parties; failure to reach agreement thereon shall not be subject to dispute
resolution pursuant to Section 2.6 or otherwise. 
 (h) If a Commercialization Plan Deadlock arises with respect to the
Country-Specific Commercialization Plan for a given country for a given Calendar Year (or part thereof) prior to the end of the Initial Launch Period with respect to such country, the minimum number of Details for such period shall be fixed, upon
notice given by a Party to the other Party, at (i) in the case of disputes as to annual updates of such Country-Specific Commercialization Plan, the minimum number of Details for such country set forth in the Initial Launch Period Detail
Commitment for such period (apportioned, if appropriate, to account for a period in dispute that is shorter than twelve (12) months) with respect to such country, or (ii) in the case of disputes as to interim updates of such
Country-Specific Commercialization Plan, the minimum number of Details then in effect for such country for the relevant part of the then-current Calendar Year. For clarity, minimum Detail requirements are not required for any country in Territory A.

 (i) If a Commercialization Plan Deadlock arises with respect to the Country-Specific Commercialization Plan for any country
for a given Calendar Year (or part thereof) during the Subsequent Launch Period with respect to such country, (i) the minimum number of Details for such period with respect to such country shall be fixed, upon notice given by a Party to the
other Party, at (A) in the case of disputes as to annual updates of such Country-Specific Commercialization Plan, seventy-five percent (75%) of the minimum number of Details for such period for such country set forth in the Initial Launch
Period Financial Commitment for the second twelve (12) month period of the Initial Launch Period for such country (apportioned, if appropriate, to account for a period in dispute that is shorter than twelve (12) months) unless 

  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 27 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 
both Parties, through their respective representatives on the JEC have proposed minimum numbers of Details for such period in dispute both of which are lower
than the aforesaid seventy-five percent (75%) level, in which case the minimum number of Details for such period in dispute with respect to such country shall instead be fixed with respect to such country at the higher of the two minimum
numbers proposed by the Parties for such period in dispute through their respective representatives on the JEC, or (B) in the case of disputes as to interim updates of such Country-Specific Commercialization Plan, the minimum number of Details
then in effect for the relevant part of the current Calendar Year for such country in the Commercialization Plan. For clarity, minimum Detail requirements are not required for any country in Territory A. 
 (j) For any period commencing after the Subsequent Launch Period with respect to a given country, the minimum number of Details for such
country for such period shall be decided by the mutual agreement in writing of the Parties; failure to reach agreement thereon shall not be subject to dispute resolution pursuant to Section 2.6 or otherwise. 
 2.8 Relationship to Other Committees. The EUOC and, with respect to the Territory, the JEC and the JFC shall each coordinate with the EDC and any
other committees established pursuant to any Covered Agreement to which the Parties (or their respective Affiliates) are parties, as appropriate, and shall act in a manner consistent with the decisions of the EDC or any such other committee made
pursuant to the applicable agreement. 
 2.9 Committee-Related Expenses. Gilead Sub and BMS shall each bear its own expenses related
to the operations of the JEC, the Operating Committees and the JLOCs, including all expenses relating to the meetings of such committees, the participation of the Parties’ representatives in such meetings, communications with the other Party in
connection with such meetings or matters within the authority of the committees, and travel to and from such meetings, and such expenses shall not be deemed Authorized Expenses. 
 SECTION 3 
 REGULATORY MATTERS 
 3.1 Generally. This Section 3 shall govern any country-specific regulatory matters arising with respect to Territory Combination Product that
are not governed by Section 4.1 (and the Pricing Rules and the Discount Rules), the MAH Shareholder Agreement or the SDEA (any such regulatory matters, “Local Regulatory Matters”). In the event of a conflict between this
Section 3 and any provision of any of the foregoing agreements, such provision of such agreement shall control and this Agreement shall be construed in a manner consistent with such provision. For clarity, any Party that is the Local Regulatory
Lead with respect to any Third Party Distributor Country may delegate its responsibilities hereunder as the Local Regulatory Lead to the Third Party Distributor in such country. 
 3.2 Regulatory Filings. Under the oversight of the EUOC (which shall coordinate with the EDC as appropriate) and participation of each Party as
set forth in this Section 3, Gilead Sub and BMS (or their respective designated Affiliates) shall jointly prepare any submissions with respect to any Local Regulatory Matter and the Local Regulatory Lead shall have primary responsibility for
filing such submissions with the applicable Regulatory Authority. All 

  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 28 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 
submissions with respect to any Local Regulatory Matter shall be approved in advance by the applicable JLOC (or in the case in which (a) disclosing the
applicable submission to the JLOC would violate Section 3.3 or (b) there is no JLOC with respect to the applicable country in the Territory (e.g., in the case of a Sole-Promote Country), the EUOC). Each member of such committee
shall indicate, within a time period to be established by such committee with respect to the applicable submission, whether he or she approves such proposed submission; provided, that such time period shall, in each case, allow the Local
Regulatory Lead sufficient time to comply with Applicable Law and any deadlines required or reasonably requested by the applicable Regulatory Authority with respect to such submission. Notwithstanding the foregoing, the review and approval
requirements of this Section 3.2 shall not apply to any minor regulatory submissions of an administrative nature; provided, however, that the Local Regulatory Lead shall make copies of such submissions available to the other Party for
review promptly upon request of the other Party. 
 3.3 Regulatory Documentation. 
 (a) Notwithstanding the restrictions on use set forth in Section 5.4(b) of the MAH Shareholder Agreement, subject to
Section 3.3(d), each Party (and its Affiliates) shall have the right to use any BMS Regulatory Documentation and Gilead Regulatory Documentation (each, as defined in the MAH Shareholder Agreement) provided or made available pursuant to such
Section to the extent reasonably necessary to comply with Applicable Law. Further, without limitation of the foregoing, in the event that a Party desires to use such information of the other Party to perform its obligations hereunder and does not
have the right to use such information pursuant to the immediately preceding sentence, such first Party shall obtain the consent of such other Party, such consent not to be unreasonably withheld. 
 (b) Subject to Section 3.3(d), in the event that either Party (or any of its Affiliates) reasonably requires any information in the
possession and control of the other Party (other than any BMS Regulatory Documentation and Gilead Regulatory Documentation described in the foregoing clause (a)) to comply with Applicable Law, the Parties shall coordinate in good faith to ensure
that such information is provided by the applicable Party to the other Party for such purpose in a timely manner. Further, without limitation of the foregoing, in the event that a Party desires to use any such information of the other Party to
perform its obligations hereunder, such first Party shall obtain the consent of such other Party, such consent not to be unreasonably withheld, and if such consent is obtained, the consenting Party shall provide such information to such first Party.

 (c) In the event that a Party (or its EUOC representatives) does not provide the consent required pursuant to this
Section 3.3 to permit the other Party to obtain or use any BMS Regulatory Documentation, Gilead Regulatory Documentation or other information, or does not provide any such information, then, to the extent that such information is reasonably
required for the other Party to perform its obligations hereunder, such other Party shall not be obligated to perform such obligations. 
 (d) Notwithstanding anything in this Section 3.3 to the contrary, except as provided in this Section 3.3(d) or required by the SDEA, (i) Gilead Sub shall not provide or 

  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 29 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 
make available any BMS Regulatory Documentation or other information provided by BMS to Gilead Sub pursuant to this Section 3.3 that relates to EFV as
an API to any local country Affiliate of Gilead Sub without the prior written consent of BMS (or consent of its EUOC representatives), provided that such consent may not be unreasonably withheld if the information is required to be submitted
for regulatory or other legal reasons; and (ii) BMS shall not provide or make available any Gilead Regulatory Documentation or other information provided by Gilead Sub to BMS pursuant to this Section 3.3 that relates to either TDF or FTC
as an API, or to both, to any local country Affiliate of BMS without the prior written consent of Gilead Sub (or consent of its EUOC representatives), provided that such consent may not be unreasonably withheld if the information is required
to be submitted for regulatory or other legal reasons. Notwithstanding the foregoing, in the event that a local country Affiliate of a Party is required under Applicable Law to provide any of the foregoing information of the other Party to any
Regulatory Authority, such first Party shall be permitted to provide such information to such local country Affiliate if and only if (x) such first Party has first notified the other Party and allowed such other Party an opportunity to provide
such information directly to such Regulatory Authority, if and to the extent that such direct provision would fulfill such local country Affiliate’s obligation under Applicable Law, and (y) to the extent such information is Confidential
Information of the other Party, such first Party ensures that the information related to the other Party’s API(s) that is provided to a local country Affiliate of such first Party is only used for Permitted Purposes (as defined in the EU Master
Agreement) and in accordance with this Section 3.3 and not for any other purpose. In the event that a Party determines that it is reasonably necessary to provide any such information of the other Party to such first Party’s local country
Affiliate for the purpose of fulfilling such first Party’s obligations hereunder, such other Party shall consider a request of such Party to do so. Such other Party shall not unreasonably withhold or delay its request to any such request. If
such request is denied, for the avoidance of doubt, Section 3.3(c) shall apply. 
 (e) For the avoidance of doubt,
nothing set forth in this Section 3 or elsewhere in this Agreement shall be construed to limit the rights and obligations of the Parties or its Affiliates with respect to safety-related information, data or other documentation required to be
provided, maintained or disclosed pursuant to the SDEA. 
 3.4 Regulatory Communications. Communications regarding any Local
Regulatory Matter shall be treated (a) with respect to countries for which Gilead Sub is the Local Regulatory Lead, as if such communications were communications covered by Section 5.4(d) and Section 5.4(e) of the MAH Shareholder
Agreement, without giving effect to either such Section to the extent it affords the MAH any rights with respect thereto, or (b) with respect to countries for which BMS is the Local Regulatory Lead, as if BMS were the Regulatory Lead (as
defined in the MAH Shareholder Agreement) under the MAH Shareholder Agreement and as if such communications were communications covered by Section 5.4(d) and Section 5.4(e) of the MAH Shareholder Agreement, without giving effect to either
such Section to the extent it affords the MAH any rights with respect thereto. 
 3.5 Medical Affairs and Medical Communications.

 (a) Subject to this Section 3.5 and the MAH Shareholder Agreement, the Parties shall determine independently how to
utilize and deploy their respective medical science liaisons for activities relating to the Combination Product in each country in the Territory. 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 30 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 (b) Subject to the MAH Shareholder Agreement, the EUOC shall develop and approve
presentation materials for use by each Party’s medical science liaisons when engaging in activities to support the Combination Product. Each Party’s medical science liaisons shall use only such approved presentation materials and any
standard response documents approved pursuant to the MAH Shareholder Agreement in connection with such activities. The EUOC shall develop, and the Parties shall implement, procedures to coordinate the training of each Party’s medical science
liaisons on any approved presentation materials and standard response documents. 
 (c) Each Party shall cause its (and its
Affiliates’) medical science liaisons to comply with the provisions of this Section 3.5 and the MAH Shareholder Agreement. 
 3.6
Records. Each Party shall maintain, or cause to be maintained, records with respect to its activities pursuant to this Section 3 in sufficient detail and in material compliance with Applicable Law. Such records shall be retained
for at least (a) three (3) years or (b) such longer period as may be required by Applicable Law. 
 3.7 Compliance-Related
Matters. 
 (a) Role of QPPV. Notwithstanding anything herein to the contrary, nothing herein shall preclude the
QPPV (as defined in the MAH Shareholder Agreement) for the Combination Product from performing his or her obligations as QPPV for the Combination Product under Applicable Law and no such performance, to the extent reasonably required by Applicable
Law, shall constitute a breach of this Agreement by either Party. 
 (b) Certain Compliance Matters. Notwithstanding
anything herein to the contrary, and except as otherwise provided in the Co-Promotion Agreements, as between the Parties, each Party shall have sole responsibility for any submissions to, or communications with, any Regulatory Authority in the
Territory with respect to any matter relating to such Party’s or any of its Affiliates’ or subcontractors’ compliance with Applicable Law in connection with its performance of (i) such Party’s Commercialization Activities or
(ii) any other activities of such Party or any of its Affiliates or subcontractors under any Co-Promotion Agreement. Notwithstanding anything in this Section 3.7(b) to the contrary, the foregoing shall not apply to any submissions or
communications made in connection with obtaining or maintaining the applicable Territory Marketing Authorization. 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 31 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 3.8 Local Regulatory Expenses. Any external, out-of-pocket costs and expenses incurred by
either Party in connection with the performance of its obligations under this Section 3 (other than Section 3.7(b)) shall constitute Authorized Other Expenses. 
 SECTION 4 
 PRICING AND REIMBURSEMENT 
 4.1 Pricing and Reimbursement; Discounts. The provisions set forth in this Section 4.1 and Annex C shall apply to the pricing of Territory
Combination Product sold by the Selling Entity or any of its applicable Affiliates to any Third Party and shall not be construed to apply to the pricing of any other Combination Product (or any other sale). The Selling Party shall cause the Selling
Entity to sell the Combination Product at prices that comply with the determinations of the EU Pricing Discount Committee (as defined below) made pursuant to the provisions of this Section 4.1, the Pricing Rules and the Discount Rules.
Notwithstanding anything in this Section 4, the Pricing Rules or the Discount Rules, except to the extent mutually agreed in writing by the Parties, this Section 4.1, the Pricing Rules and the Discount Rules shall not apply with respect to
any Third Party Distributor Country. 
 (a) European Pricing Discount Committee. 
 (i) Each Party shall appoint two (2) members of a committee to determine any discounts to be applied in connection with the sale of
Territory Combination Product (the “EU Pricing Discount Committee” or “EPDC”). One (1) representative from each Party (the “Business Representative”) shall be an employee of such Party (or any
of its Affiliates) and shall not be, at the time of his or her appointment, or at any time during his or her service on the EPDC, otherwise involved, directly or indirectly, in the pricing of such Party’s (or any of its Affiliates’)
antiviral products (provided, that for purposes of this Section 4.1(a)(i), duties solely with respect to accounts receivable analysis, bookkeeping and accounting shall not, without more, be deemed involvement in pricing). The other
representative from each Party (the “Attorney Representative”) shall be an attorney for such Party. Such representatives shall have skills reasonably appropriate to their responsibilities and functions as members of the EPDC.
Furthermore, each Party covenants that, for twelve (12) months immediately after an individual’s service on the EPDC (or for such shorter period as he or she is employed by such Party or its Affiliate), he or she will not be assigned to a
function or position that involves, directly or indirectly, the pricing of such Party’s (or any of its Affiliates’) antiviral products. Each Party shall have the right to approve the other Party’s proposed Business Representative and
Attorney Representative on the EPDC (or any replacement therefor), which approval shall not be unreasonably withheld. Subject to the preceding sentence, each Party shall have the right to replace its Business Representative or Attorney
Representative from time to time during the term of this Agreement, provided that the composition of the EPDC as so changed meets the requirements set forth above in this Section 4.1(a)(i). For the avoidance of doubt, the EPDC is not an
Operating Committee. 
 (ii) Each Party shall be responsible for the performance of its representatives on the EPDC and their
compliance with the terms of this Section 4.1, the Pricing Rules and the Discount Rules. Any issue regarding the functioning of the EPDC shall be 

  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 32 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 
reviewed jointly by the Parties’ respective Attorney Representatives. Each Party shall bear its own expenses related to the EPDC, including all expenses
relating to the meetings of the EPDC, the participation of the Parties’ representatives in such meetings, communications with the other Party in connection with such meetings or matters within the authority of the EPDC, and travel to and from
such meetings, and such expenses shall not be deemed Authorized Expenses. 
 (iii) The EU Pricing Discount Committee shall
meet at least each Calendar Quarter (which meeting may be conducted by telephone or videoconference equipment, so long as each attendee is able to hear the others), and as otherwise required from time to time, to determine such matters as are within
the jurisdiction of the EU Pricing Discount Committee as set forth in this Section 4.1. 
 (iv) The EU Pricing Discount
Committee shall perform only such functions as are assigned to the EU Pricing Discount Committee hereunder. The EU Pricing Discount Committee shall apply the Discount Rules to make such calculations and determinations as are specified in the
Discount Rules. 
 (v) The representatives of each Party on the EU Pricing Discount Committee shall, in connection with any
proposed GOA with respect to a Customer, provide the EU Pricing Discount Committee with (A) if applicable, its Proposed Existing Customer Discount, and (B) such other limited pricing information, if any, with respect to such Customer as
the Attorney Representatives shall agree is necessary and appropriate. 
 (vi) In the event that interpretation or application
of the Discount Rules is necessary in order to implement the provisions of the Discount Rules, the Business Representatives shall discuss the matter with the Attorney Representatives and attempt to resolve the matter by consensus. In the event that
the Attorney Representatives disagree regarding any such interpretation or application, either Attorney Representative may refer the dispute to the JEC for resolution pursuant to Section 2.6. 
 (vii) The EU Pricing Discount Committee may determine, by consensus and in its sole discretion, to retain independent legal counsel, in
which case the expenses of such counsel shall be deemed to be Authorized Other Expenses. 
 (b) Default Rules and Related
Matters. 
 (i) In the event that, after following the procedures set forth in this Section 4.1, the Pricing Rules
and the Discount Rules, as applicable, to completion (including those set forth in Section 3 of Annex C, if applicable), the Parties are unable to agree upon (A) any modification of a Country Price for a given country, the existing Country
Price shall remain in effect, except in the case of a permitted modification to the existing Country Price pursuant to the Pricing Rules; or (B) a GOA (as defined below) with respect to a Customer, there shall be no GOA with respect to such
Customer, except in the case of a GOA that applies automatically to an Existing Discount Customer pursuant to Section 4.1(d) or in the event that a GOA has been previously established pursuant to the Discount Rules or in the case of a permitted
modification to the GOA with respect to a given Customer pursuant to this Section 4.1 

  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 33 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 
or the Discount Rules. In the event that there is no GOA with respect to a given Customer, the Selling Party shall not, and shall cause the Selling Entity
not to, enter into any contract with respect to the Combination Product with such Customer at a price less than the applicable Country Price. Further, in the event that the Parties cannot (x) reach agreement on a Country Price with respect to a
country other than a Price Approval Country or Reference Price Country, or (y) obtain any initial pricing approval required by a national pricing authority in a Price Approval Country [*] (as defined in Annex C), the Combination Product
shall not be Launched in such country. For clarity, Launch of the Combination Product in any Designated Territory A Country shall occur solely if and when approved by the Parties. Further, Launch in any Third Party Distributor Country or any country
for which BMS is the Selling Party shall occur solely as provided in Section 5.1. 
 (ii) Notwithstanding
Section 4.1(b)(i) or any other provision of this Agreement, in the event that, following the Launch of the Combination Product in a given Price Approval Country or Reference Price Country, any national pricing authority in such country reduces
(despite the commercially reasonable efforts of the Selling Party or without advance notice to the Selling Party) an Approved Price to a price that is [*] the Selling Party shall submit to the other Party, promptly following the date on which
the Selling Party becomes aware that such a reduction has been imposed and in no event less than twenty (20) Business Days after such date, the Selling Party’s good faith interpretation of how such reduced Approved Price should be
implemented and the effect of such reduced Approved Price on other prices with respect to the Combination Product in the country in which such Approved Price applies and on any Approved Prices in other countries in the Territory. If the non-Selling
Party, based on its good faith assessment, objects in writing within ten (10) Business Days that the Selling Party’s interpretation is incorrect, the dispute resolution provisions of Section 2.6 shall apply and, if such matter is not
resolved by the Executives within the time period set forth therein, the matter shall constitute an Arbitration Matter. Prior to the resolution of such matter pursuant to Section 2.6, the Selling Party shall continue to fulfill orders for the
Combination Product in the Territory (unless and until the Combination Product is withdrawn in such country by mutual written agreement of the Parties) and shall fulfill such orders at a price that is consistent with the Selling Party’s good
faith interpretation of any adjustment to the Country Price for the applicable country that shall be required to comply with the new Approved Price. Following the resolution of such matter pursuant to Section 2.6, the Country Price for the
applicable country shall be adjusted in accordance with such resolution. In the event that the non-Selling Party does not object to the Selling Party’s interpretation of any new Approved Price pursuant to this Section 4.1(b) within the
time period required for such objection, the Country Price with respect to the applicable country shall be adjusted to reflect the Selling Party’s interpretation of such new Approved Price. In no event shall (A) an incorrect interpretation
of any adjusted Approved Price, or the effect of such an adjustment on the Country Price, or (B) any sales by the Selling Party or the Selling Entity made based on such interpretation, constitute a breach of this Agreement, so long as such
interpretation was made in good faith by the Selling Party. 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 34 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 (c) Country Prices and Pricing Approvals. 
 (i) In each country in the Territory, the respective Selling Party shall cause the respective Selling Entity to sell Territory Combination
Product to any Third Party in such country at the Country Price for such country except as otherwise permitted in this Section 4.1, including Section 4.1(d). 
 (ii) For any country for which, as a matter of Applicable Law, the applicable Regulatory Authority approves a maximum reimbursement price
or a maximum price at which the Selling Party may sell the Combination Product in such country (each, a “Price Approval Country”), the Country Price (as defined in Annex C) shall be set in accordance with this
Section 4.1(c)(ii) and the Pricing Rules. Without limitation of any other country in the Territory that may constitute a Price Approval Country, the Parties acknowledge and agree that, as of the Effective Date, the United Kingdom, France, Italy
and Spain each constitute a Price Approval Country. Except as otherwise agreed by the Parties, the Selling Party shall be responsible for managing the negotiation with the relevant agency in each country relating to obtaining and maintaining such
reimbursement or other pricing approval. In conducting such negotiations, the Selling Party shall cooperate with the other Party and act in accordance with this Section 4.1(c)(ii) and the Pricing Rules. For each Price Approval Country, the
Selling Party with respect to such country shall be responsible for any reporting required in connection with obtaining and maintaining reimbursement or other pricing approvals for the Combination Product in such country and shall handle dealings
with any applicable agencies with respect to compliance with the rules, regulations and guidelines of such agencies with respect to obtaining and maintaining reimbursement or other pricing approvals for the Combination Product; provided,
however, that the Selling Party shall provide to the other Party a copy of the initial submission for obtaining reimbursement or other pricing approval for the Combination Product in each Price Approval Country in the Territory for review in
advance of its filing. The Selling Party shall promptly furnish the other Party with a copy of all materials received from such agencies, together with all reports and other communications submitted by the Selling Party to such agencies, in each
case solely to the extent relating to Territory Combination Product. In addition, at least five (5) Business Days prior to filing any periodic reports with such agencies pursuant to this Section 4.1(c)(ii), the Selling Party shall furnish
the other Party with a copy of such report. 
 (iii) For any country for which, as a matter of Applicable Law, the applicable
Regulatory Authority determines the maximum reimbursement price or the maximum price at which the Selling Party may sell the Combination Product using reference pricing based on the pricing of Combination Product in one or more other countries
(each, a “Reference Price Country”), the Selling Party shall notify the other Party promptly of the approved reference price (any such price, an “Approved Reference Price”) for the Combination Product in such
country once such price has been set, or thereafter modified by the Regulatory Authority in the country. The Country Price for any Reference Price Country shall be determined as set forth in Section 1(B) of the Pricing Rules. Without limitation
of any other country in the Territory that may constitute a Reference Price Country, the Parties acknowledge and agree that, as of the Effective Date, the Republic of Ireland constitutes a Reference Price Country. Except as otherwise agreed by the
Parties, the Selling Party shall be responsible for managing the discussions with the relevant agency in the Reference Price Country relating to obtaining and 

  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 35 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 
maintaining such reference pricing approval. For each Reference Price Country, the Selling Party with respect to such country shall be responsible for any
reporting required in connection with obtaining and maintaining reference pricing approvals for the Combination Product in such country and shall handle dealings with any applicable agencies with respect to compliance with the rules, regulations and
guidelines of such agencies with respect to obtaining and maintaining reference pricing approvals for the Combination Product; provided, however, that the Selling Party shall provide to the other Party a copy of the initial submission for
obtaining reference pricing approval for the Combination Product in each Reference Price Country in the Territory for review in advance of its filing. The Selling Party shall promptly furnish the other Party with a copy of all materials received
from such agencies, together with all reports and other communications submitted by the Selling Party to such agencies, in each case solely to the extent relating to Territory Combination Product in such country. In addition, at least five
(5) Business Days prior to filing any periodic reports with such agencies pursuant to this Section 4.1(c)(iii), the Selling Party shall furnish the other Party with a copy of such report. 
 (iv) Any country in the Territory for which the Country Price is not established pursuant to Section 4.1(c)(ii) or 4.1(c)(iii), the
Country Price for such country shall be determined based on Section 1(C) of the Pricing Rules. The Parties acknowledge and agree that, as of the Effective Date, Germany is governed by this Section 4.1(c)(iv) and Section 1(C) of the
Pricing Rules (which classification shall be without limitation of any other countries in the Territory that may be so governed). 
 (v) Prior to the commencement of pricing negotiations in any country in Territory A, the EUOC shall designate such country in the Territory as a Price Approval Country, a Reference Price Country, or a country for which the Country Price is
governed by Section 4.1(c)(iv). 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 36 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 (d) Customer Discounts. 
 (i) This Section 4.1(d) shall cover any request by any customer, whether a public or private entity (each, a
“Customer”), to purchase, or otherwise establish the price for any proposed sale of (e.g., in the case in which such entity is a third-party payor), the Combination Product at a price that is lower than the Country Price for
the applicable country (such price, a “Discounted Price”). The EU Pricing Discount Committee shall be responsible, on an on going basis, for calculating and providing to the Selling Party any grant of authority
(“GOA”) as calculated in accordance with this Section and the Discount Rules with respect to each Customer that seeks to obtain a Discounted Price. The GOA, if any, for each Customer shall serve as the maximum discount that may be
offered by the Selling Party (or its applicable Affiliate) in its negotiations with such Customer. The Selling Party shall cause the applicable Selling Entity not to sell any Territory Combination Product to any Customer at a price, or agree to a
reimbursement price for the Combination Product in connection with any formulary listing of a Customer, that is less than the price calculated by applying the GOA, if any, for such Customer. The term for any agreement to sell Combination Product to
a Customer at a Discounted Price shall not exceed [*] or, if applicable, such longer period as is agreed by the Parties pursuant to Section 2(D) of the Pricing Rules. 
 (ii) At least thirty (30) days prior to the Launch of the Combination Product in each country in the Territory (or such shorter
period as is mutually agreed by the Parties), each Party shall submit to the EPDC [*] 
 (iii) In the event that
any Customer, including an Existing Discount Customer, requests a Discounted Price, the Discount Rules shall apply. 
 (e)
Independent Accounting Expert. Either Party (the “Requesting Party”) may, upon written notice to the other Party, cause the Independent Accounting Expert to confirm the accuracy, with respect to any Customer, of (i) any
calculation by the EU Pricing Discount Committee or (ii) any pricing or discounting information provided to the EU Pricing Discount Committee or to the other Party pursuant to this Section 4.1, the Pricing Rules or the Discount Rules,
including any Net Component Price (as defined in Annex C) so provided. In such case, each Party and the EU Pricing Discount Committee shall cooperate with the Independent Accounting Expert and (upon the Independent Accounting Expert’s entry
into an appropriate confidentiality agreement) provide him or her with the data necessary to make the requisite calculations. Further, upon the written request of either Party, the calculations of the Independent Accounting Expert shall be audited
by a second Third Party mutually agreed by the Parties. The Independent Accounting Expert and the Third Party auditor, if any, shall notify the JEC of their respective determinations, which notifications shall not contain any information provided to
such Independent Accounting Expert (or such Third Party auditor) by either Party. The calculations made by the Independent Accounting Expert pursuant to this Section 4.1(e) shall be binding upon the EU Pricing Discount Committee and the
Parties; provided, however, that in the event that a Third Party auditor identifies a discrepancy in the Independent Accounting Expert’s calculations, the Parties shall cause the Independent Accounting Expert and such Third Party
auditor to confer and agree upon the final calculations and advise the Parties in writing of same, whereupon such final agreed calculations shall be binding on the Parties. The 

  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 37 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 
Requesting Party shall bear the fees and costs of the Independent Accounting Expert and any Third Party auditor in connection with his or her engagement
pursuant to this Section 4.1(e). Nothing in this Section 4.1(e) shall be deemed to limit any remedy available to either Party in the event of a breach of any of the provisions of this Section 4.1, the Pricing Rules or the Discount
Rules by the other Party. Notwithstanding anything in this Agreement to the contrary, such breach shall not be subject to the cure provisions set forth in Section 5.4 of the Standard Terms as incorporated herein. For clarity, Section 4.5,
and not this Section, governs the audit of the Net Selling Prices of Stocrin provided by Merck Parent or its applicable Affiliate. 
 (f) Pricing Information. All information provided to the EU Pricing Discount Committee that is not publicly available (“Territory Pricing Information”) shall be considered Confidential Information of the disclosing
Party and shall be used solely for the purpose of making the applicable calculation under the Discount Rules and setting any applicable GOAs and for no other purpose. Notwithstanding Section 4 of the EU Master Agreement, except as expressly
permitted by this Section 4.1, the Pricing Rules or the Discount Rules, each Party shall cause its representatives to not disclose any Territory Pricing Information of the other Party except to (i) counsel, the Independent Accounting
Expert, or any Third Party auditor selected pursuant to Section 4.1(e), or (ii) the extent permitted by Section 4.2(a) of the EU Master Agreement (but not any other subsection of Section 4.2 of the EU Master Agreement). All
Territory Pricing Information shall be segregated in locked or password protected files maintained by the EU Pricing Discount Committee, which files shall not be accessible by Persons other than the members of EU Pricing Discount Committee (and as
required, counsel, the Independent Accounting Expert and any Third Party auditor performing activities described in this Section 4). Without limiting the foregoing, each Party shall cause its representatives not to reference or use, directly or
indirectly, any information from the EU Pricing Discount Committee in pricing its or any of its Affiliate’s own products. 
 (g) Review of Rules. On an annual basis, or as requested by either Attorney Representative in the event that such representative believes that the Pricing Rules or the Discount Rules do not cover a scenario with respect to Territory
Combination Product that needs to be addressed, the JEC shall review the Pricing Rules and the Discount Rules (in each case, as most recently modified pursuant to this Section 4.1(g), if applicable) in light of the then-prevailing market
conditions and any marketing and sales strategies agreed by the Parties. If appropriate, the JEC shall recommend to the Parties changes to the Pricing Rules and the Discount Rules. For the avoidance of doubt, the JEC’s action or inaction under
this Section 4.1(g) shall not be subject to arbitration. If (and only if) the Parties agree in writing to any changes to the Pricing Rules or the Discount Rules, as the case may be, proposed by the JEC, then the Pricing Rules or the Discount Rules,
as applicable, as so changed shall be deemed to be the “Pricing Rules” or the “Discount Rules” hereunder. 
 4.2
Pricing and Other Contract Negotiations. 
 (a) As between the Parties (and their respective Affiliates), the
applicable Selling Entity (and its Affiliates) shall have sole responsibility for conducting pricing and discounting negotiations (and all other contracting matters) with respect to the Combination Product with Customers in the applicable country in
the Territory in accordance with the Pricing 

  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 38 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 
Rules; provided, however, that except as otherwise agreed by the Parties in writing, subject to Section 5.1, the Third Party Distributor in any
Third Party Distributor Country shall have all rights and responsibilities with respect to the foregoing activities. 
 (b)
Each Party shall ensure that none of its employees or contractors, other than a Designated Negotiator (as defined below), conduct any negotiations with any Customer in the Territory with respect to pricing or discounting matters (or any other terms
of any contract to be entered into between such a Customer and the applicable Selling Entity or its applicable Affiliate) with respect to the Combination Product (such matters, “Contracting Matters”) or discuss the availability of
discounts to such Customer (or any other matter with respect to discounts with respect to the Combination Product) without the prior consent of a Designated Negotiator. 
 (c) For each country other than a Third Party Distributor Country, a “Designated Negotiator” shall mean an employee(s) of
the applicable Selling Entity (or its applicable Affiliate) that has been authorized by the applicable Selling Entity (or such Affiliate), from time to time, to conduct price and discount negotiations with Customers in the applicable country in the
Territory. The applicable Selling Party shall cause the applicable Selling Entity to keep the non-Selling Party (or its applicable Affiliate) apprised, from time to time, of the names(s) and contact information for the Designated Negotiator(s).

 (d) In the event that any Customer desires to discuss any Contracting Matter, the non-Selling Party shall ensure that such
matter is referred to a Designated Negotiator (or in the case of a Third Party Distributor Country, the Third Party Distributor). 
 4.3
Consequence of Generic Launch on Pricing. The consequences of a Generic Version Launch on pricing and discounting shall be solely as set forth in the applicable sections of the Pricing Rules and Discount Rules. For the avoidance of
doubt, nothing in such sections shall be construed to modify the Parties’ respective rights and obligations with respect to the calculation of the Parties’ respective Country-Specific Percentages (as set forth in the Financial Agreement,
as modified by Section 8.5) with respect to the applicable country or any other related calculations under any other Covered Agreement. 
 4.4 Pricing of Single Agent Products/Double Agent Product. Gilead Sub and BMS shall each retain sole discretion with respect to price-setting and discounts for its respective Single Agent Products and Double Agent Product.
Notwithstanding the foregoing, each Party covenants that it shall act in good faith in setting the price and discounts for its respective Single Agent Products and Double Agent Product in the Territory and shall not directly or indirectly manipulate
pricing or discounting arrangements of its own Single Agent Products or Double Agent Product in the Territory solely or primarily for the purpose of increasing the Gilead Territory-Wide Percentage or the BMS Territory-Wide Percentage, as the case
may be, or any Country-Specific Percentage. 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 39 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 4.5 Net Selling Price of Stocrin Information. Unless and until BMS acquires rights to
commercialize Stocrin in the Territory, the following shall apply: 
 (a) BMS shall cause Merck Parent or its applicable
Affiliate to provide to BMS the Net Selling Price of Stocrin (600 mg dosage form) for each country in the Territory in which Stocrin is sold and BMS shall promptly provide to Gilead Sub any such information provided by Merck Parent or such Affiliate
thereof for use as set forth in this Section 4.5 (and for no other purpose). Such Net Selling Prices shall be provided for (i) the first three Calendar Quarters of each Calendar Year sixty (60) days prior to the end of such Calendar
Year or on such later date as such information is reasonably available and (ii) each Calendar Year within thirty (30) days following the end of such Calendar Year or on such later date as such information is reasonably available. Each such
Net Selling Price shall be calculated based on the definition of “Net Sales” set forth in the EFV License Agreement for the applicable country and period divided by the number of Units (as defined in the Financial Agreement) of Stocrin
(600 mg dosage form) sold in such country and period. In the event that the Stocrin (600 mg dosage form) is not on the market in a given country, BMS shall cause Merck Parent or its applicable Affiliate to provide the Net Selling Price of Stocrin
(200 mg dosage form) and Gilead and BMS shall negotiate in good faith to determine the manner of converting such Net Selling Price into a proxy for the Net Selling Price of Stocrin (600 mg dosage form) in such country for use in connection with
calculations hereunder and under any other Covered Agreement. 
 (b) Gilead Sub shall calculate, based on the Net Selling
Prices supplied by Merck Parent or its applicable Affiliate as described in the foregoing clause [*]. 
 (c) BMS
shall ensure that the EFV License Agreement permits an independent accountant acceptable to BMS and Gilead Sub to audit the Net Selling Price of Stocrin information provided by Merck Parent or its applicable Affiliate pursuant to the EFV License
Agreement at least once a Calendar Year (with a reasonable look-back period). Except as otherwise agreed by the Parties in writing, BMS shall invoke such audit right each Calendar Year for the Calendar Year information supplied by Merck Parent or
its applicable Affiliate with respect to the prior Calendar Year. Any reasonable costs and expenses incurred by BMS in connection with any such audit shall constitute Authorized Other Expenses. Gilead Sub shall be entitled to a copy of any
information provided by BMS by the independent accountant in connection with any such audit. The findings of the audit shall be binding on the Parties (and each Party shall cause such findings to be binding on its Affiliates). 
 (d) In the event that the independent accountant determines, pursuant to clause (c), that any Net Selling Price of Stocrin provided by
Merck Parent or its applicable Affiliate was inaccurate, the independent accountant shall calculate and provide to BMS and Gilead the correct Net Selling Price. Any calculations made based on the erroneous Net Selling Price hereunder or under any
other Covered Agreement shall be recalculated based on the correct Net Selling Price and any amounts due hereunder or under any Covered Agreement that were determined based on such calculations shall be adjusted and appropriate credit notes or
invoices shall be issued within thirty (30) days after the results of the audit are obtained by the Parties. Any such invoice shall be due thirty (30) days after such invoice is provided to a Party or its applicable Affiliate. Each Party
shall cause its Affiliates to be bound by the foregoing. 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 40 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 (e) Gilead Sub shall ensure that any information provided to it pursuant to this
Section 4.5 shall (i) not be shared with any of its or its Affiliates’ employees that is involved with the pricing or marketing strategies for any of its or its Affiliates’ HIV-related products, (ii) shall not be used for
any purpose other than those specified in this Section 4.5 and (iii) be treated as Proprietary Information (as defined in the EFV License Agreement as such agreement is in effect as of the Effective Date and as such definition has been
provided to Gilead Sub prior to the Effective Date) of Merck Parent (or its applicable Affiliate) in accordance with the EFV License Agreement (as such agreement is in effect as of the Effective Date) to the extent the applicable provisions of the
EFV License Agreement have been provided to Gilead Sub in writing prior to the Effective Date. 
 SECTION 5 
 COMMERCIALIZATION ACTIVITIES 
 5.1
Generally; Arrangements for Certain Territory A Countries. 
 (a) Generally. 
 (i) The Parties shall, and shall cause their respective Affiliates to, commercialize the Combination Product in the Territory in
accordance with this Section 5, the other terms of this Agreement, any applicable Co-Promotion Agreement and the MAH Shareholder Agreement. The Parties acknowledge the rights granted by the MAH to the Parties to commercialize the Combination
Product in the Territory. 
 (ii) Unless otherwise agreed by the Parties in writing, (A) Gilead Sub shall (and shall
cause its Affiliates to) sell all Combination Product purchased by Gilead Sub pursuant to the Product Supply Agreement solely in the Territory (or as otherwise mutually agreed by the Parties) in accordance with the terms of this Agreement and
(B) if applicable, BMS shall (and shall cause its Affiliates to) sell any Combination Product purchased by BMS or any of its Affiliates pursuant to any BMS Product Supply Agreement solely in the Territory and in accordance with the terms of
this Agreement and such BMS Product Supply Agreement. 
 (iii) Each of Gilead Sub and BMS shall comply, and shall cause its
Affiliates to comply, with Applicable Law, including the applicable Territory Marketing Authorization, in conducting their respective Commercialization Activities. 
 (iv) Promptly following the Effective Date, the Parties shall negotiate in good faith (A) to complete the designations set forth in
Annex L, (B) without limitation of the foregoing, to determine which Party shall be the Selling Party with respect to such country, and (C) to determine the supply arrangements with respect to such country, including any modifications to
the financial transactions set forth in the Covered Agreements as may be required to reflect such supply arrangements (provided that, in no event shall either Party be entitled to a distribution fee or other additional compensation or commission for
serving as the distributor in any such country (other than reimbursement for any Authorized Distribution Expenses to the extent provided herein) unless otherwise mutually agreed by the Parties). In connection with the foregoing, the Parties shall
amend this Agreement, including amending Annex L to specify the foregoing designations, and amend (or cause their respective Affiliates to amend) any other applicable Covered Agreement to reflect the Parties’ determinations with respect to the
foregoing and enter into any BMS Product Supply Agreement(s) that are determined to be required. 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 41 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 (v) Neither Party shall have any right or obligation to distribute, Promote, Launch,
or seek pricing approvals for the Combination Product in any Third Party Distributor Country until (A) the foregoing amendments with respect to such country have been made, (B) the Parties have complied with any other applicable
provision(s) of this Section 5.1, including Section 5.1(b), and (C) any applicable BMS Product Supply Agreement or Third Party Distributor Agreement (or modifications thereto) has been executed. Further, prior to Launch in any Third
Party Distributor Country, the Parties shall mutually agree in writing on the price at which the Combination Product will be sold to the Third Party Distributor for such country. 
 (vi) For any country other than (A) those countries in the Co-Promote Territory and (B) the Gilead Sole-Promote Countries, the
Parties agree that, until such time as the distributor for such country has been determined (i.e., a Selling Entity or Third Party Distributor has been designated for such country hereunder), the Parties shall specify an Affiliate of BMS,
designated by BMS, as the local distributor in any applicable regulatory filings with respect to the Combination Product in the Territory on or after the Effective Date and on any applicable Product SmPC, Labeling and Package Leaflets for the
Combination Product; provided, that the foregoing shall not apply to the extent and for so long as such designation is inconsistent with any Territory Marketing Authorization that may require the designation of Merck Parent (or its applicable
Affiliate) as the local distributor. 
 (b) Third Party Distributor Countries. 
 (i) It is anticipated that, for certain countries in the Territory, a Third Party distributor (“Third Party Distributor”)
will be engaged to distribute the Combination Product (such country, for so long as a Third Party is so engaged to distribute the Combination Product, a “Third Party Distributor Country”). 
 (ii) With respect to any anticipated Third Party Distributor Country, promptly following the Effective Date, the applicable Party shall
provide to the other Party redacted copies of its relevant existing agreement(s) with the anticipated Third Party Distributor and the proposed terms to be included in such agreement in connection with extending such agreement to cover the
Combination Product in the applicable country(ies) in the Territory. Such copies may be redacted to exclude provisions to the extent relating solely to products other than the Combination Product. Such Party shall provide the other Party an
opportunity to comment on the (anticipated) terms of such Third Party arrangements (including the applicable transfer price and the commercialization plan (including discounts to be offered to such Third Party Distributor, the volume thresholds
associated with such discounts, and initial launch pricing) and the term of the agreement(s) as it/they apply to the Combination Product) with respect to the Combination Product. In the event that the terms of such Third Party arrangements are
unacceptable to one of the Parties or one of the Parties notifies the other Party that it elects not to Launch the Combination Product in the applicable country, the anticipated Third Party Distributor shall not be granted the right to distribute
the Combination Product in such country. Further, the applicable Party shall provide the other Party an opportunity to comment on 

  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 42 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 
modifications to the relevant commercialization plan that the Third Party Distributor intends to adopt from time to time, and in the event that such
modifications are unacceptable to one of the Parties, then the applicable Party shall terminate such Third Party Distributor’s right to distribute the Combination Product in such country. For clarity, until such time as the Third Party
Distributor has the right to sell Combination Product in the applicable Third Party Distributor Country, the Parties shall make available Combination Product to Customers located in such country in a manner determined by the EUOC by way of sales by
a Selling Entity in another country in the Territory to the extent that orders are received from such country. 
 (iii) In no
event shall the Selling Party (A) extend the term of any Third Party Distributor Agreement (as the term applies to Territory Combination Product), (B) grant any further rights to any Third Party Distributor with respect to Territory
Combination Product, or (C) otherwise materially modify any Third Party Distributor Agreement as it relates to Territory Combination Product without the consent of the non-Selling Party. For the avoidance of doubt, nothing in this
Section 5.1(b)(iii) shall preclude either Party (or its applicable Affiliate) from negotiating, extending or modifying any Third Party Distributor Agreement (or any other agreement) as it applies to any of its products other than the
Combination Product. 
 (iv) In the event that one of the Parties desires to assume the responsibilities of distributor of the
Combination Product in any Third Party Distributor Country (e.g., in the case of expiration or termination of the Third Party arrangements), such Party shall notify the other Party as promptly as possible. (In the event that both Parties
desire to assume the responsibilities of distributor of the Combination Product in such country, the Parties shall negotiate in good faith to determine which Party would assume such responsibilities.) Promptly following receipt of such notice, the
Selling Party shall use commercially reasonable efforts to terminate such arrangement with such Third Party Distributor with respect to distribution of the Combination Product in such country. Upon expiration or termination of the applicable
agreement(s) with the Third Party Distributor (as they relate to Territory Combination Product), the applicable Party shall become the Sole Promoting Party (and the distributor) in such country. 
 (v) For clarity, Third Party Distributor Countries shall include only those countries with respect to which the Combination Product is
sold to a Third Party Distributor and shall not include any country as a result of the Selling Party’s engagement of a Distribution Subcontractor. 
 (vi) The Parties shall (and shall cause their respective Affiliates to) negotiate in good faith appropriate amendments to this Agreement and any other applicable Covered Agreement to ensure that the transfer price
obtained from any Third Party Distributor in connection with its purchase of Territory Combination Product, taking account of any permitted discounts, is apportioned between the Parties (or their respective Affiliates) in a manner consistent with
the apportionment of Net Sales (as defined in the Financial Agreement) of the Combination Product between the Parties (or their respective Affiliates) pursuant to the Covered Agreements. 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 43 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 (c) Promotion Rights. Subject to this Section 5.1 (and any restrictions
on Launch set forth therein), both Parties shall have the right to Promote the Combination Product in each country in the Territory (other than any Third Party Distributor Country, in which country neither Party shall Promote the Combination Product
without the written consent of the other Party); provided, that the non-Sole Promoting Party shall have the right to Promote the Combination Product in the other Party’s Sole-Promote Countries pursuant to this Section 5.1(c) only.
With respect to any Sole-Promote Country, the non-Sole Promoting Party shall have the right to commence co-Promotion of Territory Combination Product in such country upon ninety (90) days’ written notice to the Sole Promoting Party, which
notice shall specify the date on which such non-Sole Promoting Party intends to commence such Promotion; provided, that such non-Sole Promoting Party shall not have the right to commence such co-Promotion until the date on which such non-Sole
Promoting Party has established an HIV sales force in such country. Upon such notice, the Parties shall negotiate in good faith and, prior to the anticipated date on which such non-Sole Promoting Party (or any of its Affiliates) will commence
co-Promotion of the Combination Product in such country, enter into (i) a Co-Promotion Agreement (as defined below) with respect to such country, and (ii) any appropriate amendments to this Agreement and any other applicable Covered
Agreement then in effect, including the Financial Agreement, to reflect such non-Sole Promoting Party’s co-Promotion of the Combination Product in such country, including any updates to the Commercialization Plan and the Commercialization
Budget, if applicable, for such country commencing as of the date on which such non-Sole Promoting Party commences co-Promotion of the Combination Product in such country. 
 (d) [*] 
 5.2 Co-Promotion
Agreements. Prior to the Launch of the Combination Product in each country in the Co-Promote Territory, Gilead Sub and BMS shall cause their applicable Affiliates to, enter into a co-promotion agreement with respect to the co-promotion of
the Combination Product in such country substantially in the form of the agreement set forth in Annex D (each such agreement, a “Co-Promotion Agreement”). 
 5.3 Promotion Obligations. 
 (a) Generally. Without limitation of Section 5.2, Gilead Sub and BMS each shall use Commercially Reasonable Efforts to perform in each country in the Territory (other than any Third Party Distributor Country) the
Commercialization Activities that such Party is required to perform under the Commercialization Plan in accordance with the Commercialization Budget, for so long as there is a Commercialization Plan in effect. Subject to the Commercialization Plan
and, in the case of any country in the Co-Promote Territory, the applicable Co-Promotion Agreement, each Party and any of its Affiliates that has the right to Promote the Combination Product in a given country shall be free to (i) engage in
Details in such country in its sole discretion, and (ii) select independently the target prescribers to which it shall Promote the Combination Product in such country. Gilead Sub and BMS shall each Detail the Combination Product and perform its
other Promotional activities under this Agreement in the Territory in strict adherence with Applicable Law and any professional requirements, including those relating to promotion of pharmaceutical products, consumer protection, fraud and abuse and
false claims. Gilead Sub and BMS shall each cause its Field Force to (A) comply with Section 5.6 and (B) make only such statements and claims regarding the Combination Product as are consistent with Applicable Law and the applicable
Product SmPC, Labeling and Package Leaflets. The Parties shall agree in good faith on appropriate metrics for tracking and assessing the performance and effectiveness of the Parties’ respective Commercialization Activities of the Parties and
their applicable Affiliates. 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 44 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 (b) Countries without Minimum Detail Requirements. Without limitation of the
foregoing clause (a), each Party shall use Commercially Reasonable Efforts to Promote the Combination Product in any Territory A Country (other than a Third Party Distributor Country). Not performing any Details in any Sole-Promote Country may be
consistent with such level of effort; provided, however, in the event the Sole Promoting Party determines not to perform any Details in a given country (or to cease performing Details in such country), it shall notify the other Party of such
determination. 
 5.4 Distribution Obligations and Related Matters. 
 (a) Except in the case of any Third Party Distributor Country, each Party (or its applicable Affiliate) shall have the sole responsibility
and right to fill orders with respect to the Combination Product in each country in the Territory for which it is the Selling Party (“Territory Customer Orders”). If for any reason the non-Selling Party or any of its Affiliates with
respect to a given country receives a Territory Customer Order for the Combination Product from a Customer located in such country, such Party shall, or shall cause such Affiliate to, promptly forward such order to the Selling Party (or its
applicable Affiliate), or to the applicable Third Party Distributor in such country approved pursuant to Section 5.1, if any. 
 (b) Without limitation of Section 5.4(a), the Selling Party shall perform the following activities with respect to sales of the Combination Product in each country in the Territory for which it is the Selling Party: inventory
management and control, warehousing and distribution, invoicing, collection of sales proceeds, preparation of sales records and reports, customer relations and services, the handling of returns, and such other activities for which the Selling Party
has responsibility pursuant to Annex E, if any, in each case in accordance with the terms set forth in Annex E and, to the extent not inconsistent therewith, customary practice in the pharmaceutical industry. 
 (c) Any reasonable, external, out-of-pocket expenses incurred by the applicable Selling Party in connection with the performance of its
activities conducted pursuant to this Section 5.4 (and Annex E) (including any amounts paid to any Distribution Subcontractor (as defined in Annex E) but subject to the remainder of this Section 5.4, and excluding any expenses incurred by
the applicable Selling Party’s Third Party Distributor, if applicable) shall constitute “Authorized Distribution Expenses”. Without limitation of the foregoing, any shipping and warehousing costs incurred by or on behalf of
either Party or any Affiliate thereof in connection with the shipping of Territory Combination Product to the applicable Customer or warehousing of Territory Combination Product after it is sold to Gilead Sub pursuant to the Product Supply Agreement
or to BMS or its applicable Affiliate pursuant to any BMS Product Supply Agreement shall constitute Authorized Distribution Expenses (and not Local Expenses under any Co-Promotion Agreement). Notwithstanding the foregoing, in the event that a
Distribution Subcontractor is engaged to perform certain activities (other than shipping) in a given country, (i) the amount to be paid to such Distribution Subcontractor for performing such 

  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 45 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 
activities, or if such amount is not fixed, the basis for calculating such amount, shall be provided to the other Party and the JFC prior to the engagement
of such Distribution Subcontractor to perform such activities, and (ii) the amounts paid to such Distribution Subcontractor shall constitute Authorized Distribution Expenses to the extent that the JFC determines that such amounts are
reasonable, which determination the JFC shall make by comparing such amounts to the amounts that BMS pays to its subcontractors for the same activities in such country or a similar country or, if not available, an appropriate benchmark selected by
the JFC. For the avoidance of doubt, Authorized Distribution Expenses shall not include any expenses that are reimbursable pursuant to any Co-Promotion Agreement. 
 5.5 [*] 
 5.6 Marketing Materials. Subject to the remainder of this Section 5.6,
each Party’s Promotion of the Combination Product in the Territory shall be in accordance with the Approved Marketing Materials (as defined below) (including any localized version thereof) and the applicable Product SmPC, Labeling and Package
Leaflets for the Combination Product; provided, however, that subject to the foregoing (and any applicable provisions of the Co-Promotion Agreements), each Party (and its Affiliates) shall have a right to position the Combination
Product within its HIV product portfolio in its sole discretion. Except as otherwise provided in this Section 5.6, each Party shall use the Approved Marketing Materials (and only the Approved Marketing Materials) for a given country in the
Territory, together with the applicable Product SmPC, Labeling and Package Leaflets, in Promoting the Combination Product in such country. In the absence of any Approved Marketing Materials for a given country in the Territory, each Party shall
Promote the Combination Product in such country using only the applicable Product SmPC, Labeling and Package Leaflets for the Combination Product. The obligations set forth in this Section 5.6 shall be without limitation of any obligations of
any Parties or its Affiliates set forth in the provisions of the MAH Shareholder Agreement with respect to Marketing Materials (as defined in such agreement), advertising and promotional compliance, and Combination Product Trademarks (as defined in
such agreement). The Parties agree that, subject to any applicable provisions of the MAH Shareholder Agreement, the applicable Product SmPC, Labeling and Package Leaflets for Territory Combination Product and any Approved Marketing Materials shall
include the two names “Bristol-Myers Squibb” and “Gilead Sciences” displayed with equal prominence, to the extent permitted by Applicable Law. Except as otherwise mutually agreed by the Parties in writing, any Party that is a
party to a Third Party Distributor Agreement shall cause its Third Party Distributor to (i) use only the Approved Marketing Materials (which may be localized by the Third Party Distributor for the applicable country provided that no material
modification is made in connection therewith) and the applicable Product SmPC, Labeling and Package Leaflets to Promote the Combination Product in the applicable countries and (ii) Promote the Combination Product in accordance with Applicable
Law. 
 (a) The EUOC shall develop and approve an initial set of advertising and promotional materials for the Combination
Product for use in each country in the Territory. If the EUOC cannot reach agreement with respect to such materials, the JEC shall attempt to resolve any disputed issues relating to the materials. Any such materials approved by the EUOC 

  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 46 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 
or the JEC pursuant to this Section 5.6(a) with respect to a given country (and any updates thereto approved pursuant to Section 5.6(b) or
Section 5.6(c)) shall be deemed “Approved Marketing Materials” with respect to such country. Further, any localization of any Approved Marketing Materials shall constitute Approved Marketing Materials without requiring approval
of the EUOC; provided, that such localization is limited to translation and other non-material modifications. (Any material modifications made to the Approved Marketing Materials in the course of localization shall require the approval of the
EUOC pursuant to this Section 5.6.) 
 (b) Each Party may propose interim updates to the Approved Marketing Materials for
each country in the Territory from time to time, independent of the semi-annual reviews conducted pursuant to Section 5.6(e). The EUOC shall be required to consider, and shall adopt, such updates only if they satisfy the following conditions:
(i) the update is based on relevant new scientific, medical or clinical data, relevant new regulatory or legal developments, or changes to the applicable Product SmPC, Labeling and Package Leaflets for the Combination Product; and (ii) in
the absence of such update, the use of the Approved Marketing Materials would not comply with Applicable Law (any update satisfying such conditions, a “Required Update”). 
 (c) Approximately six (6) months after the Launch of the Combination Product in a country in the Territory, the EUOC, as applicable,
shall review and, if appropriate, update the Approved Marketing Materials, if any, for such country. Such updates shall include, at a minimum, any Required Updates. If the EUOC cannot reach agreement on a Required Update proposed by a Party, then
the matter shall be referred to the JEC and shall be subject to dispute resolution under Section 2.6. In the event that none of the EUOC, the JEC, and the Executives is/are able to reach agreement on a proposed Required Update, and after the
conclusion of any arbitration relating to Required Updates, each Party may elect upon written notice to the other Party to Promote the Combination Product in such country using (i) the applicable Product SmPC, Labeling and Package Leaflets for
the Combination Product alone or (ii) the applicable Product SmPC, Labeling and Package Leaflets for the Combination Product or the Approved Marketing Materials as modified to reflect any Required Updates (as finally determined by the
arbitrator(s), as applicable). 
 (d) In connection with the review conducted pursuant to Section 5.6(c), the EUOC may
make other appropriate changes arising from business or other considerations (each, an “Optional Update”) as proposed by a Party. In the event that the EUOC cannot reach agreement on any proposed Optional Update to the Approved
Marketing Materials for a country in the Territory, then the dispute shall be referred to the JEC and shall be subject to dispute resolution under Section 2.6; provided, however, that for the avoidance of doubt, the dispute shall
not constitute an Arbitration Matter. In the event that none of the EUOC, the JEC, and the Executives is/are able to reach agreement on a proposed Optional Update, each Party may elect upon written notice to the other Party to Promote the
Combination Product in such country using (i) the applicable Product SmPC, Labeling and Package Leaflets for the Combination Product alone or (ii) the applicable Product SmPC, Labeling and Package Leaflets for the Combination Product or
the Approved Marketing Materials without such Optional Update. 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 47 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 (e) Following the review conducted pursuant to Section 5.6(c), the EUOC shall
review the Approved Marketing Materials on a semi-annual basis and shall make Required Updates and consider any Optional Updates proposed by a Party. Any disputes within the EUOC relating to such updates shall be resolved using the procedures set
forth in Sections 5.6(c) and 5.6(d), as applicable. 
 (f) The EUOC shall (i) select an advertising agency or agencies to
assist with the Marketing of the Combination Product in each country in the Territory and (ii) oversee the activities of such agency or agencies. The EUOC shall determine the Party that shall contract with each such agency, which Party shall
enter into a contract with such agency on commercially reasonable terms, and the Parties shall include the external, out-of-pocket costs and expenses anticipated to be incurred in connection with such contract in the Commercialization Budget.

 (g) The EUOC shall develop, implement and oversee an orderly, systematic process, involving representatives from the legal,
medical and regulatory functions of each Party, for the review and approval of advertising and promotional materials to be used in each country in the Territory. 
 (h) Without prejudice to the other provisions of this Section 5.6, with respect to Approved Marketing Materials for use in
any country in the Territory, Gilead Sub shall be responsible for obtaining and maintaining any governmental approvals required with respect to the use of such Approved Marketing Materials and, for the avoidance of doubt, shall have
the right to file for routine renewal of any such approvals annually without approval of the JEC or any Operating Committee. 
 5.7 Use of
Trademarks. Each Party shall conduct its activities hereunder in a manner consistent with Section the provisions of the MAH Shareholder Agreement with respect to Combination Product Trademarks (as defined is such agreement). 
 5.8 Commercialization Plan and Budget. 
 (a) The Commercialization Plan shall (i) be developed on a country-by-country basis and, with respect to Territory Centralized Expenses and related activities, a Territory-wide basis, (ii) specify any
Territory-wide activities and country-specific activities to be conducted in each country in the Territory, which country-specific activities shall be mutually agreed by the parties to the applicable Co-Promotion Agreement, if any, in accordance
with such agreement, subject to any applicable provisions of this Agreement, and (iii) cover only activities for commercialization of Territory Combination Product that shall be conducted by or on behalf of one Party or its applicable Affiliate
or that must be coordinated between the Parties or their respective Affiliates hereunder or under any Co-Promotion Agreement, which activities shall conform to the other terms of this Agreement, including the provisions of this Section 5 and
the Co-Promotion Agreement, if any, for the applicable country. Such plan shall specify (A) such activities and (B) the Party that shall take the lead role with respect to such activities on a country-by-country basis (or Territory-wide
basis, if applicable). 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 48 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 (b) The initial Commercialization Plan attached hereto as Annex F covers Calendar
Years 2006, 2007 and 2008 (such plan, as updated from time to time in accordance with this Section 5.8, the “Commercialization Plan”) for certain countries in the Territory. From time to time, the Parties or the JEC shall amend
the Commercialization Plan to include each other country in the Territory prior to the anticipated date of Launch in such country. The Commercialization Plan and any update thereto shall contain a budget for each Party’s out-of-pocket expenses
for such Party’s activities set forth therein (such budget, the “Commercialization Budget”), which budget shall be set forth on a country-by-country basis (for the countries included in the Commercialization Plan) and with
respect to Territory Centralized Expenses, on a Territory-wide basis. The initial Commercialization Plan covers, and any updates thereto shall cover (i) unit volume and market share forecasts for the Combination Product in each country in the
Territory that is included in the Commercialization Plan for the foregoing period, (ii) certain Marketing and other commercialization activities for the Combination Product that are required to be conducted in each such country by or on behalf
of one Party or its applicable Affiliate or that must be coordinated between the Parties or their respective Affiliates hereunder or under the applicable Co-Promotion Agreement, (iii) the total minimum number of Details by each Party in each
country in the Territory in each Calendar Quarter (or part thereof); provided, however, that, without limitation of the obligations of each Party set forth in Section 5.3 to use Commercially Reasonable Efforts to perform such
Party’s Commercialization Activities and to Promote the Territory Combination Product, no minimum number of Details are required for any country in Territory A; and (iv) any other matters or activities determined by the EUOC. With respect
to each country, except as otherwise agreed by the JEC or by the Parties in writing, the total amount included in the Country-Specific Commercialization Budget for the Initial Launch Period for such country shall be at least the amount of the
Initial Launch Period Financial Commitment for such country. 
 (c) For each Calendar Year commencing with Calendar Year 2009
(other than (i) any such Calendar Year for which the Parties agree that there shall be no Commercialization Plan or Commercialization Budget or (ii) any such Calendar Year that follows a Calendar Year in which the Commercialization Budget
is zero), the Parties shall jointly prepare, based on country-by-country plans and budgets developed by the JLOCs pursuant to the Co-Promotion Agreements or as otherwise agreed by the Parties, any proposed updates to the Commercialization Plan and
Commercialization Budget (which updates shall be prepared in sufficient time to permit Gilead Sub to submit, in a timely manner, such updates to the EUOC and the JFC in accordance with this Section 5.8(c)). Gilead Sub shall submit to the EUOC
and the JFC, not less than sixty (60) days prior to the start of each Calendar Year for such Calendar Year, any jointly-agreed proposed updates to the Commercialization Plan and Budget. In the event that Gilead Sub and BMS fail to reach
agreement with respect to any such proposed updates, each Party shall submit its proposed updates to the EUOC and the JFC by the deadline set forth in the immediately preceding sentence. The JFC shall provide its comments on any Commercialization
Budget submitted to the JFC to the EUOC, for its consideration, within ten (10) Business Days following such submission. Following review, discussion and appropriate revision of such proposed update, no later than forty-five (45) days
prior to the start of the applicable Calendar Year, the EUOC shall (A) agree upon an update to propose to the JEC and submit such proposed update to the JEC, or (B) in the event the EUOC cannot reach agreement on such any such proposed
update, to submit to the JEC the proposed update submitted by Gilead Sub (or each Party) to the EUOC pursuant to this Section 5.8(c) and any other relevant materials, including any comments that the JFC and either Party’s EUOC members may
have on such proposed update, so as to enable the JEC to reach agreement with respect to such an update. 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 49 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 (d) Without limitation to the annual updates covered by Section 5.8(c), either
Party, directly or through its representatives on the EUOC, as the case may be, may propose interim updates to the Commercialization Plan and the Commercialization Budget to the EUOC from time to time as appropriate in light of changed
circumstances. The EUOC shall review, discuss and revise, as appropriate, any such proposed update at its next quarterly meeting. In the event that any such proposed update would cause the updated Commercialization Budget to exceed one hundred and
five percent (105%) of the Commercialization Budget most recently approved by the JEC pursuant to Section 5.8(c) (a “Significant Interim Update”), the EUOC shall forward such proposed update, with its recommendation, if
any, with respect to such proposed update, to the JEC for review and approval. In the event that such proposed update is not a Significant Interim Update, including in the case in which the proposed update would reallocate funds between or among two
or more countries in the Territory, but not increase the Commercialization Budget beyond the foregoing threshold, the EUOC shall determine whether or not to approve such proposed update, which determination shall be final and not subject to dispute
resolution pursuant to Section 2.6. 
 (e) Subject to Section 2.2(c) and Section 2.7, if a proposed update to
the Commercialization Plan or Commercialization Budget is not approved by the JEC (or if applicable, the EUOC), then such Commercialization Plan or Commercialization Budget, as the case may be, shall continue in effect as approved and most recently
updated pursuant to this Section 5.8. 
 5.9 Commercialization Expenses. The Parties agree that any expenses incurred by a Party
or any of its Affiliates in connection with the performance of its respective Commercialization Activities hereunder or under any Co-Promotion Agreement shall constitute “Authorized Commercialization Expenses” solely to the extent
that such expenses are Territory Centralized Expenses and: (a) such Commercialization Activities are covered in and consistent with the Territory Centralized Plan and are within an area of responsibility for such Party listed in the Territory
Centralized Budget and are not eligible for sharing or reimbursement pursuant to any Co-Promotion Agreement; (b) the total expenses for such Party’s designated activities under the Territory Centralized Plan for the relevant period do not
exceed the aggregate amount set forth in the Territory Centralized Budget for such activities in such period; (c) the expenses are external, out-of-pocket costs of such Party or Affiliate, without any markup, and not internal costs, including
internal costs incurred in maintaining or operating a Field Force or marketing organization (including marketing personnel and sales support personnel); and (d) the relevant Commercialization Activities are for the Marketing of the Combination
Product in the Territory only and not for the Marketing of any other proprietary products of such Party or any of its Affiliates. The Parties acknowledge and agree that certain of the activities set forth in the Commercialization Plan may have been
performed prior to the Effective Date under the Interim Agreement and that the costs and expenses associated therewith shall be reimbursable under this Agreement as Authorized Commercialization Expenses to the extent that they satisfy the foregoing
criteria. Notwithstanding the limitation contained in clause (d) above, in the event that 

  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 50 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 
either Party reasonably believes that there are cost or other efficiencies that can reasonably be expected to be achieved through one or both Parties’
conducting Commercialization Activities with respect to the Combination Product as part of, or in coordination with, activities being conducted by one or both Parties with respect to its or their Single Agent Product(s) or Double Agent Product, such
Party(ies) may propose, by and through its applicable EUOC member(s), that such activities be coordinated and an appropriate and reasonable allocation of the related costs be made between the Combination Product, on the one hand, and such other
product or products, on the other hand, and that the amount allocated to the Combination Product be treated as Authorized Commercialization Expenses (each such proposal, a “Cost Allocation Proposal”). If, and only to the extent that, such
Cost Allocation Proposal is reviewed by the EUOC and JFC and approved by the JEC (with any modifications made by the JEC), the amount approved by the JEC for allocation to the Combination Product shall constitute Authorized Commercialization
Expenses. 
 5.10 Reports. Except as otherwise agreed by the EUOC, with respect to each country in the Territory, Gilead Sub and BMS
shall each present to the other, at a meeting of the EUOC at least once per Calendar Quarter until the second anniversary of the Launch of the Combination Product in such country and, thereafter, at a meeting of the EUOC at least semiannually, a
report (oral and written, which written report shall not be required to contain more detail than that typically included in an executive summary) describing (a) the Commercialization Activities it has performed, or caused to be performed,
including Details, since the preceding meeting at which such a report was presented (or, in the case of the first meeting of the EUOC, prior to such meeting) and on a Calendar Year-to-date basis, evaluating the work performed in relation to the
goals and timeline of each Commercialization Plan, (b) its Commercialization Activities in process and the future activities it expects to initiate during the then-current Calendar Year, as compared to each Commercialization Plan, and
(c) in the case of the written report, the Authorized Commercialization Expenses incurred, and expected to be incurred, by such Party (and its applicable Affiliates) for the then-current Calendar Year, as compared to the applicable
Commercialization Budget. In addition, Gilead Sub and BMS shall report promptly to the EUOC through their respective committee members any material developments with respect to Commercialization Activities that they are responsible for performing
under the Commercialization Plan. Notwithstanding anything contained in this Section 5.10 to the contrary, each Party’s reporting obligations under this Section 5.10 shall automatically be deemed to terminate with respect to any
period in which there is not then in effect a Commercialization Plan or Commercialization Budget. Without limitation of any of the foregoing, the Parties shall negotiate in good faith and mutually agree in writing upon any additional reporting
requirements with respect to any Third Party Distributor Country. 
 5.11 Records. 
 (a) Maintenance of Records. Gilead Sub and BMS each shall (in accordance with their respective allocations of responsibility with
respect to the Commercialization Activities) maintain and retain, or cause to be maintained and retained, final records (but not draft records or documents except as otherwise required by Applicable Law) of its (and its Affiliates’) respective
Commercialization Activities covered in the Commercialization Plan for at least (i) three (3) years or (ii) such longer period as may be required by Applicable Law. 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 51 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 (b) Access to Records. Subject to this Section 5.11(b), each Party shall
have the right, with respect to records maintained by the other Party (and its Affiliates) of such other Party’s (and its Affiliates’) Commercialization Activities covered in the Commercialization Plan, during normal business hours and
upon reasonable notice, to inspect and copy any such records pursuant to this Section 5.11(b) solely to the extent relating to the Combination Product and solely to the extent (i) necessary in order for the inspecting Party (or its
Affiliates) to perform its obligations with respect to Commercialization Activities in a manner consistent with the applicable Commercialization Plan, (ii) necessary for the inspecting Party to confirm compliance with, or to comply with,
Applicable Law, as it relates to the activities conducted hereunder or under any Co-Promotion Agreement, or (iii) necessary to enable the inspecting Party to conduct reasonable diligence on matters potentially giving rise to liability on the
part of the Supply JV, the MAH or such Party or any of its Affiliates, or to conduct a defense of itself or any of the foregoing Persons, if and to the extent that a fact, circumstance or event has arisen that gives the inspecting Party a reasonable
basis to believe that it or any such Person has or may incur such liability, in each case for use by the inspecting Party for the purpose set forth in clause (i), (ii) or (iii) above, as the case may be. Clause (iii) of the
immediately preceding sentence shall not require any Party or any of its Affiliates to provide such data, documentation or records in the event that the Parties’ (or their respective Affiliates’) interests in such matter are or may be
adverse in any material respect, in which case Applicable Law, including discovery rules and procedures shall apply. Each such request shall be made in writing and shall state the reason(s) therefor (each a “Commercial Record
Request”). The Party (or its applicable Affiliate) from which such records, documentation or data are requested shall have the right to raise reasonable objections in writing in response to such Commercial Record Request, including based on
such Party’s or Affiliate’s interests in protecting from disclosure to the requesting Party trade secrets or other competitive business information. Upon any such objection being asserted, the Parties shall promptly confer in an attempt to
address each Party’s concerns and reach a resolution with respect to the matter, and in the event that the Parties are unable to agree upon a mutually agreeable resolution, either Party shall have the right to refer the matter to the EUOC. In
the event that any such dispute is referred by a Party to arbitration pursuant to Section 2.6 (and Section 6.7 of the Standard Terms), the arbitrators shall determine as a threshold matter whether and to what extent one or more criteria
set forth in clauses (i), (ii) or (iii) above have been satisfied by the requesting Party, and, if so, shall make a determination with respect to whether and to what extent the disclosure of such information shall be required, by
balancing, on the one hand, the requesting Party’s need to obtain such records, documentation or data, and on the other hand, the objecting Party’s interests in protecting such records, documentation and data from disclosure. In making
such determination, the arbitrator(s) shall (x) confine their consideration to the facts and arguments set forth in the Commercial Record Request and the other Party’s written response thereto, and (y) have the right to require the
receiving Party to abide by terms and conditions for the handling, use and non-disclosure (either within such Party’s organization or to other Persons) of such information as may be reasonable under the circumstances. Except as
provided in this Section 5.11, a Party shall not have the right to obtain from the other Party access to or copies of the other Party’s records, documentation and data described above, unless 

  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 52 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 
otherwise expressly permitted pursuant to this Agreement or any other Covered Agreement to which the Parties (or their respective Affiliates) are parties or
the other Party gives its consent in its sole discretion. Notwithstanding the foregoing, neither Party shall have any obligation to (and, with respect to pricing and discounting matters as set forth in Section 4.1, neither Party shall) provide
(or cause to be provided) to the other Party any information pursuant to the Section 5.11 to the extent it relates to price setting and discounting, or inventory management agreements, or which such first Party (or any of its Affiliates) is
restricted from disclosing pursuant to Applicable Law or confidentiality or other contractual arrangements with Persons other than the Parties or their Affiliates. 
 (c) Notwithstanding the foregoing, nothing in this Section 5.11 shall limit the rights or obligation of the Parties (or any of their
respective Affiliates) under Section 3 of the Standard Terms as incorporated herein or any audit provision set forth in the Financial Agreement. In the event of a conflict between this Section 5.11 and Section 3 of the Standard Terms
or any such audit provision, Section 3 of the Standard Terms or such audit provision, as the case may be, shall control. The Parties shall negotiate in good faith and mutually agree in writing upon any audit rights with respect to Third Party
Distributor records. 
 5.12 Samples and Product Donations. 
 (a) Except to the extent mutually agreed in writing, Gilead Sub and BMS shall not provide, or give access to, samples of the Combination
Product to health care practitioners or patients in connection with Promotion of the Combination Product in the Territory. 
 (b) Further, no Party shall donate any Territory Combination Product to any Third Party unless (i) mutually agreed in writing by the Parties (or their respective Affiliates) or (ii)(A) such Party provides notice to the other Party of
its intention to donate Territory Combination Product, which notice shall specify (x) the price at which such Party intends to purchase such Territory Combination Product, (y) the quantity of Territory Combination Product such Party
intends to purchase for purposes of such donation, and (z) the Person to which such Party intends to donate such Territory Combination Product and (B) the other Party consents to such proposed donation, which consent shall not be
unreasonably withheld or delayed. In the event that such consent is provided and the donating Party proceeds with the donation, (a) if the donating Party is the Selling Party with respect to the donated Combination Product, the donating Party
shall treat any Combination Product so donated as Net Sales (as defined in the Financial Agreement) for the country for which the Combination Product is labeled, or (b) if the donating Party is the non-Selling Party, the Selling Party shall
sell the Combination Product to the donating Party at the price specified in the foregoing clause (x). Notwithstanding the foregoing, nothing in this clause (b) shall apply to any Combination Product to be used in any Clinical Trial.

  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 53 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 SECTION 6 
 SUPPLY-RELATED MATTERS 
 6.1 Generally. Without limitation of the other provisions of this
Section 6, semiannually or on such other schedule as the EUOC may agree from time to time, the EUOC shall (a) review the Manufacturing arrangements for Territory Combination Product, including availability of API and Manufacturing
capacity, the anticipated Manufacturing schedule, and inventory levels of Territory Combination Product, including safety stock, held by the Supply JV, (b) provide general oversight of the process with respect to Forecasts and Orders set forth
in Section 6.2 and (c) make such recommendations to the Parties with respect to any of the foregoing as the EUOC deems appropriate. 
 6.2 Forecasts and Orders. 
 (a) Forecasts and Related Supporting Data. 
 (i) Each Party shall appoint a designated employee to oversee the preparation of Forecasts (as defined below) pursuant to this
Section 6.2(a), which designated employee may be an employee of an Affiliate of such Party. Any Forecast proposed by a Party hereunder shall be based on Local Demand in each country in the Territory as determined based on the Forecast
Principles and Supporting Data set forth in Annex K. Further, all Forecasts agreed pursuant to clause (ii) below shall be based on Local Demand in each country in the Territory as determined based on the Forecast Principles and Supporting
Data set forth in Annex K and shall be prepared in good faith and with due diligence, care and consideration. The Parties, through their respective designated employees, shall discuss any proposed Forecasts and review and exchange Supporting Data as
appropriate and on such schedule as the Parties may establish from time to time; provided that neither Party shall have any obligation to provide any Supporting Data hereunder to the other Party to the extent that such Supporting Data is
licensed by such Party (or any of its Affiliates) from any Third Party if such Party (or any of its Affiliates) does not have the right to provide such Supporting Data as required hereunder. 
 (ii) Based on the Supporting Data exchanged pursuant to clause (i), the Parties shall jointly develop and agree on such forecasts for each
country in the Territory as Gilead Sub is required to submit to the Supply JV pursuant to the Product Supply Agreement (such forecasts, “Forecasts”) in accordance with the requirements for such Forecasts set forth in the Product Supply
Agreement and in sufficient time to allow Gilead Sub to submit such Forecast to the Supply JV by the date on which such Forecast is due under the Product Supply Agreement. 
 (iii) In the event that the Parties have not agreed upon any Forecast by ten (10) Business Days prior to the date on which such
Forecast is due to be submitted under the Product Supply Agreement, either Party may refer such matter to the Designated EUOC Members, in which case the Designated EUOC Members shall consider and agree upon such Forecast not less than four
(4) days prior to the date on which such Forecast is due under the Product Supply Agreement. The determination of the Designated EUOC Members shall be made based on Local Demand. In the event that the Designated EUOC Members cannot reach

  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 54 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 
agreement by such deadline with respect to any Forecast, such matter shall be escalated to the Commercial Executives for resolution not less than two
(2) days prior to the date on which such Forecast is due under the Product Supply Agreement. With respect to any meetings or other discussions between the Commercial Executives regarding the resolution of such dispute, such meetings and
discussions shall relate solely to the applicable Forecast or Order which is the subject of such dispute. In the event that the Commercial Executives are not able to reach agreement, Gilead Sub shall submit to the Supply JV, pursuant to the Product
Supply Agreement, the required Forecast based on the previous Forecast that was most recently submitted to the Supply JV, where the forecast for any period not covered by such previous forecast shall be equal to the forecast for the immediately
preceding period. The terms of Section 2.6 shall not apply with respect to any such dispute. 
 (b) Orders. Based
on the Forecasts, and, if applicable, the relevant Supporting Data, Gilead Sub shall prepare and submit such orders for the Territory (each, a “Order”) for the Combination Product as (i) are required to be submitted by Gilead Sub
pursuant to the Product Supply Agreement, or (ii) Gilead Sub is permitted to submit pursuant to the Product Supply Agreement and determines, in connection with its management of the inventory of Territory Combination Product, are appropriate,
in each case ((i) and (ii)) in accordance with the requirements for such orders set forth in the Product Supply Agreement. 
 6.3
Supply-Related Expenses. Any external, out-of-pocket amounts incurred by Gilead Sub in the Territory pursuant to the Product Supply Agreement other than amounts incurred by Gilead Sub pursuant to Section 6.1 or Section 6.2 of the
Product Supply Agreement, shall constitute “Authorized Supply Expenses”, except that (a) any such amounts incurred by Gilead Sub to the extent arising out of the gross negligence or intentional misconduct of Gilead Sub or any
of its Affiliates shall not constitute Authorized Supply Expenses and shall be borne in full by Gilead Sub; and (b) any such amounts incurred by Gilead Sub to the extent arising out of the gross negligence or intentional misconduct of BMS or
any of its Affiliates shall not constitute Authorized Supply Expenses and shall be borne by BMS. 
 SECTION 7 
 LICENSE GRANTS AND INTELLECTUAL PROPERTY 
 7.1 Licenses and Related Matters. 
 (a) Trademark Licenses and Related Matters. 
 (i) Subject to the terms and conditions of this Agreement, Gilead Sub hereby grants, on behalf of itself and its Affiliates, to BMS a
non-exclusive, royalty-free, fully paid-up, license, with right to sublicense through multiple tiers, to use in the Territory (A) the Trademarks listed on Annex G hereto (the “Gilead Licensed Trademarks”) for the sole purposes
of commercialization of the Combination Product (but not to the commercialization of the active pharmaceutical ingredients thereof individually or in combination other than in the Combination Product or other Exploitation of the Combination Product)
in the Territory and (B) the name and company logo/identifiers of Gilead Sub or its applicable Affiliate(s) for use (alone or as part of the name of the MAH) on Approved Marketing Materials and the applicable Product SmPC, Labeling and Package
Leaflets for the Combination Product. 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 55 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 (ii) Subject to the terms and conditions of this Agreement, BMS hereby grants, on
behalf of itself and its Affiliates, to Gilead Sub a non-exclusive, royalty-free, fully paid-up, license, with right to sublicense through multiple tiers, to use in the Territory (A) the Trademarks listed on Annex H hereto (the “BMS
Licensed Trademarks”) for the sole purposes of commercialization of the Combination Product (but not to the commercialization of the active pharmaceutical ingredients thereof individually or in combination other than in the Combination
Product or other Exploitation of the Combination Product) in the Territory and (B) the name and company logo/identifiers of BMS or its applicable Affiliates(s) for use (alone or as part of the name of the MAH) on Approved Marketing Materials
and the applicable Product SmPC, Labeling and Package Leaflets for the Combination Product. 
 (iii) Gilead Sub hereby
recognizes BMS’s and its Affiliates’ right, title, and interest in and to the BMS Licensed Trademarks. Gilead Sub further recognizes that this Agreement, or use of the BMS Licensed Trademarks in connection with this Agreement, in no way
confers to Gilead Sub any right, title, and interest in and to the BMS Licensed Trademarks or any other trademarks or intellectual property rights owned by BMS or any of its Affiliates, except as may otherwise be expressly provided in this
Agreement. BMS hereby recognizes Gilead Sub’s and its Affiliates’ right, title, and interest in and to the Gilead Licensed Trademarks. BMS further recognizes that this Agreement, or use of the Gilead Licensed Trademarks in connection with
this Agreement, in no way confers to BMS any right, title, and interest in and to the Gilead Licensed Trademarks or any other trademarks or intellectual property rights owned by Gilead Sub or any of its Affiliates, except as may otherwise be
expressly provided in this Agreement. 
 (iv) Gilead Sub acknowledges that the goodwill generated by any use of the BMS
Licensed Trademarks in connection with this Agreement will inure solely to the benefit of BMS or its applicable Affiliate. BMS acknowledges that the goodwill generated by any use of the Gilead Licensed Trademarks in connection with this Agreement
will inure solely to the benefit of Gilead Sub or its applicable Affiliate. 
 (b) Sublicense of Gilead Commercialization
Rights. Subject to the terms and conditions of this Agreement, Gilead Sub hereby grants to BMS a royalty-free, non-exclusive sublicense, with the right to sublicense through multiple tiers of sublicensees to any of its Affiliates or permitted
subcontractors, under any and all licenses granted to Gilead Sub in each Commercial License Agreement (to the extent that such a sublicense is permitted to be granted under such agreement) for the sole purpose of performing BMS’s obligations
hereunder and BMS’s (or its Affiliates’) obligations under the Co-Promotion Agreements and, if applicable, any BMS Product Supply Agreement. 
 (c) All license rights not specifically granted in this Section 7.1 are expressly reserved by each licensing Party. Any license granted in Section 7.1 may be transferred or assigned by the licensee Party
only in connection with a permitted assignment of this Agreement by such Party pursuant to Section 6.5 of the Standard Terms as incorporated herein. 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 56 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 7.2 Ownership of Trademarks and Related Matters. 
 (a) Gilead Licensed Trademarks. Gilead Sub shall have the sole right, at its sole cost and expense, to search, clear, file,
register, prosecute, maintain and enforce the Gilead Licensed Trademarks. Gilead Sub shall have the sole right and option, at its sole cost and expense, to respond to any infringement with respect to any Gilead Licensed Trademark by appropriate
steps, including by filing an infringement suit or taking other similar action. Gilead Sub shall also have the sole right and option not to prosecute, maintain or enforce Gilead Licensed Trademarks or take action to respond to any such infringement.

 (b) BMS Licensed Trademarks. BMS shall have the sole right, at its sole cost and expense, to search, clear, file,
register, prosecute, maintain and enforce the BMS Licensed Trademarks. BMS shall have the sole right and option, at its sole cost and expense, to respond to any infringement with respect to any BMS Licensed Trademark by appropriate steps, including
by filing an infringement suit or taking other similar action. BMS shall also have the sole right and option not to prosecute, maintain or enforce BMS Licensed Trademarks or take action to respond to any such infringement. 
 (c) Combination Product Trademarks. The Parties acknowledge that the ownership of the Combination Product Trademarks (as defined in
the US JV Collaboration Agreement) and any response to any infringement or potential infringement of such Trademark (and the costs and expenses associated therewith) shall be governed by the US JV Collaboration Agreement. Gilead Sub shall be solely
responsible for searching, clearing, filing, registering, prosecuting and maintaining any such Trademarks in the Territory in the name of the US JV and the external, out-of-pocket expenses incurred by Gilead Sub in connection therewith shall be
treated as Authorized Other Expenses hereunder. 
 (d) EU Combination Product Trademarks. In the event that there are
any EU Combination Product Trademarks (as defined in the MAH Shareholder Agreement), the Parties shall coordinate in good faith (i) to secure from the owner(s) of such Trademarks (the ownership of which is governed by the MAH Shareholder
Agreement) such licenses or other rights as are reasonably necessary to conduct the Parties’ activities hereunder and under the Co-Promotion Agreements, (ii) to allocate responsibility as between the Parties and such owner(s) for
(A) the searching, clearing, filing, registering, prosecuting and maintaining any such Trademarks in the Territory and (B) any response to any infringement or potential infringement of any such Trademarks in the Territory and (iii) to
allocate, as between the Parties and such owner(s), any costs with respect to any of the foregoing. 
 7.3 Ownership of Marketing
Materials. Any Approved Marketing Materials, and any intellectual property rights with respect thereto, shall be jointly owned by the Parties; provided, that (a) except as otherwise provided in clause (b), each Party shall have the right to
use the Approved Marketing Materials solely as set forth herein and (b) in the event that either Party desires to use the Approved Marketing Materials (as modified appropriately) in connection with the Marketing of the Combination Product
outside the Territory, the other Party shall not unreasonably withhold or delay its consent to such use and, if such consent is granted, shall grant such licenses with respect to the Approved Marketing Materials as may be reasonably necessary

  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 57 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 
in connection therewith; provided, that such grant shall not be required to include any grant of any rights to use any Trademark; and, provided,
further that the foregoing shall not be construed to modify the rights and obligations of the Parties or their respective Affiliates under Section 5.7 of the US JV Collaboration Agreement. 
 7.4 IP Expenses. In the event that Gilead Sub reimburses the US JV pursuant to any Covered Agreement for amounts incurred by or on behalf of the
US JV with respect to obtaining, maintaining or enforcing any intellectual property rights, including Trademarks, that are licensed to Gilead Sub under such agreement with respect to the Territory, such amounts reimbursed by Gilead Sub shall
constitute Authorized Other Expenses to extent attributable to the Territory. 
 SECTION 8 
 PAYMENTS 
 8.1 Authorized
Expenses. 
 For clarity, any amounts paid or payable pursuant to this Section 8 shall be subject to adjustment pursuant to the
Financial Agreement to the extent provided therein. 
 (a) Allocation. Gilead Sub and BMS shall each bear any
Authorized Expenses in accordance with the Working Percentage for the Gilead Territory-Wide Percentage and the BMS Territory-Wide Percentage, respectively, as set forth in this Section 8.1. For the avoidance of doubt, with respect to any costs
and expenses incurred by a Party in performing the Commercialization Activities or other activities hereunder, the other Party shall bear a portion of such costs and expenses pursuant to this Section 8.1 only if such costs and expenses
constitute Authorized Expenses. 
 (b) Authorized Commercialization Expenses. 
 (i) Each Party shall report to the other Party, no later than ten (10) Business Days after the end of each Calendar Quarter, the
Authorized Commercialization Expenses incurred by such Party during such Calendar Quarter. Such report shall specify in reasonable detail all amounts included in such Authorized Commercialization Expenses during such Calendar Quarter. All Authorized
Commercialization Expenses shall be reported in Euros. For reporting purposes, any Authorized Commercialization Expenses incurred in a currency other than Euros shall be converted to Euros from the applicable currency by the incurring Party in a
manner consistent with its then-current standard worldwide currency conversion methodology, as consistently applied. For the avoidance of doubt, any expenses that are reimbursable pursuant to any Co-Promotion Agreement shall not constitute
Authorized Commercialization Expenses hereunder. 
 (ii) Authorized Commercialization Expenses shall be subject to
reimbursement, as follows. Within thirty (30) days after the date on which the Authorized Commercialization Expense reports for a particular Calendar Quarter are due pursuant to Section 8.1(b)(i), the Party that has paid less than its
share (based on the allocation principles set forth in Section 8.1(a)) of the aggregate Authorized Commercialization Expenses for such Calendar Quarter shall make a reconciling payment in Euros to the other Party to achieve the appropriate
allocation of Authorized Commercialization Expenses as provided in Section 8.1(a). 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 58 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 (c) Authorized Supply Expenses. Gilead Sub shall submit an invoice to BMS, no
later than ten (10) Business Days after the end of each calendar month, for an amount equal to the Working Percentage for the BMS Territory-Wide Percentage multiplied by the total amount of Authorized Supply Expenses incurred by Gilead Sub
during such month. Such invoice shall specify in reasonable detail all amounts included in such Authorized Supply Expenses. All Authorized Supply Expenses shall be invoiced in United States Dollars. For invoicing purposes, any Authorized Supply
Expenses incurred in a currency other than United States Dollars shall be converted to United States Dollars from the applicable currency by Gilead Sub in a manner consistent with its then-current standard worldwide currency conversion methodology,
as consistently applied. BMS shall pay any invoice submitted by Gilead Sub pursuant to this Section 8.1(c) within twenty (20) days after the date on which BMS receives such invoice. 
 (d) Authorized Distribution Expenses. The Selling Party shall submit an invoice to the non-Selling Party, no later than ten
(10) Business Days after the end of each calendar month, for an amount equal to the Working Percentage for the BMS Territory-Wide Percentage (in the case that Gilead Sub is the Selling Party in such country) or the Gilead Territory-Wide
Percentage (in the case that BMS is the Selling Party in such country) multiplied by the total amount of Authorized Distribution Expenses incurred by the Selling Party (or its applicable Affiliate) during such month. Such invoice shall specify in
reasonable detail all amounts included in such Authorized Distribution Expenses. All Authorized Distribution Expenses shall be invoiced in United States Dollars. For invoicing purposes, any Authorized Distribution Expenses incurred in a currency
other than United States Dollars shall be converted to United States Dollars from the applicable currency by the Selling Party in a manner consistent with its then-current standard worldwide currency conversion methodology, as consistently applied.
The non-Selling Party shall pay any invoice submitted by the Selling Party pursuant to this Section 8.1(d) within thirty (30) days after the date on which the non-Selling Party receives such invoice. 
 (e) Authorized Other Expenses. 
 (i) Each Party shall report to the other Party, no later than ten (10) Business Days after the end of each calendar month, any Authorized Other Expenses that are incurred during such month. Such report shall
specify in reasonable detail all amounts included in such Authorized Other Expenses during such month. All Authorized Other Expenses shall be reported in Euros. For reporting purposes, any Authorized Other Expenses incurred in a currency other than
Euros shall be converted to Euros from the applicable currency by the incurring Party in a manner consistent with its then-current standard worldwide currency conversion methodology, as consistently applied. 
 (ii) Authorized Other Expenses shall be subject to reimbursement, as follows. Within thirty (30) days after the date on which the
Authorized Other Expense reports for a particular month are due pursuant to Section 8.1(e)(i), the Party that has paid less than its share (based on the allocation principles set forth in Section 8.1(a)) of the aggregate Authorized Other
Expenses for such month shall make a reconciling payment in Euros to the other Party to achieve the appropriate allocation of such Authorized Other Expenses as provided in Section 8.1(a). 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 59 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 (f) Notwithstanding anything in this Section 8.1 to the contrary, any invoice
that a Party has a right to submit to the other Party pursuant to this Section 8.1 may be submitted to such other Party by a designated Affiliate of such invoicing Party, in which case such other Party shall submit payment to such designated
Affiliate. 
 (g) Notwithstanding anything in this Section 8.1 to the contrary, no cost or expense shall be reimbursable
hereunder to the extent that it is reimbursable pursuant to the Financial Agreement, the EU Master Agreement or the MAH Shareholder Agreement. 
 8.2 Manufacturing Fee. 
 (a) BMS shall pay to Gilead Sub an amount equal to the Working Percentage (as
defined in the Financial Agreement) for the BMS Territory-Wide Percentage multiplied by the Manufacturing Fee (as defined in the Product Supply Agreement) paid or payable by Gilead Sub pursuant to Section 6.2 of the Product Supply Agreement,
subject to any adjustments made pursuant to the Financial Agreement. Notwithstanding the foregoing, (i) with respect to any Manufacturing Fee incurred by Gilead Sub pursuant to the Product Supply Agreement that arises out of the gross
negligence or intentional misconduct of Gilead Sub or any of its Affiliates, BMS shall have no payment obligation pursuant to this Section 8.2(a), and (ii) with respect to any Manufacturing Fee incurred by Gilead Sub pursuant to the
Product Supply Agreement that arises out of the gross negligence or intentional misconduct of BMS or any of its Affiliates, BMS shall pay, pursuant to this Section 8.2(a), such Manufacturing Fee in its entirety. For the avoidance of doubt, this
Section 8.2 shall apply with respect to the Manufacturing Fee for any Territory Combination Product, including any such Combination Product that is Lost (as defined in the Product Supply Agreement). 
 (b) Unless otherwise agreed by the Parties, upon receipt of an invoice from the Supply JV pursuant to the Product Supply Agreement for any
Manufacturing Fee with respect to which BMS has a corresponding payment obligation pursuant to Section 8.2(a), Gilead Sub shall invoice BMS in U.S. Dollars for the corresponding amount due under this Section 8.2. BMS shall pay any such
invoice within twenty (20) days following receipt of such invoice from Gilead Sub. 
 8.3 Sharing of Recoveries Obtained from the
Supply JV. 
 (a) Gilead Sub shall pay to BMS such proportion of any recoveries paid by the Supply JV to Gilead Sub
pursuant to Section 5.6.2 of the Product Supply Agreement, after deduction of any out-of-pocket expenses of Gilead Sub in obtaining such recoveries from the Supply JV pursuant to the Product Supply Agreement, that corresponds to the proportion
of the expenses to which such recoveries relate that were borne by BMS hereunder. 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 60 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 (b) In the event that a Party (or its applicable Affiliate) causes (during the period
in which such Party (or its Affiliate) holds title to a given quantity of Territory Combination Product), due to its gross negligence or intentional misconduct, the Loss (as defined in the Product Supply Services Agreement) of any such Combination
Product, then such Party shall be responsible for reimbursing the other Party (or its designated Affiliate) for the API Replacement Fee (as defined in the Product Supply Services Agreement) for the quantity(ies) of such other Party’s API(s)
contained in such Lost Combination Product (which remedy shall be the sole remedy of the non-Selling Party or any of its Affiliates with respect to such Loss of API). 
 8.4 Other Payments. Unless otherwise agreed by the Parties, and except as otherwise provided in this Section 8, each Party promptly shall invoice the other Party for any amounts due under this Agreement in
the currency in which the corresponding expense is incurred by such Party and each Party shall pay any invoice provided by the other Party pursuant to this Section 8.4 within thirty (30) days after receipt of such invoice. 

 8.5 Adjustment to Country-Specific Percentages Following Generic Launch. On a country-by-country basis, this Section 8.5 shall
apply with respect to the Country-Specific Percentages for each Affected Country commencing as of the first Calendar Quarter following the Calendar Quarter during which the applicable Generic Version Launch occurs in such country (where the
Country-Specific Percentages for the Calendar Year in which such Calendar Quarter occurs shall be calculated based on the Standard Country-Specific Percentages for the portion of such Calendar Year from its commencement through the Calendar Quarter
in which such Generic Version Launch occurs and thereafter pursuant to this Section 8.5). Notwithstanding anything to the contrary herein or in any Covered Agreement, the Country-Specific Percentages for the applicable country, for all purposes
under the Financial Agreement, the EU Master Agreement and any other Covered Agreement, shall be modified as follows (where any capitalized terms used in this Section 8.5 and not defined in this Agreement shall have the meaning set forth in the
Financial Agreement): 
 (a) Country-Specific Percentage of the Affected Party for any Country in the Territory. The
Country-Specific Percentage of the Affected Party with respect to the applicable Affected Country in the Territory for each Calendar Year shall equal, stated in percentage terms: a fraction, 
 the numerator of which is (i) the [*] in such country minus (ii) the sum of (A) the [*] in such country and
(B) in the event that there is a [*] with respect to such country, the Non-Affected Party’s [*]; and 
 the denominator of which is the Net Selling Price of the Combination Product in such country. 
 (b)
Country-Specific Percentage of the Non-Affected Party for any Country in the Territory. The Country-Specific Percentage of the Non-Affected Party with respect to the applicable country for a given Calendar Year shall equal: one hundred
percent (100%) minus the [*] with respect to such country and such Calendar Year, as determined pursuant to this Section 8.5. 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 61 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 (c) Generic Version Launch of Two Components. Notwithstanding the foregoing,
in the event that there has been a Generic Version Launch with respect to Sustiva or Stocrin and either Viread or Emtriva, but not both (and not Truvada) in a given country, commencing as of the first Calendar Quarter following the Calendar Quarter
during which the Generic Version Launch triggering this clause (c) occurs in such country the following shall apply with respect to such country: 
 (i) Gilead Sub’s Country-Specific Percentage shall equal the sum of (in each case stated in percentage terms): 
 (A) a fraction, the numerator of which equals the [*] (such product, the “Proprietary Product”) in such country, and the denominator of which equals the [*] in such
country, and 
 (B) (1) a fraction, the numerator of which equals the [*] that is not the Proprietary Product
(“Gilead Non-Proprietary Product”) and the denominator of which is the sum of such [*], multiplied by (2) a fraction, the numerator of which equals (x) the [*] in such country minus (y) the
[*], and the denominator of which equals the [*] in such country; provided, that if any [*] described in clause (1) is not available, the fraction in clause (1) shall equal
[*]. For purposes of clause (1) of this Section 8.5(c)(i)(B), the [*] 
 By way of illustration, in the event that the
Proprietary Product is Viread (and the foregoing proviso does not apply), Gilead Sub’s Country-Specific Percentage would be equal to the sum of: 
 [*] 
 (ii) BMS’s Country-Specific Percentage shall equal one hundred percent
(100%) minus [*], as determined pursuant to the foregoing clause (i). 
 (d) Generic Version Launch of
Three Components. Notwithstanding the foregoing, in the event that there has been a Generic Version Launch with respect to Sustiva or Stocrin, as applicable, and both Single Agent Products of Gilead Sub (or Truvada) in a given Affected Country,
with respect to such country, the Parties shall negotiate in good faith the appropriate adjustments to the Country-Specific Percentages for the applicable Affected Country for the period commencing as of the first Calendar Quarter following the
Calendar Quarter during which the Generic Version Launch triggering this clause (d) occurs in such country. 
 (e)
Effect of Modifications. For the avoidance of doubt, the Working Percentages (as defined in the Financial Agreement) with respect to the Country-Specific Percentages, and any calculations to be made hereunder or under the EU Master Agreement
or any Covered Agreement using Country-Specific Percentages (or such Working Percentages), including the calculation of any applicable Transfer Price or the Interim Transfer Price, shall be adjusted to reflect any modifications to the
Country-Specific Percentages pursuant to this Section 8.5. Each Party shall, and shall cause its Affiliates to, be bound by any such adjustments. 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 62 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 8.6 Payment Terms. Except as otherwise agreed by the Parties, all payments hereunder to a
Party shall be made by wire transfer or electronic funds transfer to such bank account as the payee Party may designate from time to time by notice to the payor Party. Any amounts due hereunder shall be paid in the currency in which such amounts are
invoiced. 
 8.7 Interest. Interest on any payments due and owing pursuant to this Agreement that are not timely made shall accrue
from the date such payments are due at the lesser of (i) an annual rate equal to the sum of (a) the prime rate of interest in force on the date the payment is due as published in The Wall Street Journal (Eastern United States Edition) (in
the case of payments to be made in United States dollars) or the European Central Bank main refinancing rate (as published in the Central Bank and Financial Services Authority for Ireland website www.centralbank.ie) (in the case of payments to be
made in any currency other than United States dollars) and (b) three hundred (300) basis points and (ii) the maximum rate of interest permissible under Applicable Law. 
 8.8 Taxes. Each Party shall be responsible for any and all sales, use, excise, value added, goods and services and similar taxes and charges
imposed with respect to any payments to such Party by the other Party pursuant to this Section 8, provided that each Party shall be responsible for any taxes (including any such taxes imposed by way of withholding) in the nature of
income or franchise taxes or based on or measured by gross or net income imposed with respect to its income. Each Party shall pay any and all withholding taxes or similar charges imposed by any governmental unit that are required to be withheld from
any amounts due to the Party to be paid pursuant to this Section 8 to the proper taxing authority, and proof of payment of such taxes or charges shall be secured and sent to such Party as evidence of such payment. All amounts paid by a Party
pursuant to the immediately preceding sentence with respect to taxes for which the other Party is responsible pursuant to the first sentence of this Section 8.8 shall be paid for the account of such other Party and deducted from the amounts due
from the paying Party to such other Party pursuant to this Section 8. 
 8.9 Royalty Payments to Third Parties.  
 (a) If a Patent of any Third Party is or would be infringed or any such Person’s trade secrets are or would be misappropriated solely
as a direct result of the incorporation of TDF, FTC or both TDF and FTC in the Combination Product, then Gilead Sub shall be solely responsible for any royalty, license fee or other payment obligation to such Person (which shall not qualify as an
Authorized Expense) in connection with any such infringement or misappropriation in connection with the Manufacture of Territory Combination Product (or the TDF or FTC included therein) or any Commercialization Activities or other activities
conducted hereunder or under any Co-Promotion Agreement. If a Patent of any Third Party is or would be infringed or any such Person’s trade secrets are or would be misappropriated solely as a direct result of the incorporation of EFV in the
Combination Product, then BMS shall be solely responsible for any royalty, license fee or other payment obligation to such Person (which shall not qualify as an Authorized Expense) in connection with any such infringement or misappropriation in
connection with the Manufacture of Territory Combination Product (or the EFV included therein) or any Commercialization Activities or other activities conducted hereunder or under any Co-Promotion Agreement. 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 63 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 (b) All royalty, license fee or other payments by Gilead Sub or BMS (or any of their
respective Affiliates), other than those covered by Section 8.9(a), to any Third Party (other than to the extent comprising Losses (as defined in the EU Master Agreement) covered by Section 3 of the EU Master Agreement) in connection with
licenses granted to any Party or any of its Affiliates under any Patents or trade secrets owned or controlled by any Third Party that are reasonably necessary for (i) the performance of either Party’s obligations under this Agreement or
any Co-Promotion Agreement or (ii) the Manufacture of Territory Combination Product, in each case ((i) and (ii)), shall constitute Authorized Commercialization Expenses. For the avoidance of doubt, no royalty, licensee fee or other payment by
BMS (or any of its Affiliates) pursuant to the EFV License Agreement shall constitute Authorized Commercialization Expenses. 
 (c) Notwithstanding Section 8.9(b), the royalties, license fees or other payments described therein shall constitute Authorized Commercialization Expenses solely to the extent that (i) with respect to any license agreement
existing as of the Effective Date, the Party that is a party to the applicable license agreement has notified the other Party, on or before the Effective Date, of the obligation to pay such royalty, license fee or other payment in connection
with the foregoing activities, (ii) with respect to any license agreement not covered by clause (i), the Party has conferred with the other Party prior to entering into such license agreement and has obtained the other Party’s consent
to the applicable terms of such agreement and (iii) in the event that any such fee or payment is not attributable solely to the foregoing activities (e.g., it covers not only the Exploitation of Territory Combination Product, but
also the Exploitation of any other product(s) or Combination Product other than Territory Combination Product), the Parties shall negotiate in good faith an appropriate manner of apportionment). In the event that a Party denies its consent pursuant
to the foregoing clause (ii) with respect to a given license agreement and, as a result, the royalties, license fees or other payments incurred by the other Party pursuant to such Agreement are excluded from Authorized Commercialization
Expenses and such first Party and its Affiliates are not licensed under such agreement, then, notwithstanding Section 3.5(c) of the EU Master Agreement, such unlicensed Party shall be responsible, as between Gilead Sub (and its Affiliates) and
BMS (and its Affiliates), for any Losses (as defined in the EU Master Agreement) that would be borne (in the absence of application of this sentence) by the Parties (or their applicable respective Affiliates) pursuant to Section 3.5(c) of the
EU Master Agreement, to the extent that such Losses would not have arisen if such unlicensed Party had been licensed under such license agreement. 
 (d) Nothing herein shall be construed to prevent either Party or any of its Affiliates from entering into any license agreement with respect to the Combination Product or otherwise; provided, however, that in
the event that a Party desires to enter into such a license agreement with respect to the Combination Product, such Party shall notify the other Party. If following such notification, the Parties mutually agree to coordinate with respect to entering
into such a license agreement and the negotiations with respect thereto, the Parties shall coordinate in good faith with regard to the foregoing. 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 64 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 SECTION 9 
 TERRITORY COMBINATION PRODUCT RECALLS 
 Each Party acknowledges that any determinations with respect to any product
disposal, recall or withdrawal of Territory Combination Product that are made pursuant to the MAH Shareholder Agreement or any other applicable Covered Agreement are binding on the Parties and that any expenses with respect to any of the foregoing
are allocated between the Parties (and their respective Affiliates) as set forth in the MAH Shareholder Agreement. 
 SECTION 10

 REPRESENTATIONS AND WARRANTIES 
 10.1 Generally. Each Party represents and warrants to the other Party that: (a) it is not aware of any pending or threatened litigation (and has not received any communication) that alleges that such
Party’s activities related to this Agreement or any Co-Promotion Agreement have violated, or that by conducting the activities as contemplated in this Agreement or any Co-Promotion Agreement such Party would violate, any of the intellectual
property rights of any other Person (after giving effect to the license grants in this Agreement), and (b) such Party has the right to grant the licenses granted by such Party to the other Party hereunder, and has not, prior to the Effective
Date, made a grant to any other Person of any right or license that would conflict with any grant of rights or licenses granted by such Party to the other Party hereunder. 
 10.2 Relationship to Standard Terms. The representations and warranties set forth in Section 10.1 shall be without limitation of the
representations, warranties and covenants set forth in the Standard Terms. 
 SECTION 11 
 LIMITATIONS ON LIABILITY AND RELATED MATTERS 
 11.1 Limits on Liability. Notwithstanding anything herein to the contrary, and without limitation of any liability limitation set forth in the Standard Terms or herein or any indemnity obligation set forth in the EU Master Agreement,
(a) with respect to any losses resulting from any breach by Gilead Sub of any representation or covenant hereunder, to the extent such losses arise out of any corresponding breach by the Supply JV of any representation or covenant under the
Product Supply Agreement, the liability, if any, of Gilead Sub to BMS hereunder [*] for such losses (less any reasonable, out-of-pocket expenses of Gilead Sub in obtaining such compensation from the Supply JV thereunder) and
(b) with respect to losses other than those covered by the foregoing clause (a), a Party shall be liable hereunder with respect to losses of the other Party (other than Losses as defined in the EU Master Agreement) [*] by such
Party or its Affiliates or subcontractors. 
 11.2 Exceptions to Standard Terms Limitations. Notwithstanding Section 4.3 of the
Standard Terms as incorporated herein, the Parties shall be liable to each other for [*], if applicable, in connection with any breach of Section 4.1, the Pricing Rules or the Discount Rules, provided that such breach
arises out of acts or omissions constituting gross negligence or intentional misconduct. 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 65 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 11.3 Relationship to EU Master Agreement. Nothing in this Section 11 is intended to, or
shall operate to limit, a Party’s (or its Affiliates’) rights to indemnification or obligations of indemnity under any other agreement, including the EU Master Agreement, and for clarity, “losses” as used in Section 11.1
shall not be construed to include losses arising from Third Party Claims (as defined in the EU Master Agreement). 
 SECTION 12

 TERM AND TERMINATION 
 12.1 Term. The term of this Agreement (“Term”) shall commence as of the Effective Date and shall continue until the expiration of the last to expire Patent which affords market exclusivity in the Territory with
respect to the Combination Product or any component thereof unless earlier terminated pursuant to this Section 12 or the Standard Terms as incorporated herein. 
 12.2 Voluntary Termination. Without limitation of the bases for termination set forth in the Standard Terms, either Party (the “Terminating Party”) may terminate this Agreement in its entirety
by written notice to the other Party (the “Continuing Party”), which termination shall be effective on the later of (a) the last day of the second (2nd) Calendar Quarter after the Calendar Quarter in which such notice is
delivered to the other Party and (b) [*]. In the event that, at least ninety (90) days prior to the date on which such termination would become effective (in the absence of application of this sentence), the other Party
provides written notice to the Terminating Party indicating that such other Party does not desire to continue to commercialize the Combination Product in the Territory, the effective date of such termination shall be, notwithstanding the foregoing,
the earlier of (i) the date on which the Territory Combination Product is withdrawn in each country in the Territory and (ii) if the Combination Product is licensed to a Third Party for distribution in the Territory, the date on which such
Third Party assumes such distribution. Further, in the case in which a notice is provided pursuant to the immediately preceding sentence, the Parties shall coordinate to seek any required approvals to withdraw the Territory Combination Product in
each country in the Territory and, provided that any such approvals are obtained, to withdraw the Territory Combination Product in all countries in the Territory or, if mutually agreed by the Parties, to license the Combination Product to a Third
Party. In the case of any such withdrawal or licensing to a Third Party, the Parties shall negotiate in good faith appropriate wind-down provisions in connection therewith (and Section 12.3(b) shall apply solely to the extent applicable). For
clarity, termination of this Agreement does not automatically terminate any other Covered Agreement (other than the Co-Promotion Agreements) but may entitle a Party or its Affiliates to terminate one or more of such other Covered Agreements pursuant
to their terms (including the Standard Terms as incorporate therein). 
 12.3 Consequences of Expiration or Termination. 

(a) Expiration or Termination Pursuant to the Standard Terms. Upon expiration of this Agreement or termination of this Agreement
pursuant to the Standard Terms, the provisions of this Section 12.3(a) shall apply. The license grants in Section 7 to a Party shall survive only to the extent necessary to enable such Party to perform any obligations hereunder 

  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 66 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 
that survive such termination. No later than thirty (30) days after the date of such expiration or termination, each Party shall make arrangements for,
at the election of the other Party, either the return or disposal of any Confidential Information of the other Party, whether such Confidential Information is in tangible or intangible form (except for one (1) copy which may be retained solely
for archival purposes); provided, however, that the foregoing shall not apply with respect to any such Confidential Information to the extent that this Agreement or any other binding agreement between the Parties (or their
respective Affiliates) expressly provides that the Returning Party retains the right to use such Confidential Information (e.g., in the case of a surviving license) following such termination. Further, with respect to any termination of this
Agreement pursuant to the Standard Terms, the Parties shall coordinate in good faith to ensure an appropriate wind down of the activities conducted under this Agreement. 
 (b) Consequences in the Case of Voluntary Termination. Upon termination of this Agreement pursuant to Section 12.2, the
provisions of this Section 12.3(b) shall apply: 
 (i) The license grants in Section 7 from the Terminating Party to
the Continuing Party shall survive only to the extent necessary to enable the Continuing Party to identify the Terminating Party on the applicable Product SmPC, Labeling and Package Leaflets for the Combination Product to the extent required by
Applicable Law. 
 (ii) The Continuing Party shall pay to the Terminating Party such amounts as are determined pursuant to the
formula set forth in Annex I on the dates specified therein. Each such payment shall be accompanied by a written report, providing a detailed breakdown of the calculation of amounts paid for the relevant period. For the avoidance of doubt, Sections
8.6 through 8.9 shall apply to any such payments. 
 (iii) The Terminating Party, at its own election (of which it shall
promptly notify the Continuing Party in writing), shall (pursuant to a license or supply agreement containing the following terms and any other terms upon which the Parties mutually agree) either (A) enable the Continuing Party to Manufacture
quantities of the API(s) of the Terminating Party for use in the Manufacture of the Combination Product for distribution in the Territory, in which event the Terminating Party shall (1) automatically be deemed to grant a royalty-free, exclusive
(as to the Combination Product, but not any other product) license to the Continuing Party (or its Third Party designee, which shall be reasonably acceptable to the Terminating Party) (x) under the Terminating Party’s Patents covering such
Manufacture and Information and Inventions used in such Manufacture by or on behalf of the Terminating Party, to Manufacture such API(s) for use in the Manufacture of the Combination Product for distribution in the Territory, and (y) under the
Terminating Party’s Patents covering the composition or use of such API(s), to sell or otherwise distribute such API(s) (for inclusion in such Combination Product or as included in such Combination Product) in such country, which license shall
be sublicensable to any Third Party distributor of such Party or any of its Affiliates, and (2) provide reasonable technical assistance to such Continuing Party or Third Party designee (which choice of recipient shall be subject to the prior
approval of the Terminating Party, such approval not to be unreasonably withheld or delayed), at the Continuing Party’s expense on the Terminating Party’s then-current standard terms and conditions; or (B) continue to supply to the
Supply JV (or, at the election of the Continuing Party, a designee of the Continuing Party) on a non-exclusive basis such 

  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 67 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 
quantities of such API(s) as such Continuing Party may request for Manufacture of the Combination Product for distribution in the Territory, at a transfer
price of such supply equal to [*] of the Cost of Goods of such API. Notwithstanding the foregoing, the Terminating Party may elect to cease the Manufacture of such API(s) or to terminate the supply arrangement referred to in the
foregoing clause (B), in which case the Terminating Party shall (x) give the Continuing Party at least twelve (12) months’ written notice prior to ceasing such Manufacture or otherwise terminating such agreement unless the Continuing
Party obtains an alternate source for the supply of such API(s) in which case the Terminating Party may cease Manufacture upon the Continuing Party obtaining such alternate supply of API(s), (y) grant to the Continuing Party the license
described in clause (A)(1) above, and (z) provide to the Continuing Party the technical assistance described in clause (A)(2) above. Further, in event that, as an initial matter, the Terminating Party elects to proceed under the foregoing
clause (A) rather than clause (B), the Terminating Party shall supply its API(s) for use in the Manufacture of the Combination Product for distribution in the Territory at a transfer price of such supply equal to [*] of the Cost
of Goods of such API(s) unless and until the Terminating Party has performed its obligations under clause (A) and the Continuing Party has secured a source of supply of such API(s) (and any necessary regulatory approvals have been obtained with
respect to such source of supply), provided that the Continuing Party is using diligent efforts to secure such source of supply and such approvals. In the event that the Terminating Party and the Supply JV or designee of the Continuing Party enter
into a supply arrangement for API(s) pursuant to the first sentence of this Section 12.3(b)(iii), and thereafter the Supply JV or such designee, as the case may be, desires to terminate such supply arrangement (without receiving from the
Terminating Party the license described in clause (A)(1) above or the technical assistance described in clause (A)(2) above), the Continuing Party shall provide twelve (12) months’ written notice thereof to the Terminating Party.

 (iv) Except to the extent necessary to enable the Continuing Party to identify the Terminating Party (or its applicable
Affiliate) on the applicable Product SmPC, Labeling and Package Leaflets for the Combination Product to the extent required by Applicable Law, the Continuing Party shall not (and shall cause its Affiliates not to) use the Trademark or name of the
Terminating Party (or any of its Affiliates) (A) on any labeling, packaging and advertising materials for the Combination Product in the Territory or (B) otherwise in connection with the Continuing Party’s business with respect to the
Combination Product in the Territory. 
 (v) The Terminating Party shall promptly (and in any event within thirty
(30) days thereafter) make arrangements for the return or disposal, at the Continuing Party’s option, of any Confidential Information, in tangible or intangible form, except for (x) one (1) copy which may be retained solely for
archival purposes and (y) Confidential Information relating to any surviving licenses and other rights pursuant to any Covered Agreement. 
 (vi) For the avoidance of doubt, the pricing and other provisions contained in Section 4, the Pricing Rules and the Discount Rules shall terminate. 
 12.4 Accrued Rights; Survival. 
 (a) Termination or expiration of this Agreement shall be without prejudice to any rights that shall have accrued to the benefit of a Party prior to such termination or expiration. Such termination or expiration shall
not relieve a Party from obligations that are expressly indicated to survive the termination or expiration of this Agreement. 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 68 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 (b) Without limiting anything contained in Section 12.3, in the event of any
expiration or termination of this Agreement for any reason, this Section 12.4 and Sections 3.6, 4.4, 5.9, 5.11, 6.3, 7.2, 7.3, 8 (except Section 8.5), 9, 10, 11, 12.3 and 13 (except 13.4) shall survive such expiration or termination;
provided, however, that Section 5.9, Section 6.3, Section 8.1, Section 8.2, and Section 8.9(b) shall survive solely to the extent that the applicable expenses (or in the case of Section 8.9(b), royalties, license
fees or other payments) were incurred in connection with activities, including Manufacturing, performed prior to the date of expiration or termination of this Agreement. 
 SECTION 13 
 MISCELLANEOUS 
 13.1 Standard Terms. The Standard Terms are hereby incorporated herein. 
 13.2 Assignment; Subcontracting. 
 (a) In the event that, with respect to a Party, there is a sale of substantially all of the assets of such Party and its Affiliates to which the Covered Agreements, collectively, relate or a change of control of such
Party’s Parent (such Party, the “Transferring Party”, and such event, a “Change of Control”), without limitation of Section 6.5 of the Standard Terms as incorporated herein, the Transferring Party shall
give the other Party written notice thereof within ten (10) days, identifying the purchaser, acquirer or surviving entity (the “Third Party Acquirer”), as the case may be. If immediately prior to such Change of Control, such
Third Party Acquirer is marketing in the Territory a Competing Product that was commercially available as of the Effective Date, then, upon written notice from the other Party, at its election, to the Transferring Party within thirty (30) days
of such other Party’s receiving written notice of such Change of Control, such Third Party Acquirer shall have six (6) months to divest any such Competing Product. If such Third Party Acquirer fails to complete a timely divestiture of such
Competing Product: (i) the performance obligations (other than payment obligations and related financial reporting obligations) of the Parties under this Agreement shall terminate, except to the extent of those minimum obligations reasonably
required for Gilead Sub (or its applicable Affiliate) to sell the Combination Product in the Territory and to perform its obligations with respect to pricing with respect to the Combination Product as set forth in Section 4.1 and the Pricing
Rules and the Discount Rules (as modified by Section 4.3, if applicable), (ii) the Commercialization Plan and Commercialization Budget shall terminate, (iii) each Co-Promotion Agreement shall terminate as set forth in such agreement,
(iv) each Party shall have the right to Promote, Market and otherwise commercialize (but, in the case of BMS, not to sell or otherwise distribute) the Combination Product in the Territory without coordination with the other Party under this
Agreement (including without any obligation to reach agreement on Marketing materials); provided that each Party shall ensure that its Marketing materials with respect to the Combination Product in the Territory comply with Applicable Law
and, without limitation of the foregoing, shall be consistent with applicable Product SmPC, Labeling and Package Leaflets, and (v) Gilead Sub shall prepare and submit to the Supply JV any and all Forecasts and Orders, along with any required
Supporting Data, in its sole discretion. 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 69 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 (b) Either Party may subcontract the performance of its obligations hereunder,
including any Commercialization Activities assigned to it under the Commercialization Plan; provided, however, that the subcontracting Party shall oversee the performance by its subcontractors of such subcontracted activities in a
manner that would be reasonably expected to result in their timely and successful completion and shall remain responsible for the performance of such activities and, to the extent applicable, the Commercialization Plan. Notwithstanding the
foregoing, neither Gilead Sub nor BMS may engage any subcontractor, including any contract sales organization, to perform any Details of the Combination Product in the Territory; provided, however, that, subject to Section 5.1, the
conduct of Details by a Third Party Distributor consistent with the arrangements entered into with such Third Party Distributor by one or both of the Parties pursuant to this Agreement shall be permitted. 
 13.3 Employees. The Parties agree that, as between the Parties, all actions taken or omitted to be taken by any employee of a Party (or any of its
Affiliates) in his or her capacity as a member of any committee established pursuant to this Agreement or any Co-Promotion Agreement, and all other actions taken or omitted to be taken by any employee of a Party (or any of its Affiliates) with
respect to the Commercialization Activities and any other activities conducted hereunder or under any Co-Promotion Agreement, shall be attributed only to such Party. 
 13.4 Nonsolicitation of Employees. During the Term, each Party agrees that neither it nor any of its Affiliates that participates in or is responsible for the commercialization of the Combination Product
pursuant to this Agreement shall recruit, solicit or induce any employee of the other Party’s, or any of its Affiliates’, HIV/Virology sales force (including any manager) or any HIV/Virology marketing or medical personnel employed in the
Territory to terminate his or her employment with such other Party or its Affiliate and become employed by or consult for such other Party or its Affiliate, whether or not such employee is a full-time employee of such other Party or its Affiliate,
and whether or not such employment is pursuant to a written agreement or is at-will. For purposes of the foregoing, “recruit,” “solicit” or “induce” shall not be deemed to mean (a) general solicitations by Third
Party placement specialists or firms (e.g., headhunters) or (b) other general solicitations of employment (including responses to general advertisements), in each case ((a) and (b)) not specifically targeted at employees of a
Party or any of its Affiliates. 
 13.5 Notice. The “Notice Address” for each Party is as follows: 
 if to Gilead Sub, to: 
 John F. Milligan, Ph.D, Chief
Operating Officer 
 Gilead Sciences Limited 
 333 Lakeside Drive Foster City, CA 94404 
 Facsimile No.: [*] 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 70 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 with copies to: 
 Gregg H. Alton, Esq. 
 Senior Vice President and General Counsel 
 Gilead Sciences Limited 
 333 Lakeside Drive

 Foster City, CA 94404 
 Facsimile No.: [*] 
 and: 
 Julie O’Neill, General Manager 
 Gilead Sciences Limited 
 Unit 13 Stillorgan Industrial Park 
 Blackrock, Co. Dublin, Ireland 
 Facsimile No.: [*] 
 and: 
 Monica Viziano, Director, Project
Management 
 Gilead Sciences Limited 
 333 Lakeside Drive 
 Foster City, CA 94404 
 Facsimile No.: [*] 
 and: 
 Covington & Burling LLP 
 One Front
Street 
 San Francisco, CA 94111 
 Attn: James C. Snipes, Esq. 
 if to BMS, to: 
 Bristol-Myers Squibb 
 3 rue Joseph Monnier 
 Rueil Malmaison, France 92500 
 Attn: Sr. VP
Europe Marketing & Brand Commercialization 
 Facsimile No.: [*] 
 with a copy to: 
 Bristol-Myers Squibb Company

 Route 206 and Province Line Road 
 Princeton, NJ 08540 USA 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 71 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 Attn:  Vice President and Senior Counsel, 
             Corporate and Business Development 
 Facsimile No.: [*] 
 and:

 Frank Kuchma, Director, Alliance Management 
 Bristol-Myers Squibb Company 
 Route 206 and Province Line Road 
 Princeton, NJ 08543 USA 
 13.6 Public
Announcements. The following shall constitute a “Restricted Matter,” and as such shall be subject to Section 2.2 of the Standard Terms: any matter concerning this Agreement or its subject matter. 
 13.7 Entire Agreement. This Agreement, together with the Annexes attached hereto, the EU Master Agreement and any other Existing Covered
Agreements (as defined in the EU Master Agreement) to which the Parties are parties that set forth rights or obligations of the Parties with respect to the subject matter of this Agreement shall constitute, on and as of the Effective Date, the
entire agreement of the Parties with respect to the subject matter of this Agreement, and all prior or contemporaneous understandings or agreements (other than the foregoing agreements), whether written or oral, between the Parties with respect to
such subject matter are hereby superseded in their entireties, including the Interim Agreement and the Interim Manufacturing Agreement (and the Parties shall, or shall cause their respective applicable Affiliates to, terminate the Interim
Agreement). 
 [Signature Pages Follow] 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 72 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 IN WITNESS WHEREOF, the Parties have caused this Commercialization Agreement to be duly
executed and delivered as of the date first above written. 
  

					
	 SIGNED for and on behalf of
 Gilead Sciences Limited

	 		 	
			
	/s/ John F. Milligan	 		 	December 10, 2007
	John F. Milligan, Ph.D	 		 	Date
	Chief Operating Officer	 		 	

 SIGNATURE PAGE TO COMMERCIALIZATION AGREEMENT 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

					
	 SIGNED for and on behalf of
 Bristol-Myers Squibb
Company
	 		 	
			
	/s/ Graham Brazier	 		 	December 10, 2007
	Graham Brazier	 		 	Date
	Vice President and Head of Business Development	 		 	

 SIGNATURE PAGE TO COMMERCIALIZATION AGREEMENT 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 List of Annexes 
  

			
	Annex A	  	Cost of Goods
		
	Annex B	  	Initial EUOC Members and Initial Alliance Managers
		
	Annex C	  	Pricing Rules and Discount Rules
		
	Annex D	  	Form of Co-Promotion Agreement
		
	Annex E	  	Distribution Terms
		
	Annex F	  	Initial Commercialization Plan and Initial Commercialization Budget
		
	Annex G	  	Gilead Licensed Trademarks
		
	Annex H	  	BMS Licensed Trademarks
		
	Annex I	  	Voluntary Termination Compensation Formula
		
	Annex J	  	Initial Launch Period Commitments
		
	Annex K	  	Forecast Principles and Supporting Data
		
	Annex L	  	Territory A Countries

  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 75 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 Annex A 
 Cost of Goods 
 “Cost of Goods” shall mean, with respect to the applicable API, the amount equal to
the sum (expressed in U.S. Dollars per kilogram of the applicable API) of [*]. 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 A-1 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 Annex B 
 Initial EUOC Members and Initial Alliance Managers 
 Gilead EUOC Members: 
 [*] 
 [*] 
 [*] 
 [*] 
 Gilead Alliance Manager: 
 [*] 
 BMS EUOC Members: 
 [*] 
 [*] 
 [*] 
 [*] 
 BMS Alliance Manager: 
 [*] 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 B-1 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 Annex C 
 Pricing Rules and Discount Rules 
 [*] 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 C-1 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 Annex D 
 Form of Co-Promotion Agreement 
 [*] 
 [Omitted] 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 D-1 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 Annex E 
 Distribution Terms 
 Capitalized terms used in this Annex and not defined herein shall have the meaning set forth in
the agreement to which this Annex is attached (the “Agreement”). Section references used in this Annex shall refer to Sections in the Agreement except as otherwise provided. The terms set forth in this Annex shall apply solely (a) in
the case of Gilead Sub as the Selling Party, with respect to Territory Combination Product intended for distribution in the Co-Promote Territory or any other country in Territory A for which Gilead Sub has been designated as the Selling Party
pursuant to the Agreement, from and after the date on which the Supply JV transfers title to such Combination Product to Gilead Sub pursuant to the Product Supply Agreement or (b) in the case of BMS as the Selling Party, with respect to
Territory Combination Product intended for distribution in any country in Territory A for which BMS has been designated as the Selling Party pursuant to the Agreement, from and after the date on which Gilead Sub transfers title to such Combination
Product to BMS or its applicable Affiliate pursuant to the BMS Product Supply Agreement(s). For purposes of this Annex, a Third Party Distributor shall not constitute a Distribution Subcontractor unless mutually agreed by the Parties in writing;
provided, that each Party shall cause its Third Party Distributors to be subject to obligations with respect to its distribution of Territory Combination Product that are substantially similar to the obligations of the Selling Party set forth
in this Annex E. 
 “Distribution Subcontractor” shall mean any Third Party subcontractor that performs storage, warehousing,
shipping or other distribution activities on behalf of a Selling Party (or its Affiliates) (acting in such capacity) under the Agreement; provided that such Distribution Subcontractor does not take title to such Combination
Product. For the avoidance of doubt, neither a Contract Manufacturer nor a Third Party Distributor shall be deemed to be a Distribution Subcontractor and a Distribution Subcontractor shall not be deemed to be a Contract Manufacturer or a Third Party
Distributor.  
 “Material Safety Data Sheet” shall have the meaning set forth in the Product Supply
Agreement. 
 “Quality Agreement” shall have the meaning set forth in the Product Supply Services Agreement. 
 “Selling Party Products” shall mean the Selling Party’s (or its Affiliates’) own products for the treatment of HIV infection in adult humans.
For the avoidance of doubt, the Combination Product is not a Selling Party Product. 
 1. General. The Selling Party with respect to a given country
in the Territory shall (a) be the exclusive distributor of Combination Product in such country and (b) perform or cause to be performed activities as are reasonably required to distribute Combination Product in such country (any such
activities, the “Distribution Activities”), including inventory management and control, warehousing and storage, order filling, invoicing, collection of sales proceeds, determination and processing of charge-backs and rebates,
preparation of sales records and reports, customer relations and services, and handling of returns. 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 E-1 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 2. Inventory Management and Control. 
 (a) The Selling Party shall, or shall cause an Affiliate of the Selling Party or a Distribution Subcontractor to, receive Territory Combination Product
inventory (i) in the case of Gilead Sub as the Selling Party, directly from the Contract Manufacturer (as defined in the Product Supply Services Agreement) or (ii) in the case of BMS as the Selling Party, as specified in the BMS Product
Supply Agreement(s). Prior to distributing any quantity of Territory Combination Product, the Selling Party shall, or shall cause an Affiliate of the Selling Party or a Distribution Subcontractor to, ensure that it has the proper certificate of
analysis and other appropriate documentation with respect to such Combination Product as required by Applicable Law, including GMP. 
 (b)
The Selling Party shall, or shall cause an Affiliate of the Selling Party or a Distribution Subcontractor to, (i) monitor Territory Combination Product inventory for products that are short-dated and out-dated, as determined in accordance with
the Selling Party’s standard operating procedures (“SOPs”) and GMP, and (ii) withhold any such product from use and ensure its proper destruction. 
 (c) The Selling Party shall, or shall cause an Affiliate of the Selling Party or a Distribution Subcontractor to, perform a periodic stock reconciliation
by comparing the actual and recorded quantities of Territory Combination Product. If there are any significant stock discrepancies, the Selling Party shall promptly notify the non-Selling Party and shall investigate any such discrepancies. The
non-Selling Party shall have the right to participate in the investigation made by the Selling Party with respect to such discrepancies, upon written request made promptly after receiving notice of any discrepancy. 
 3. Warehousing and Storage. 
 (a) The Selling Party
shall, or shall cause an Affiliate of the Selling Party or a Distribution Subcontractor to, maintain temperature, humidity (if applicable) and other environmental controls in compliance with storage requirements listed on the labeling of Territory
Combination Product and the Material Safety Data Sheet for the Combination Product. The Selling Party shall, or shall cause an Affiliate of the Selling Party or a Distribution Subcontractor to, ensure that Territory Combination Product is received,
stored, segregated, and distributed in compliance with Applicable Law and quality, storage and distribution requirements referred to in the Material Safety Data Sheet. 
 (b) The Selling Party shall, or shall cause an Affiliate of the Selling Party or a Distribution Subcontractor to, maintain premises and control systems that provide a commercially reasonable level of security against
the theft or alteration of Territory Combination Product. The Selling Party shall, or shall cause an Affiliate of the Selling Party or a Distribution Subcontractor to, maintain, or cause to be maintained, a clean environment, pest control program,
and any other deterrent measure normally utilized by the Selling Party to provide a commercially reasonable level of contamination prevention for Territory Combination Product. 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 E-2 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 (c) The Selling Party shall, or shall cause an Affiliate of the Selling Party or a Distribution
Subcontractor to, perform receipt and inspection of all incoming shipments to confirm item(s), quantity and suitability (as may reasonably be determined by such receipt and inspection) before authorizing such shipments for approval for distribution.
The Selling Party shall notify the non-Selling Party promptly in the event of any deviation(s) with respect to such shipments that requires an investigation (as well as the results of such investigation) pursuant to the Selling Party’s SOPs,
Applicable Law and any applicable Covered Agreement. The Selling Party shall keep or cause to be kept appropriate reconciliation records of the receipts with respect to such shipments. 
 (d) Without limitation of its obligations under any Covered Agreement with respect to product recalls or withdrawals, the Selling Party shall ensure that
a system is in place to immediately withhold released quantities of Territory Combination Product from shipment when notified to do so by or on behalf of the MAH. 
 (e) The Selling Party shall, or shall cause an Affiliate of the Selling Party or a Distribution Subcontractor to, investigate and prepare an incident report for damage to any significant quantity of Territory
Combination Product that occurs under its, its Distribution Subcontractor’s or its Affiliate’s control. The Selling Party shall make available to the non-Selling Party pursuant to Section 9(a) of this Annex, or pursuant to the
non-Selling Party’s reasonable request, such incident reports indicating the cause of such damage and shall propose an action plan and corrective measures needed in order to avoid reoccurrence of any such incident resulting in damage to
significant quantities of Territory Combination Product. 
 4. Order Filling. 
 (a) The Selling Party shall receive orders for Territory Combination Product through means used by the Selling Party for the Selling Party Products. The
Selling Party may reject an order for Territory Combination Product only if such rejection is reasonable under the circumstances. 
 (b) The
Selling Party shall distribute Territory Combination Product according to the shipping orders received based on remaining shelf life as reflected on the product label (i.e., inventory with the shortest remaining shelf life shall be shipped
first), and only in the quantities and to those markets within the Territory indicated in the applicable shipping orders. A picking order shall be created only against an existing shipping order. The Selling Party shall perform appropriate checks
before a picking order can be shipped and shall follow the Selling Party’s SOPs and Applicable Law in conducting such checks. 
 (c) The
Selling Party shall transport, or cause to be transported, all quantities of Territory Combination Product to Customers, its Affiliates and its Distribution Subcontractors in a manner that provides commercially reasonable protection of product
integrity and maintenance of the applicable storage conditions. 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 E-3 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 5. Purchase of Combination Product by Customers. 
 (a) The Selling Party (or its applicable Affiliate) shall invoice the Customer for Territory Combination Product upon delivery of such Combination
Product to the Customer. Such invoices shall be inclusive of any applicable taxes. 
 (b) For each order of Territory Combination Product
shipped pursuant to the Agreement, the Selling Party shall, or shall cause its applicable Affiliate or a Distribution Subcontractor to, be responsible for collecting payment from the applicable Customer pursuant to the invoice delivered by the
Selling Party and shall otherwise manage the receivable resulting from such order using the same collection procedures and efforts applicable to the Selling Party Products. 
 6. Customer Relations and Services. The Selling Party shall, or shall cause an Affiliate of the Selling Party or a Distribution Subcontractor to, provide customer relations services with respect to Combination
Product sales in the Territory. Such services shall consist of handling incoming customer calls and documenting and resolving customer complaints in accordance with the Selling Party’s SOPs for the Selling Party Products. 
 7. Returns. The Selling Party shall, or shall cause an Affiliate of the Selling Party or a Distribution Subcontractor to, accept and process
Territory Combination Product returns in accordance with the Selling Party’s return policy for the Selling Party Products. 
 8. Records Retention. The Selling Party shall, or shall cause an Affiliate of the Selling Party or a Distribution Subcontractor to, retain all records relating to the performance of Distribution Activities (including
records of receipt, storage, picking, shipping, and environmental controls) for at least the duration of the applicable Combination Product’s labeled shelf life plus one (1) year, but in all cases for not less than the periods required by
the Selling Party’s record retention policies. The Selling Party shall retain all records of any disposal of Territory Combination Product by or on behalf of the Selling Party (or its Affiliates) in accordance with the Selling Party’s
record retention policies, unless Applicable Law dictates otherwise in which case such records will be kept in accordance with Applicable Law. Subject to the preceding provisions of this Section 8, the non-Selling Party shall have access to the
original documents pursuant to Section 9 of this Annex.  
 9. Inspection of Facilities; Certain Regulatory Matters. 
 (a) During the Term, the non-Selling Party shall have the right to visit the facilities used in the performance of Distribution Activities once per
Calendar Year during normal business hours upon reasonable prior notice to the Selling Party, its applicable Affiliate or its applicable Distribution Subcontractor, as appropriate; provided that (i) the visit does not unreasonably
interfere with the operations at the applicable facility and (ii) if the visit requires access to the facilities of a Distribution Subcontractor, the non-Selling Party must obtain such Distribution Subcontractor’s consent with the
reasonable assistance of the Selling Party. In 

  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 E-4 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 
addition, during the Term, the non-Selling Party shall have the right to conduct a “For Cause” audit at any time, when requested as a reasonable
response to any audit notice or inquiry regarding Territory Combination Product by any Regulatory Authority, an unresolved deviation in relation to the performance of Distribution Activities, or customer complaints or Adverse Events (as defined in
the SDEA) regarding Territory Combination Product. During any such visit or audit, the non-Selling Party shall have the right to inspect and audit the Selling Party’s quality system, materials management, records, and facilities for the purpose
of determining compliance with Applicable Law and this Annex. The Selling Party shall, and shall use its reasonable efforts to cause any Distribution Subcontractor to, cooperate fully in any such inspection conducted pursuant to this
Section 9(a). For any contractual or regulatory deficiencies determined as a result of such a visit or audit, the Selling Party shall, or shall cause the applicable Distribution Subcontractor to, take a commercially reasonable course of action
and resolution, and the non-Selling Party shall be entitled to conduct additional audits to ensure that any such deficiencies have been resolved by the Selling Party or the applicable Distribution Subcontractor, as applicable. 
 (b) The Selling Party shall (i) notify the non-Selling Party of any inspections by any Regulatory Authority of any facility used in the performance
of Distribution Activities within five (5) Business Days of the inspection and (ii) provide the non-Selling Party with copies of all regulatory correspondence relating to any such inspection and Territory Combination Product within five
(5) Business Days of receipt of the correspondence; provided that the Selling Party may redact the correspondence to protect the names of and identifying information for Third Parties and products other than the Combination Product, as
applicable. If any Territory Combination Product is implicated in any regulatory inspection findings, the Selling Party shall provide a draft of the pertinent responses to the non-Selling Party for review and comment prior to submission to the
applicable Regulatory Authority. In addition, the non-Selling Party shall have the right to have a representative present during the portion of the inspection that involves the Combination Product. 
 10. Employees. The Selling Party’s (or its Affiliate’s) employees engaged in performing Distribution Activities pursuant to the Agreement shall be
deemed its (or its Affiliate’s) own employees (and not the employees of the non-Selling Party or any of its Affiliates) for all purposes, including federal, state and local tax and employment laws. 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 E-5 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 Annex F 
 Initial Commercialization Plan and Initial Commercialization Budget 
 Territory B Initial Commercialization Budget
- 2006 & 2007 
 The 2006 and 2007 expenses are not intended to be subject to adjustment pursuant to the Financial Agreement. 

 

											
	 	  	Estimated Number of Units (Bottles)	  	Commercialization Expenses
(in thousands of
Euros)	 
	 Country
	  	Total
Year 20062	  	Total Year Forecast
20073	  	Total Year 20062	 	 	Total Year Forecast
20073	 
	 Germany
	  	—  	  	—  	  	—  	 	 	[	*]
	 United Kingdom1 (and
Ireland)
	  	—  	  	—  	  	—  	 	 	[	*]
	 Spain
	  	—  	  	—  	  	—  	 	 	—  	 
	 Italy
	  	—  	  	—  	  	—  	 	 	—  	 
	 France
	  	—  	  	—  	  	—  	 	 	—  	 
	 EU Headquarters
	  	N/A	  	N/A	  	[	*]	 	[	*]
		  	 	  	 	  	 	 	 	 	 
	 Total
	  	—  	  	—  	  	[	*]	 	[	*]
		  	 	  	 	  	 	 	 	 	 

  

	 1
	 GBP/Euro exchange rate for 2007: GBP 1 = €1.4763. 

  

	 2
	 Actual Expenses 2006 as approved and reflected in the Interim Commercialization Agreement. 

 

	 3
	 Total Spend of [*] is in line with JEC approved Latest Estimate. 

  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 F-1 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 Territory B Initial Commercialization Plan and Budget - 2008 
 The number of Details to be performed for Calendar Year 2008 for each country in Territory B shall be as set forth in Annex J, provided, that the numbers set forth
therein for the first 12-month period shall be adjusted to account for the date on which Launch occurred in the applicable country (e.g., in the event a country were to Launch at the commencement of the third Calendar Quarter of 2008, then the
minimum number of Details for such country for 2008 would be fifty percent (50%) of the minimum number of Details specified in Annex J for the first twelve (12) month period for such country). 
  

																
	  	  	Estimated Number of units (Bottles)	 
	 Country
	  	Q1 2008	 	 	Q2 2008	 	 	Q3 2008	 	 	Q4 2008	 	 	Total Year
Budget 2008	 
	 Germany
	  	[	*]	 	[	*]	 	[	*]	 	[	*]	 	[	*]
	 United Kingdom (and Ireland)
	  	[	*]	 	[	*]	 	[	*]	 	[	*]	 	[	*]
	 Spain
	  	[	*]	 	[	*]	 	[	*]	 	[	*]	 	[	*]
	 Italy
	  	[	*]	 	[	*]	 	[	*]	 	[	*]	 	[	*]
	 France
	  	[	*]	 	[	*]	 	[	*]	 	[	*]	 	[	*]
		  	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 Total
	  	[	*]	 	[	*]	 	[	*]	 	[	*]	 	[	*]
		  	 	 	 	 	 	 	 	 	 	 	 	 	 	 

  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 F-2 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

																
	 Country
	  	Commercialization Expenses (in thousands of Euros)	 
	  	Q1 2008	 	 	Q2 2008	 	 	Q3 2008	 	 	Q4 2008	 	 	Total Year
Budget 2008	 
	 Germany
	  	[	*]	 	[	*]	 	[	*]	 	[	*]	 	[	*]
	 United Kingdom1 (and
Ireland)
	  	[	*]	 	[	*]	 	[	*]	 	[	*]	 	[	*]
	 Spain
	  	[	*]	 	[	*]	 	[	*]	 	[	*]	 	[	*]
	 Italy
	  	[	*]	 	[	*]	 	[	*]	 	[	*]	 	[	*]
	 France
	  	[	*]	 	[	*]	 	[	*]	 	[	*]	 	[	*]
	 EU Headquarters
	  	[	*]	 	[	*]	 	[	*]	 	[	*]	 	[	*]
		  	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 Total
	  	[	*]	 	[	*]	 	[	*]	 	[	*]	 	[	*]
		  	 	 	 	 	 	 	 	 	 	 	 	 	 	 

  

	 1
	 GBP/Euro exchange rate for 2008: GBP 1 = €1.4763. 

  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 F-3 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 Annex G 
 Gilead Licensed Trademarks 
  

									
	 Country
	  	Mark	  	App. /Reg. No.	  	Filing /Reg. Date	  	Class
	Bulgaria	  	TRUVADA	  	Int’l Reg. No. 834700	  	17 Aug. 2004	  	5
	European Community	  	TRUVADA	  	Reg. No. 3965861	  	8 Aug. 2004	  	5, 16, 44
	Iceland	  	TRUVADA	  	Int’l Reg. No. 834700	  	17 Aug. 2004	  	5
	Ireland	  	TRUVADA	  	Reg. No. 229350	  	22 March 2004	  	5
	Liechtenstein	  	TRUVADA	  	Int’l Reg. No. 834700	  	17 Aug. 2004	  	5
	Norway	  	TRUVADA	  	Int’l Reg. No. 834700	  	17 Aug. 2004	  	5
	Romania	  	TRUVADA	  	Int’l Reg. No. 834700	  	17 Aug. 2004	  	5
	Serbia & Montenegro	  	TRUVADA	  	Int’l Reg. No. 834700	  	17 Aug. 2004	  	5
	Switzerland	  	TRUVADA	  	Int’l Reg. No. 834700	  	17 Aug. 2004	  	5
	Bulgaria	  	VIREAD	  	Int’l Reg. No. 822747	  	20 Jan. 2004	  	5
	European Community	  	VIREAD	  	Reg. No. 1815364	  	20 Aug. 2000	  	1, 5, 42
	Iceland	  	VIREAD	  	Int’l Reg. No. 822747	  	20 Jan. 2004	  	5
	Liechtenstein	  	VIREAD	  	Int’l Reg. No. 822747	  	20 Jan. 2004	  	5
	Norway	  	VIREAD	  	Reg. No. 209953	  	16 Aug. 2001	  	5
	Romania	  	VIREAD	  	Int’l Reg. No. 822747	  	20 Jan. 2004	  	5
	Serbia-Montenegro	  	VIREAD	  	Int’l Reg. No. 822747	  	20 Jan. 2004	  	5
	Switzerland	  	VIREAD	  	Reg. No. 485710	  	12 Dec. 2000	  	5
	Bulgaria	  	EMTRIVA	  	Reg. No. 51433	  	16 Oct. 2003	  	5
	Czech Republic	  	EMTRIVA	  	Reg. No. 264137	  	10 Oct. 2003	  	5
	Estonia	  	EMTRIVA	  	Reg. No. 40344	  	15 Dec. 2004	  	5
	European Community	  	EMTRIVA	  	Reg. No. 3399466	  	10 Oct. 2003	  	5, 16, 44

  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 G-1 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

									
	Hungary	  	EMTRIVA	  	Reg. No. 180771	  	14 Oct. 2003	  	5
	Iceland	  	EMTRIVA	  	Reg. No. 951/2003	  	28 Nov. 2003	  	5
	Latvia	  	EMTRIVA	  	Reg. No. M53901	  	16 Oct. 2003	  	5
	Liechtenstein	  	EMTRIVA	  	Reg. No. 13173	  	16 Oct. 2003	  	5
	Lithuania	  	EMTRIVA	  	Reg. No. 49985	  	13 Oct. 2003	  	5
	Norway	  	EMTRIVA	  	Reg. No. 224467	  	29 Sept. 2004	  	5
	Poland	  	EMTRIVA	  	Reg. No. 177366	  	14 Oct. 2003	  	5
	Romania	  	EMTRIVA	  	Reg. No. 57647	  	10 Oct. 2003	  	5
	Serbia & Montenegro	  	EMTRIVA	  	Reg. No. 49515	  	17 Oct. 2003	  	5
	Slovak Republic	  	EMTRIVA	  	Reg. No. 207833	  	10 Oct. 2003	  	5
	Slovenia	  	EMTRIVA	  	Reg. No. 200371487	  	10 Oct. 2003	  	5
	Switzerland	  	EMTRIVA	  	Reg. No. 516574	  	18 April 2003	  	5

  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 G-2 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 Annex H 
 BMS Licensed Trademarks 
  

									
	 Country
	  	Mark	  	App/Reg. No.	  	Filing/Reg Date	  	Class
	Austria	  	SUSTIVA	  	169 299	  	16 Oct. 1997	  	5
	Benelux	  	SUSTIVA	  	607899	  	24 Feb. 1997	  	5
	Bulgaria	  	SUSTIVA	  	30217	  	27 Feb. 1997	  	5
	Cyprus, Republic of	  	SUSTIVA	  	47297	  	30 March 2001	  	5
	Czech Republic	  	SUSTIVA	  	209211	  	28 Feb. 1997	  	5
	Denmark	  	SUSTIVA	  	VR 1997/01905	  	25 April 1997	  	5
	Finland	  	SUSTIVA	  	208767	  	31 Dec. 1997	  	5
	France	  	SUSTIVA	  	97665304	  	24 Feb. 1997	  	5
	Germany	  	SUSTIVA	  	397 07 938	  	22 April 1997	  	5
	Greece	  	SUSTIVA	  	132368	  	19 Nov. 2001	  	5
	Hungary	  	SUSTIVA	  	146 431	  	15 Sept. 1997	  	5
	Iceland	  	SUSTIVA	  	1043/1997	  	15 Sept. 1997	  	5
	Ireland	  	SUSTIVA	  	203503	  	21 Feb. 1997	  	5
	Italy	  	SUSTIVA	  	TO/2006/2986	  	2 Sept. 1999	  	5
	Liechtenstein	  	SUSTIVA	  	10220	  	10 Sept. 1997	  	5
	Malta	  	SUSTIVA	  	27130	  	28 May 1997	  	5
	Norway	  	SUSTIVA	  	187013	  	4 Dec. 1997	  	5
	Poland	  	SUSTIVA	  	116392	  	21 Dec. 1999	  	5
	Portugal	  	SUSTIVA	  	322116	  	12 March 1998	  	5
	Romania	  	SUSTIVA	  	R30097	  	23 April 1997	  	5
	Slovakia	  	SUSTIVA	  	187154	  	2 April 1997	  	5
	 Spain
	  	SUSTIVA	  	2076473	  	5 Sept. 1997	  	5
	 Sweden
	  	SUSTIVA	  	333623	  	5 Nov 1999	  	5
	 Switzerland
	  	SUSTIVA	  	444933	  	21 Feb. 1997	  	5
	 United Kingdom
	  	SUSTIVA	  	2124440	  	20 Feb. 1997	  	5
	 European Community
	  	SUSTIVA
SUNRISE
LOGO	  	969717	  	24 Feb. 2000	  	5

  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 H-1 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 Annex I 
 Voluntary Termination Compensation Formula 
 Capitalized terms used in this Annex and not defined herein shall have
the meaning set forth in the agreement to which this Annex is attached. 
 “Net Sales” shall have the meaning set forth in the Financial
Agreement. 
 “Net Selling Price” shall have the meaning set forth in the Financial Agreement. 
 “Territory-Wide Percentage” shall mean the BMS Territory-Wide Percentage or the Gilead Territory-Wide Percentage, as the case may be. 
 1. The Continuing Party shall pay to the Terminating Party with respect to the period from the effective date of such termination through the third anniversary thereof
an amount determined pursuant to the following formula (with Net Sales being determined for the applicable yearly period), where such amount shall be calculated and paid in Euros: 
 Net Sales of the Combination Product in the Territory 
 multiplied by 
 [*] 
 multiplied by the following percentages for the following twelve (12)-month periods commencing with the effective date of termination: 
 Year 1 – [*] 
 Year 2 – [*] 
 Year 3 – [*] 
 [*] 
 2. The Continuing Party shall pay any such amounts within sixty (60) days of the end of the Calendar Quarter in which the
relevant Net Sales were recognized as revenue (as set forth in the definition of Net Sales set forth in the Financial Agreement). 
 3. For purposes of
calculating any payment pursuant to this Annex I, Net Sales in a currency other than Euros shall be converted into Euros from the applicable currency by the Continuing Party in a manner consistent with its then-current standard worldwide currency
conversion methodology, as consistently applied. 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 I-1 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 Annex J 
 Initial Launch Period Commitments 
  

											
	 Plan/Budget
	  	 Expected Launch Date
	  	Minimum Financial Commitment
(in thousands)	  	Total Minimum Number of Details
(Each Party is responsible for 50% of the
Details specified for each
country)
	  	  	First 12 Months
after Launch	  	Second 12 Months
after Launch	  	First 12 Months
after Launch	  	Second 12 Months
after Launch
						
	 France
	  	[*]	  	[*]	  	[*]	  	[*]	  	[*]
						
	 Spain
	  	[*]	  	[*]	  	[*]	  	[*]	  	[*]
						
	 Italy
	  	[*]	  	[*]	  	[*]	  	[*]	  	[*]
						
	 UK
	  	[*]	  	[*]	  	[*]	  	[*]	  	[*]
						
	 Ireland
	  	[*]	  	[*]	  	[*]	  	[*]	  	[*]
						
	 Germany
	  	[*]	  	[*]	  	[*]	  	[*]	  	[*]
						
	 Territory Centralized Expenses
	  		  	[*]	  	[*]	  	[*]	  	[*]
						
	 Total
	  		  	[*]	  	[*]	  	[*]	  	[*]

  

	 1
	 In Euros unless otherwise specified. 

  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 J-1 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 Annex K 
 Forecast Principles and Supporting Data 
 Capitalized terms used in this Annex and not defined herein shall have the
meaning set forth in the agreement to which this Annex is attached (the “Agreement”). Section references used in this Annex shall refer to Sections in the Agreement except as otherwise provided. 
 The Parties have agreed that, in order to enable to manage the manufacturing arrangements associated with the supply of Territory Combination Product and, in particular,
applicable production capacity, Forecasts shall be prepared based on Local Demand (as defined in the Agreement). 
 The determination of Local Demand shall
be based solely on the objective data, information and criteria that would be used by Gilead Sub and BMS to forecast unit demand for the Combination Product in the ordinary course of business to meet the treatment needs of HIV patients within a
country in the Territory or within the Territory, as applicable (“Supporting Data”). Supporting Data may include, without limitation, the categories of data, information and criteria set out below. This list is non-exhaustive and
the Parties may agree to add further categories of data, information and criteria from time to time. 
 Supporting Data 
 The Supporting Data required to establish reasonable forecasted estimates of Local Demand may include the following (to the extent that such data is available):

  

	 	•	 	 [*] 

  

	 	•	 	 [*] 

  

	 	•	 	 [*] 

  

	 	•	 	 [*] 

  

	 	•	 	 [*] 

  

	 	•	 	 [*] 

  

	 	•	 	 [*] 

 [*] 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 K-1 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 Annex L 
 Territory A Countries 
 Territory A Co-Promote Countries: 
  

			
	 Country
	  	 Selling Party

	 Austria
	  	Gilead Sub
		
	 Belgium
	  	Gilead Sub
		
	 Denmark
	  	Gilead Sub
		
	 Finland
	  	Gilead Sub
		
	 Greece
	  	Gilead Sub
		
	 Iceland
	  	Gilead Sub
		
	 Liechtenstein
	  	Gilead Sub
		
	 Luxembourg
	  	Gilead Sub
		
	 Netherlands
	  	Gilead Sub
		
	 Norway
	  	Gilead Sub
		
	 Portugal
	  	Gilead Sub
		
	 Sweden
	  	Gilead Sub
		
	 Switzerland
	  	Gilead Sub

 BMS Sole-Promote Countries: 
  

			
	 Country
	  	 Selling Party

	 Czech Republic*
	  	To be determined pursuant to Section 5.1
		
	 Hungary
	  	To be determined pursuant to Section 5.1
		
	 Poland
	  	To be determined pursuant to Section 5.1
		
	 Romania*
	  	To be determined pursuant to Section 5.1

 Gilead Sole-Promote Countries: 
  

			
	 Country
	  	 Selling Party

	 Malta
	  	Gilead Sub

  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 L-1 

 CONFIDENTIAL TREATMENT REQUESTED 
 UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 
  

 Third Party Distributor Countries: 
  

			
	 Country
	  	 Selling Party/Third Party Distributor

		
	 Bulgaria*
	  	To be determined pursuant to Section 5.1
		
	 Cyprus
	  	 Gilead Sub/Third Party Distributor to be
 determined
pursuant to Section 5.1

		
	 Estonia*
	  	To be determined pursuant to Section 5.1
		
	 Latvia*
	  	To be determined pursuant to Section 5.1
		
	 Lithuania*
	  	To be determined pursuant to Section 5.1
		
	 Slovak Republic
	  	To be determined pursuant to Section 5.1
		
	 Slovenia
	  	To be determined pursuant to Section 5.1

 [*] 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 L-2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00137-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00137-of-00352.parquet"}]]